University of Pittsburgh School of Medicine

Transcription

UNIVERSITY OF PITTSBURGH
SCHOOL OF MEDICINE
Department of Obstetrics, Gynecology,
and Reproductive Sciences
2006 ACADEMIC YEAR ANNUAL REPORT
Leading Care, Research and Education
in Women’s Healthcare
DEPARTMENT OF OBSTETRICS,
GYNECOLOGY
AND REPRODUCTIVE SCIENCES
UNIVERSITY OF PITTSBURGH
SCHOOL OF MEDICINE
ANNUAL REPORT
Academic Year 2006
July 1, 2005 - June 30, 2006
300 Halket Street · Suite 2235
Pittsburgh, PA 15213
412.641.4212
1
DEPARTMENT OF OBSTETRICS, GYNECOLOGY & REPRODUCTIVE SCIENCES
2
TABLE OF CONTENTS
YEAR IN REVIEW
Mission Statement . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
Chair’s Address . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
Highlights of the 2006 Academic Year . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
Recruitments/Departures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
Department Professional Members . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
DIVISION SUMMARIES OF RESEARCH,
TEACHING AND CLINICAL PROGRAMS
Division of Gynecologic Specialties . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
Division of Gynecologic Oncology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
Division of Maternal Fetal Medicine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
Division of Reproductive Endocrinology and Infertility . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
Division of Reproductive Genetics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
Division of Reproductive Infectious Diseases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .45
Division of Ultrasound . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
Division of Urogynecology and Reconstructive Pelvic Surgery . . . . . . . . . . . . . . . . . . . . . . 57
RESEARCH DIVISION REPORTS
Magee-Womens Research Institute (MWRI) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65
Pittsburgh Development Center –
Division of Development
and Regenerative Medicine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67
RESEARCH GRANTS AND CONTRACTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
PUBLICATIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81
PRESENTATIONS AND INVITED LECTURES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97
TEACHING ACTIVITIES
Summary of Medical Student and Resident Training . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 115
House Staff . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 118
Graduates . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 119
Clinical Fellowship . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 120
CLINICAL REVENUE DATA AND TRENDING . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 123
3
4
MISSION STATEMENT
The mission of the Department of Obstetrics, Gynecology and Reproductive
Sciences is to improve the lives of women through:
• The provision of the highest quality of clinical care for women with complications
in pregnancy, gynecologic problems, gynecologic malignancies, infectious diseases
infertility and endocrine disorders and genetic disease.
• The conduct of clinical and basic science research devoted entirely to investigation
of the full spectrum of diseases associated with the health of women and infants
and the ability to successfully translate these clinical and basic scientific findings
into new clinical applications.
• To provide the highest level of education and training to medical students, interns,
residents, postgraduate physicians, faculty, private practitioners and other
healthcare providers that is an open-ended continuum with integration of all
the subspecialties, and to create a highly satisfied professional environment for
faculty, staff and students.
5
6
STATEMENT FROM THE CHAIR
The University of Pittsburgh Department of Obstetrics,
Gynecology and Reproductive Sciences in collaboration with
Magee-Womens Hospital has had an outstanding year in all
aspects of our mission, to provide the highest level of patient care,
to educate the next generation of obstetrician gynecologists, and to
perform state-of-the-art research. It is a pleasure to share with you
all of these successes through this Annual Report.
Our Department continues to be a leader in basic, translational,
and clinical research to benefit the health of women and infants.
W. Allen Hogge, MD
During 2006 our total grant portfolio increased nearly 14% reachThe Milton Lawrence
McCall Professor
ing an all time high of $25.4 million. Of this, $17.5 million comes
and Chairman
from the National Institutes of Health. Our federal funding had a
dramatic increase of over 20% from fiscal year 05. One of the
highlights this year was the awarding to Dr. Sharon Hillier of an NIH contract for a
Microbicide Trials Network, which will have total direct costs of approximately $92 million
over the next 7 years. This program will develop and test microbicides for the prevention
of HIV/AIDS throughout the world.
Educating both the next generation of physicians, and the next leaders in obstetrics and
gynecology remains a strong component of the Department. Three of our faculty members,
Drs. Edelstone, McIntyre-Seltman and DeLoia, were elected to the School of Medicine
Master Educators Program, and Dr. DeLoia also received the Ken Schuitt Dean’s Master
Educator Award for 2006. In addition, Drs. Jeyabalan and Wiesenfeld received teaching
awards from the School of Medicine Class of 2006. Our residents also continue to be leaders in teaching with Drs. Carolyn Sufrin and Michele Odrobina being finalists for the
Humanism and Excellence in Teaching Award from the University of Pittsburgh, and Dr.
Odrobina was one of the six winners of the award. Of the three residents inducted into the
University of Pittsburgh AOA Society this past year, Dr. Susan Lareau and Dr. Mitch
Odrobina were from our Department.
We continue to successfully recruit some of the best and brightest to our training programs. Of our nine residents entering this year, three come from top 20 U.S. medical
schools, and 11 highly qualified residents were recruited into our fellowship program in
Maternal-Fetal Medicine, Gynecologic Oncology, Reproductive Genetics, Family Planning,
Minimally Invasive Surgery, Reproductive Infectious Disease, and Urogynecology. Our faculty continues to be truly the ultimate “triple threat”. Not only are they extremely successful in education and research, their clinical productivity is outstanding. Clinical charges for
2006 were more than $44 million, an increase of 11% over fiscal year 05. Despite this
remarkable increase in clinical volume, the Department consistently met the UPMC system
objective of having appointment availability within 72 hours for any patient with an urgent
medical problem. Among new programs developed this year was a program in Midlife
7
Medicine which was instituted in August of 2005, and in its first 10 months had over 2000
patient visits. The continued excellence of our clinical faculty was clearly seen in the significant jump in the U.S. News and World Report rankings for top institutions for gynecology.
Our home institution, Magee-Womens Hospital, has rapidly moved up in the past year
from 17 to 13 which is a clear indication of the clinical excellence available through the
Department of Obstetrics, Gynecology and Reproductive Sciences.
As you can see from this brief overview, our Department has had a most successful year. It
continues to maintain its incredible excellence in education, research and clinical care, and
at the same time to have the financial stability that allows us to continue to grow, and to
develop new programs for the healthcare of women.
W. Allen Hogge, MD
The Milton Lawrence McCall
Professor and Chairman
8
RECRUITMENTS/DEPARTURES
HIGHLIGHTS OF THE 2005 ACADEMIC YEAR
RESEARCH
Federal grants now total $13,597,059 in direct costs. An additional $2,316,884 are received
in subcontracts, for total federal direct funding of $15,913,943. This represents a 20.4%
increase over FY 05.
Non-federal and industry grants now total $3,338,131.
Total grant portfolio of $25,354,949 which is a 13.7% increase over FY 05.
Division of Reproductive Infectious Disease (Sharon Hillier, Ph.D) awarded contract for a
Microbicide Trial Network with an annual direct costs of approximately 12 million, and a
total direct costs of approximately 92 million over 7 years.
TEACHING
Two faculty (Jeyabalan, Wiesenfeld) received teaching awards from SOM class of 2006.
Three faculty members were elected to the School of Medicine Master Educators Programs
(Drs. Edelstone, McIntyre-Seltman and DeLoia).
Dr. Julie DeLoia received the Ken Schuit Dean’s Master Educator Award.
Two residents were finalists for the Humanism and Excellence in Teaching Award (Carolyn
Sufrin and Michele Odrobina), and Dr. Odrobina was one of the six winners of the award.
Two of the three residents inducted into the University of Pittsburgh AOA Society were
from Obstetrics and Gynecology (Susan Lareau, Michele Odrobina).
The Department successfully recruited 11 highly qualified residents into the following subspecialty fellowships: Maternal-Fetal Medicine, Gynecologic Oncology, Reproductive
Genetics, Family Planning, Minimally Invasive Surgery, Reprodcutive Infectious Disease
and Urogynecology.
Department faculty served as course directors for two medical school courses (Genetics and
Reproductive Biology), and block coordinators for Patient, Physician and Society block.
CLINICAL
Charges were approximately 44.2 million, an increase of 11.3% over FY 05.
Net Patient Care Revenue was approximately 17.2 million, an increase of 7.3% over FY 05.
Other Revenues, which include contract revenue, are $9.1 million, an increase of 11% over
the last year.
Consistently met the system objective of appointment availability within 72 hours.
Days in A/R were 24 (a 10 day decrease from FY 05).
Midlife Center was instituted and 2002 patients were seen from 8/1-5/31. Of these, 459
were new patients or consults; 250 surgical procedures resulted.
Gynecologic Oncology increased charges from 3.8 million to 6.1 million, a 68% increase
over FY 05.
Recruited two additional nurse midwives and developed a Division of Midwifery with a goal
of increasing market share in obstetrics.
Expanded the Minimally Invasive Surgery program to an off-site location at UPMC
Passavant.
Developed Gynecologic Oncology satellite programs at Latrobe, Uniontown, Sewickley
and Erie.
9
RECRUITMENTS
PHYSICIAN
TITLE/DIVISION
HIRED
JOINING UPMC FROM:
Jennifer Hayes, MD
Assistant Professor
Gyne Specialties
7/5/05
Emory University
Thomas Krivak, MD
Assistant Professor
Gyne Oncology
8/22/05
David Grant
Medical Center, CA
Paniti Sukumvanich, MD
Assistant Professor
Gyne Oncology
8/22/05
Memorial Sloan-Kettering
Cancer Center, NY
Kristin Zorn., MD
Assistant Professor
Division of Medical Genetics
8/1/05
University of Oklahoma
HC, OK
DEPARTURES
PHYSICIAN
10
TITLE/DIVISION
RESIGNED
TO:
Bryna Harwood, MD, MS
Assistant Professor
Gyne Specialties
6/30/05
University of Illinois
Kristine Lain, MD
Assistant Professor
MFM
7/31/05
University of Kentucky
Jacqueline Novak, Ph.D
Assistant Professor
8/26/05
Walsh University
Rolando Ramirez, Ph.D
Assistant Professor
8/29/05
University of Akron, OH
Anne Weber, MD
Associate Professor
Urogynecology
4/30/06
NICHD
OB/GYN/RS DEPARTMENT PROFESSIONAL MEMBERS
PROFESSORS
Steve Caritis, MD
Kirk Conrad, MD
Brian Clark, MD
Mitchell Creinin, MD
Daniel Edelstone, MD
Robert Edwards, MD
L. Michael Hill, MD
Sharon Hiller, Ph.D
W. Allen Hogge, MD
James Roberts, MD
Joseph Sanfilippo, MD
Gerald Schatten, Ph.D
ASSOCIATE PROFESSORS
Julie DeLoia, Ph.D
Mary Ann Portman, MD
Charlene Dezzutti, Ph.D
Robert Thompson, MD
Richard Guido, MD
Morris Turner, MD
Laura Hewitson, Ph.D
Anthony Wakim, MD
Joseph Kelley, MD
Margaret Watt-Morse, MD
Marijane Krohn, Ph.D
Harold Wiesenfeld, MD
Kathleen McIntyre-Seltman, MD
Cal Simerly, Ph.D
Bernard Moncla, Ph.D
Halina Zyczynski, MD
ASSISTANT PROFESSORS
Judith Balk, MD
Thomas Krivak, MD
Bora Baysal, Ph.D
Jean Latimer, Ph.D
Judy Chang, MD
Margaret Larkins-Pettigrew, MD
Thomas Cherpes, MD
Ted Lee, MD
Bonnie Coyne, MD
Jerry Martin, MD
Anthony Csoka, Ph.D
Elizabeth McGee, MD
Ashi Daftary, MD
Pamela Moalli, MD
Robert Gedekon, MD
Kyle Orwig, Ph.D
Gabriella Gosman, MD
Robert Powers, Ph.D
Jennifer Hayes, MD
Augustine Rajakumar, Ph.D
Lih-Ching Hsu, Ph.D
Paul Sammak, Ph.D
Jie Hu, Ph.D
Hyagriv Simhan, MD
Carl Hubel, Ph.D
Arun Jeyabalan, MD
Glenn Updike, MD
Brinda Kalro, MD
Kristin Zorn, MD
David Kauffman, MD
RESEARCH ASSISTANT PROFESSORS
Chris Navara, Ph.D
Diane Carlisle, Ph.D
11
RESIDENTS
4th Year Residents
Beatrice Chen, MD
L’Tricia Oglesby Chery, MD
Theresa Mancuso Erb, MD
Amanda Nickles Fader, MD
Kimberly Sauchak Gecsi, MD
Katherine Park Himes, MD
Amy J. Park, MD
Ashlyn Holstein Savage, MD
Amy K. Whitaker, MD
3rd Year Residents
Amy N. Broach, MD
Vanita B. Dharan, MD
Elizabeth . Frankman, MD
Emily S. Lebovitz, MD
Michele R. Odrobina, MD
Minita Patel, MD
Suzanne E. Peterson, MD
Lauren E. Pray, MD
Carolyn B. Sufrin, MD
2nd Year Residents
Kathleen A. Carroll, MD
Christannah M. Domin, MD
Catherine G. Hilliker, MD
Erin M. Hott, MD
Susan M. Lareau, MD
Amanda N. Malina, MD
Gina M. Mantina, MD
Stephanie M. Owens, MD
Stephen W. Tobia, MD
1st Year Residents
Sharon L. Achilles, MD
Elizabeth E. Krans. MD
Jamie L. Lesnock, MD
Melanie E. Ochalski, MD
Amber M. Naresh, MD, MPH
David A. Rapkin, MD
Bunja J. Rungruang, MD
Wendy S. Vitek, MD
Stephanie L. Wethington, MD
FELLOWS
Contraceptive Research
& Family Planning
Matthew F. Reeves, MD
Patricia A. Lohr, MD
Maternal Fetal Medicine
Brenna L. Anderson, MD
Allison R. Durica, MD
Hilary Seglin Gammill, MD
David Hackney, MD
Carol Lin, MD
Kristiina Parviainen, MD
Female Pelvic Medicine & Reconstructive Surgery
Marianne Alperin, MD
James A. Daucher, MD
Jerry Lane Lowder, MD
Genetics
Regina L. Arvon, MD
Marta C. Kolthoff, MD
Gynecologic Oncology
Alfred Guirguis, DO
Scott D. Richards, MD
Minimally Invasive Surgery
Hye-Chun Hur, MD
12
OB/GYN/RS DEPARTMENT PROFESSIONAL MEMBERS
Sharan Abdul-Rahman, MD
James Alonzo, MD
Carey D. Andrew-Jaja, MD
Robert Atchison, MD
Edward Austin, MD
David Badway, MD
Saul Berg, MD
Sarah L. Berga, MD
Diane Borello-France, MD
James Brown, MD
Donald Carson, MD
Stephen Corey, MD
Emily DeFerrari, MD
Domenico Diclemente, MD
Robert P. Edwards, MD
Dennis English, MD
Steele Filipek, MD
Irene B. Frederick, MD
Robert L. Fronduti, MD
Rocco Fulcinetti, MD
Christine Gallis, MD
Anthony Gentile, MD
Katherine Goetz, MD
Elizabeth Hazel, MD
Renata Hoca, MD
Charles Hohing, MD
Maryanne Hugo, MD
CLINICAL FACULTY
Diane Ichikawa, MD
Kobra Karimkhani, MD
David L. Katz, MD
Charles Kremser, MD
Pamela Kridgen, MD
Carol Krupski, MD
Carolyn J. Kubik, MD
Alan Kunschner, MD
Christina LaBella, MD
Kristine Lain, MD
Daniel Lattanzi, MD
Hye-Chun Lee, MD
Merrideth Leggat, MD
Patricia Lohr, MD
Christine London, CNM
Michael Lupinetti, MD
Mark Mallinger, MD
Shannon McCabe, MD
Larry McNulty, MD
Kimberly Melen, MD
Eric Miller, MD
Stephanie Nicholas, MD
Mary Olson, MD
Murray Osofsky, MD
Mary Peterson, MD
Monica Philipkosky, MD
Dean Pollack, MD
George Poutous, MD
Christine Rause, CRNP
Nicole Rawson, CNM
Matthew Reeves, MD
Lynn Reid, PA-C, MPH
Ira Rock, MD
Karen Roperti, MD
Debra Rubinstein, MD
Deanna Rutman, MD
Sandra Rygg, MD
Mojedeh Saberin-Williams, MD
Ann Schutt-Aine, MD
Samuel Seiavitch, MD
Elizabeth Seiders, MD
Anne Shaheen, MD
Arthur Signorella, MD
Robert Simmonds, MD
Carol Simmons, MD
Pierce Soffronoff, MD
Deborah Sommer, MD
Robert Stern, MD
Lee A. Swanson, MD
Robert Thomas, MD
Tanya Walter, CNM
Robert Warner, MD
Shirley Woo, MD
Nasr Yazigi, MD
13
14
DIVISON OF GYNECOLOGIC SPECIALTIES
DIVISION OF GYNECOLOGIC SPECIALTIES
OVERVIEW
The Gynecologic Specialties Division continued growth and
development to maintain our primary mission related to the care
of women with gynecologic disorders. We had our most productive clinical year in the history of the division, seeing more patients
than ever before.
During the past academic year (July 2005 – June 2006), the
Division members provided:
Mitchell Creinin, MD
Division Director
• clinical care as both primary providers of obstetrics and
gynecology services and referral specialists within our areas of
sub-specialty.
• research including 24 peer-reviewed publications, 21 abstracts
at national meetings, and funding from government, foundation,
and industry sources totaling $3.2 million.
• teaching of medical students, residents and fellows.
RESEARCH PROGRAM
Our Division continues to be extremely productive in research, including 25 peer-reviewed
publications, 21 oral, poster or video abstracts at national meetings, and funding from government, foundation, and industry sources totaling $3.2 million in direct and indirect funding. Additionally, division members were editors of 3 books or book chapters during the
past year.
Dr. Creinin heads the NIH funded Clinical Research Training Program for support of
clinical fellows within our Department. Dr. Creinin is also a Principal Investigator in the
NICHD Contraceptive Clinical Trials Network. This year, Dr. Creinin was the principal
investigator for 2 multicenter trials, one evaluating new medical abortion technologies and
the other investigating hormonal contraceptive options. Both studies were initiated by and
overseen by Dr. Creinin as the PI for the entire study. Dr. Creinin also received government funding over the academic year for studies through USAID and the CDC involving
microbicide development. Dr. Creinin is also the Principal Investigator and co-Investigator
on several clinical trials on contraceptive innovations.
Dr. Chang was awarded a BIRCWH Scholar research career development award that
began in July 2004. She completed her funding for this award during the past academic
year when she received a federal grant from the Agency on Healthcare Research and
Quality. She continues to participate as a co-investigator on several projects regarding intimate partner violence funded by the Scaife Family Foundation and a project to develop and
evaluate a computerized screening tool for preventive women’s health funded by the Office
of Women’s Health.
Dr Guido is involved in clinical research regarding cervical cancer screening, HPV, and
colposcopy. During the last 12 months his research has been primarily industry funded
research regarding HPV testing and novel technologies to improve the specificity of colposcopy. The upcoming year’s efforts will include DOD funded study on the use of various
treatments for fibroids, a collaborative effort on the use of photosensitized therapy for the
treatment of dysplasia, and a collaborative project evaluating a medical therapy for abnormal pap tests.
15
Drs. Harwood and Hayes are the Principal Investigator or co-Investigator on several government, industry, and foundation funded clinical trials on new contraceptive technologies
and abortion methods.
Dr. Wiesenfeld is the Principal Investigator of a NIH-funded R01 grant on subclinical PID.
The primary aim of this study is to compare the impact on fertility of two antibiotic regimens for subclinical PID. Dr. Wiesenfeld is also the Principal Investigator and coInvestigator on several clinical trials on reproductive infections.
TEACHING ACTIVITIES
Our Division members maintain a position in academic medicine because of their continued commitment to teaching. All surgically active division members rotate as the Resident
Service Attending for a minimum of 4 weeks annually. We are the primary providers of
gynecologic teaching in resident continuity clinics.
Dr. Harwood, in her role as the Assistant Director of the Outpatient Clinic, completed a
year long project reorganizing the resident clinic, updating clinical programming and
expanding services. During this past academic year, our division ran specialty clinics in colposcopy (4 sessions weekly), family planning (2 sessions weekly), urgent care (9 sessions
weekly), vulvar disease (1 session weekly) and perioperative management (2 sessions weekly).
Our teaching conferences, accordingly, were also reorganized. We maintained our primary
gynecology teaching conference on Monday mornings but reorganized specialty conferences in Minimally Invasive Surgery, Family Planning and Infectious Disease into a single
conference on Friday mornings. Our division teaching conferences included:
— Gynecology Conference
Monday morning 0700-0815: a three-segment conference with:
• the first 30 minutes is a clinical presentation of patients and treatment
decisions by the Senior resident on the University Gynecology service.
• the second thirty minutes is an evidenced-base resident presentation
conference with rotating assigned topics.
• the final fifteen minutes is a review of all cases of abnormal early pregnancy,
ectopic pregnancy and molar pregnancy being followed by the residents
in a case management format.
— Colposcopy Conference
Monday morning 0815-0900: weekly review of colposcopic pattern recognition
and cytology-histology-colposcopy correlation.
— Specialty Conference
Friday 0700-0800: lectures every other week in Family Planning (by the family
planning fellows and the resident on the family planning rotation), once every
fourth week in Minimally Invasive Surgery (by the minimally invasive surgery
fellow and the resident on the minimally invasive surgery rotation), and once every
fourth week in Reproductive Infectious Disease (by the intern on the ambulatory
clinic rotation).
These changes have allowed for greater attendance by both faculty and residents at the specialty conferences. During the upcoming year, we will revisit how these changes have
impacted our teaching goal in relation to out commitment to fellows, residents and student
education.
16
Residency Rotations
University Gynecology
Family Planning
Special Clinics (colposcopy and pre-op clinics)*
Gynecology Consultation
Urgent Care Gynecology
Ambulatory Gynecology
PGY
4th, 3rd, 1st
4th
4th
4th
2nd
1st
1st
* also attends private office hours with Dr. Portman for teaching related to the care of
menopausal patients
Medical Student Education
Medical student education is also a priority. All division members participate as faculty preceptors for Problem Based Learning sessions during the 3rd year Clerkship in Obstetrics
and Gynecology. Many of the faculty participate in courses throughout the medical school
curricula.
Medical Student Education leadership
- 2nd year Reproductive Biology Course: Richard Guido, MD, course co-director
- 3rd year Obstetrics and Gynecology Clerkship: Kathy McIntyre-Seltman, MD,
clerkship director
- 4th year Obstetrics and Gynecology electives: Richard Guido, MD, director
• available electives within our division: research, University Gynecology,
- 4th year Reproductive Infectious Disease ILS Course: Harold Wiesenfeld, MD, CM,
course director
- 4th year Pelvic Anatomy ILS Course: Ted Lee, MD, course director
- 4th year Women’s Health Elective: Kathy McIntyre-Seltman, MD, clerkship co-director
The Minimally Invasive Gynecologic Surgery and Pelvic Pain 4th year elective was introduced this past year as a new 4 week clerkship under the direction of Dr. Lee. Students
learn to take pertinent history and perform the (pelvic pain specific) physical exams on
women with endometriosis as well as women with other sources of chronic pelvic pain. The
students are exposed to all disciplines of minimally invasive gynecologic surgery including
laparoscopic deep excision of endometriosis, presacral neurectomy, reconstruction for pelvic
organ prolapse, hysterectomy, myomectomy, and adnexal surgery. The students participate
in the pre-op evaluations with the faculty and intraoperatively as assistants for these procedures. Importantly, this elective deepens the student’s understanding and appreciation of
pelvic anatomy (retroperitoneal and pelvic support anatomy).
FELLOWSHIPS
The Division offers fellowships in Family Planning and Minimally Invasive Surgery (in
conjunction with the Division of Reproductive Endocrinology and Infertility). Our faculty
also contribute to the teaching of fellows and junior faculty in other University departments, including the Women’s Health fellows from the Department of Medicine.
Additionally, Dr. Chang serves as a core faculty member of the Center for Research in
Health Care where she has co-developed and co-teaches a fellow/junior faculty level course
on Qualitative Research Methods.
17
The Family Planning Fellowship is a two-year program designed to include training in family
planning clinical care, experience in gynecologic surgery and related family planning procedures, participation in the design and performance of clinical trials and international field
work. During the two years, the fellow is encouraged to complete course work at the
Graduate School of Public Health at the University of Pittsburgh to satisfy the requirements of a Master’s Degree in Public Health. Course work can involve a multidisciplinary
approach or a departmental curriculum including biostatistics, epidemiology and health
care administration. The program is intended to foster the pursuit of an academic career by
overall emphasis on and preparation for clinical research and teaching. The fellow will be
specifically trained in contraceptive counseling, contraceptive implant insertion and
removal, IUD insertion and removal, and the fitting of diaphragms. Additionally, the fellow
will gain expertise in treating complications of hormonal contraception. Although these
procedures may have been learned during residency, a concentrated experience will enable
the fellow to be proficient with unusual or complicated cases. The fellow will receive specialized training and become very experienced in performing first trimester procedures
including manual vacuum aspiration and medical abortions. The fellow will have similar
experience with second trimester abortions by dilation and evacuation (D&E). The fellow
will be an active participant in ongoing trials as well as be expected to design and conduct
his/her own research trial. The fellow will also gain experience in grant writing, budgeting,
contracts, and other administrative aspects of clinical research. Fellows are also expected to
spend time working in the developing world on advances in contraception and access to
care. This international experience is designed to further the fellow’s understanding of
issues related to the impact of high fertility rates and poor access to reproductive health
services for contraception and pregnancy care. Three-year programs are available for individuals with an additional interest in Reproductive Genetics or Reproductive Infectious
Disease.
The Minimally Invasive Surgery Fellowship is a one-year intense academic training program
which focuses on minimally invasive surgery. The program is designed to provide extensive
training in endoscopic surgery from the gynecologic and general surgical perspectives. A
research project is an integral part of the program with the expectation that it is submitted
at a national level and published in a peer-reviewed journal. Other activities include active
participation in resident and student teaching programs and private patient sessions.
CLINICAL PROGRAMS
Our clinical practice is run in three primary locations. The main office for all of the division members except Dr. Chang is located at Magee-Womens Hospital. Dr. Chang primarily sees patients in the Montefiore General Internal Medicine offices on 9 South. Dr.
Updike also sees patients at the UPMC Mt. Oliver complex. We also integrate residents
and fellows into our offices for subspecialty education. In addition to gynecologic care, Drs.
Wiesenfeld and Updike also have a busy obstetric practice.
Dr. Suketu Mansuria joined our practice last year as a fellowship trained specialist in
Minimally Invasive Surgery, brining the total number of Minimally Invasive Surgery specialists in the Department to five (three in our division). We expect continued growth as the
clinical, educational and research demands of this subspecialty continue to grow.
18
Dr. Portman initiated the Midlife Health Center as a collaborative project with the
Division of Reproductive Endocrinology and Infertility and Urogynecology and the
Departments of Medicine, Cardiology and Gastrointestinal Disorders. This center is devoted to improving the healthcare for women over the age of 35. Initially, the thrust of the
program is to provide care for women with severe menopausal symptoms. Women can self
refer or be referred by their primary care provider or gynecologist. This program is joined
in the care of these patients by Drs. Judy Balk and Brinda Kalro from our department and
Dr. Kim Pierce from Internal Medicine. This program is collaborating currently with the
following other departments or hospital services to coordinate care for midlife women:
Mammography/DEXA, Ultrasound, Cardiology, Genetics. Gastroenterology, Acupuncture,
Oncology, Behavioral medicine/psychiatry, and Dietary/Naturapathic Medicine. In the initial stages, the Midlife program is geared toward very symptomatic patients. Our future
goal is to provide coordinated care to patients at midlife and beyond. An online questionnaire has been developed as well as a web site for the center. Patients are asked to complete
the questionnaire after they have made an appointment to see a provider. The questionnaire is designed so that Lee Hart can determine if we should schedule other appointments
for an individual patient while she is at Magee for her appointment with us. We have also
started a quarterly series of evening programs for the public.
We continue to have an open access schedule into our office to maximize the availability of
our specialists for new and return problem visits. A new patient with a problem can see a
physician in our practice within 3 business days. Our total number of office visits and consultations increased 6% from the prior year, our second consecutive year with an increase.
Accordingly, the billable charges and collections increased 14% and 12%, respectively, from
the prior year.
During this past year, we developed a system with a similar availability structure of open
access for our return patients with acute problems. We continue to work on finding a balance between providing continuing routine care for women who desire to use our group as
their primary gynecologists and being available as specialists to the Pittsburgh and surrounding areas.
Specialties:
Judy Chang, MD, MPH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Domestic Violence
Mitchell Creinin, MD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Family Planning
Richard Guido, MD . . . . . . . . . . . . . . . . . . Minimally Invasive Surgery, Cervical Dysplasia
Bryna Harwood, MD, MS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Family Planning
Jennifer Hayes, MD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Family Planning
Ted Lee, MD . . . . . . . . . . . . . . . . . . Minimally Invasive Surgery, Pelvic Pain management
Suketu Mansuria, MD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Minimally Invasive Surgery
Kathy McIntyre-Seltman, MD . . . . . . . . . . . . . . . . . . . Cervical Dysplasia, Vulvar Disease
MaryAnn Portman, MD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Menopause
Glenn Updike, MD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Vulvar Disease
Harold Wiesenfeld, MD, CM . . . . . . . . . . . . . . . . . . . . . . Reproductive Infectious Disease
Outreach/contracted care:
Veteran’s Administration Hospital
Women’s Health Services: . . . . . . . . . . . . . . . . . . Drs. Mansuria and McIntyre-Seltman
Planned Parenthood of
Western Pennsylvania: . . . . . . . . . . . . . . Dr. Creinin—Medical and Laboratory Director
Allegheny County Health Department: . . . . Dr. Wiesenfeld—Co-Director, STD Program
Magee-Womens Hosptial
Outpatient Clinical Services: . . . . . . . . . . Bryna Harwood, MD, MS—Assistant Director
Magee-Womens Hospital Women with Disabilities Clinic: . . . . . . . . . Glenn Updike, MD
Magee-Womens Hospital Mt. Oliver Clinic: . . . . . . . . . . . . . . . . . . . . Glenn Updike, MD
University of Pittsburgh
Student Health Services: . . . . . . Harold Wiesenfeld, MD, CM—Gynecology Consultant
UPMC PACT (HIV) Clinic: . . . . Harold Wiesenfeld, MD, CM—Gynecology Consultant
19
Faculty
Mitchell Creinin, MD, Director
Judy Chang, MD, MPH
Family Planning
Robert Gedekoh, MD
Matthew Reeves, MD (2nd year)
Richard Guido, MD
Patricia Lohr, MD (1st year)
Bryna Harwood, MD, MS
Jennifer Hayes, MD
Ted Lee, MD
Hye-Chun Hur, MD
Suketu Mansuria, MD
Kathy McIntyre-Seltman, MD
MaryAnn Portman, MD
Glenn Updike, MD
Harold Wiesenfeld, MD, CM
Kim Barcasky, CRNP
Chris Rause, CRNP
Lynn Reid, PA-C, MPH
Helen Fries, RN (Division Manager)
WEBSITE: http://obgyn.medicine.pitt.edu/gynecology
We continue to work on finding a balance between providing continuing routine care
for women who desire to use our group as their primary gynecologists and
being available as specialists to the Pittsburgh and surrounding areas.
20
DIVISON OF GYNECOLOGIC ONCOLOGY
DIVISION OF GYNECOLOGIC ONCOLOGY
OVERVIEW
In the academic year of 2005-2006, the Gynecologic Oncology
Division continued to embrace the motto “where there is change
there is opportunity.” The division has undergone significant
restructuring with the hiring of an additional 4 full-time gynecologic oncologists as well as 3 advanced practitioners. The division’s
missions are: To provide compassionate and comprehensive care to
women afflicted with breast and gynecologic malignancies; 2. The
enhancement of care through the use of basic science, translational
and clinical research; 3. Education of future health care providers
including medical students, residents, and fellows; and 4. Advocacy
Joseph L. Kelley, MD
Division Director
for awareness of gynecologic and breast malignancies.
During this academic year the division began to improve its clinical presence with the hiring of additional faculty members. New faculty members include
Drs. Thomas C. Krivak, Kristin K. Zorn, and Paniti Sukumvanich. Dr Krivak brings mid
level academic experience to the program and has clinical interests in the use of minimally
invasive surgery in the treatment of gynecologic malignancies. Dr. Zorn and Sukumvanich
joined the department after completing fellowship training in gynecologic oncology. Both
individuals bring a fresh perspective on the evaluation and management of patients. Dr.
Zorn has a particular interest in molecular profiling of tumors and has established collaborative ties with the Magee Womens Research Institute. Dr. Sukumvanich has been charged
with the development of an informatics structure to the division. In addition, he completed
a fellowship in Breast Oncology and adds that dimension to the division. With the addition
of these faculty, our division has improved our level of service to the community of
Pittsburgh and surrounding counties.
RESEARCH PROGRAMS
Our research program was extremely productive with the maintenance of approximately 30
clinical trials and the total funding of $4,394,340 for fiscal year 2006.
The research activities of the division are multifaceted and well funded. In the past year the
divisional had 13 publications and has submitted an additional 2 manuscripts for consideration. Members of the divisional presented 8 abstracts including 2 presented at a National
meetings.
In the academic year 2005-2006 the division had 20 clinical trials available for patient
accrual. The disease sites included the ovary, endometrium, uterine sarcomas, vulvar, cervical carcinomas as well as gestational trophoblastic disease.
Drs. Edward and Kelley serve as the Co-Principal Investigators for the Gynecologic
Oncology Group (GOG) studies as well as a number of industry funded projects. The program has monthly protocol meetings and has sought collaborations with his colleagues at
the Magee Womens Research Institute (MWRI) and the Pittsburgh Cancer Institute (PCI).
Dr. Edwards serves as the Director of Gynecologic Oncology Research and the Director of
the Ovarian Cancer Center of Excellence. His interests include vaccine therapies for cervical and ovarian cancer, combining biologic and immunologic therapies with traditional
therapies in the treatment of women’s cancer and intraperitoneal therapy.
Dr. DeLoia in her role as Director of Research for the Ovarian Cancer Center of
Excellence continues to explore her interest in the pharmacogenetics of improving outcome
of women with ovarian cancer. She has been an excellent resource for translational and
basic science research for the division. She has built a cohesive team at the MWRI and
21
brings to the division a new appreciation for the importance of bench research. Drs. Baysal
and Hsu have pursued various genetic studies on ovarian cancer cell lines.
Faculty: Joseph L. Kelley, MD
22
Title: Use of MDR1 and CYP Pharmacogenetic Variables in Designing Individualized
Therapy for the Treatment of Ovarian Cancer
Background:
Current first line chemotherapy for ovarian cancer consists of a platinum compound plus a
taxane. As with other anticancer agents, the therapeutic index of taxanes is narrow.
Substantial laboratory evidence indicates that the pharmacodynamic effect will depend on
factors such as metabolism, ability of the drug to reach the target tissue and cellular exposure. In vivo, taxane compounds have been found to be actively pumped out of cells by the
P-glycoprotein pump P-gp), and ABC transporter. Drug disposition depends on both the
pump and enzyme activities. We specifically hypothesize that a major contributor to sensitivity of patients with ovarian cancer to the enzymes.
Our Goals include:
1) To evaluate the effect of tumor genotype of MDR1 and CYP genes on ex vivo sensitivity
to chemotherapeutics; 2) determine the association between the functional polymorphisms
of these pharmacogenetic variables and outcome in paclitaxel-related ovarian cancer
patients in a completed large cooperative group study; 3) simultaneously, in a prospective
trial of ovarian cancer patients, evaluate the relationship between the MDR1 and CYP3A
genotypes, haplotypes and phenotypes, as to pharmacokinetics of docetaxel; and 4) individualize docetaxel treatment, based on MDR and CYP3A5 genotypes, in patients with
advanced ovarian cancer.
Future Plans:
The data generated from this work will allow us to understand more about the pharmacokinetic variability in women with ovarian cancer and then accordingly, improve the therapeutic index by individualizing therapy, with the ultimate goal of improving outcome in women
with ovarian cancer.
Faculty: Robert P. Edwards, MD
Title: Lymph Node Mapping in Cervical Cancer
Background
Several factors influence the prognosis of a patient diagnosed with cervical cancer. These
include stage, volume, tumor grade, histology, and lymphatic spread. For most solid
tumors, the most powerful and predictive prognostic factor is the status of the regional
lymph nodes. The spread of cervical cancer is by two modes: direct local extension and
lymphatic spread. Direct local invasion can be determined by clinical examination.
However, there is currently no definitive method to evaluate lymphatic spread of the disease.
The role of surgery is still central to the characterization of nodal metastasis in this disease.
In many cases identification of positive lymph nodes at the time of planned radical hysterectomy requires the surgical procedure be discontinued. This results in a prolonged
postoperative course before curative radiation and chemotherapy can be implemented. If
the surgeon could be guided to the positive regional lymph nodes using less invasive procedures the patient may be spared more extensive surgery and delay in therapy. With regard
to diagnostic laparoscopic staging procedures, if high-risk regional lymph nodes were identified, the extent of laparoscopic dissection could be restricted with confidence given the
predictive value of the removed sentinel lymph node (SLN). The SLN is the first node in
the lymphatic basin that receives lymphatic flow through afferent lymphatics from the primary tumor. The status of a sentinel lymph node may serve as a guide to extent and focus
of nodal excision allowing a more precise intraoperative evaluation of nodal status. The sta-
tus of regional lymph nodes is important in the treatment and prognosis of cervical cancer.
Regional lymph nodes that are clinically involved with tumors are difficult to identify at the
time of surgery. Characterization of tumor-involved nodes often changes the therapeutic
approach, including the decision for surgery versus radiation.
The principle objective of this research proposal is to develop techniques using preoperative lymphoscintigraphy and intraoperative lymphatic mapping to locate the sentinel lymph
node (SLN) of invasive carcinomas of the cervix. The ability to identify the primary node
to which the tumor would drain is an essential element to optimal disease management.
Insight into the lymphatic drainage of cervical cancer can serve as a guide to ensure adequate dissection for treatment. The use of lymphoscintigraphy and intraoperative gamma
probe localization would guide the surgeon directly to the primary node or nodes of
drainage.
This could potentially allow full nodal staging information with minimally invasive procedures allowing the surgeon to provide one or two sentinel lymph nodes to the pathologist
for detailed examination instead of 20-25. The sensitivity of pathological examination can
be increased providing a more accurate treatment plan. If radiation therapy is needed, it
could be focally restricted resulting in a lower radiation dose to the patient with similar efficacy.
Study Objectives:
We hypothesize that lymphoscintigraphy and intraoperative lymphatic mapping can be used
to locate the sentinel lymph node for carcinomas of the cervix. The ability to identify the
primary node to which the tumor would drain is an essential element to optimal disease
management.
Specifically we propose to:
1). To develop techniques using preoperative lymphoscintigraphy and intraoperative
lymphatic mapping to locate the sentinel lymph node (SLN) of invasive carcinomas of
the cervix.
2). To map specific pelvic nodal regions receiving lymphatic drainage from the cervix and
lower genital tract as a function of particle size of colloid injected.
3). To identify if macrophages or dendritic cells or both are capable of transporting colloid
particles from the cervix to the lymphatic bed and to establish the kinetics of this
transport.
Faculty: Julie DeLoia, Ph.D
Title: The Role of Pharmacogenetics in Improving Outcome in Women with Ovarian
Cancer
The purpose of this proposal is to evaluate the influence of genetic polymorphisms in the
human multidrug resistance gene (MDR1), and two taxane metabolizing enzymes
(CYP2C8 and CYP3A5), on drug disposition in women with ovarian cancer. We hypothesize that a major contributor to resistance of patients with ovarian cancer to the therapeutic
effects of taxanes is common genetic polymorphisms in the genes encoding MDR1 and/or
the CYP enzymes. To test our hypothesis, we propose to: 1) evaluate the effect of tumor
genotype and gene expression of MDR1 and CYP genes on ex vivo sensitivity to
chemotherapeutics; 2) investigate the relationship between expression of CYP pharmacogenetic variables and the metabolism of taxanes by ovarian tumor cells; 3) utilize data generated from these two aims to conduct a prospective study to determine the effect of the genetic polymorphisms on gene expression levels and response to taxanes in newly diagnosed
patients with advanced ovarian cancer treated on standard clinical protocols of paclitaxel or
docetaxel.
23
Title: Noninvasive Assessment Of Cell Proliferation In Ovarian And Fallopian Tube
Cancer Using [F-18] FLT PET/CT Imaging
The hypothesis of this proposal is that [F-18] FLT PET provides reliable noninvasive
assessment of tumor cell proliferation in ovarian cancer. This proposal will involve a comparison of the relationship between [F-18] FLT tumor uptake in vivo with specific markers
of cellular proliferation in the tumors directly, after surgery. In this manner we will be able
to establish a biological basis for the observed [F-18] FLT PET/CT images. Therefore, this
proposal has two specific aims: To compare the regional uptake of [F-18] FLT in ovarian
cancer with histopathological tissue analysis and markers of cellular proliferation after
surgery.
To compare the correlation of different quantitative measures of tracer uptake with laboratory measures of cellular proliferation within the tumor.
Title: Isolation and characterization of ovarian cancer stem cells
Conventional therapy for ovarian cancer typically results in a majority of patients responding, as evidenced by tumor shrinkage, but then ultimately succumbing to the disease. We
hypothesize that there is a therapy-resistant cancer stem cell population that is the source of reemerging tumor. In preliminary studies we have been successful at isolating and growing
cells from ascites and tumor that have the phenotypic markers associated with stem cells in
other lineages. The objective of this program project is to combine the expertise of varied
scientists and clinicians to determine the functional properties of these presumed ovarian
cancer stem cells by determining whether cells isolated from ovarian cancer-associated
ascites and tumor that express phenotypic stem cell markers possess the functional properties of stem cells, proving that the isolated ovarian cancer stem cells are cancer cells by
forming tumors in vivo in immunocompromised mice, and characterizing the genetic perturbations in ovarian cancer stem cells.
Faculty: Bora E. Baysal, MD, Ph.D
Title: Genomic response to Progesterone and Ovarian Cancer
Ovarian cancer most often derives from ovarian surface epithelial (OSE) cells. Several lines
of evidence strongly suggest that progesterone exposure protects against ovarian cancer.
However, the underlying mechanisms of this protection are incompletely understood. Here,
we established short term in vitro cultures of non-neoplastic ovarian surface epithelial cells
from six subjects, exposed the cells to progesterone (10-6 M) for five days and performed
transcriptional profiling with oligonucleotide microarrays containing over 22,000 transcripts. We found that, in three of the six cultures, transcripts encoding 14 cholesterol
biosynthesis enzymes, insulin-induced gene 1, low density lipoprotein receptor, ABCG1,
endothelial lipase, stearoyl- CoA and fatty acid desaturases, long-chain fatty-acyl elongase,
and MAC30 were upregulated; steroidogenic acute regulatory protein and ABCC6 were
downregulated by progesterone. We confirmed the microarray results for a subset of the
genes by quantitative RT-PCR analysis, and in one of three additional ovarian surface
epithelial cell cultures. The cultures derived from a BRCA1 mutation carrier and another
subject with early-onset breast cancer showed no evidence of transcriptional response to
progesterone. These findings indicate that progesterone regulates a very broad network of
genes involved in cholesterol homeostasis in certain ovarian surface epithelial cells and provide new insights for understanding the protective role of progesterone against ovarian cancer. (Manuscript submitted for this project)
Future Plans: There are three specific aims to further understand the impact of progesterone on the neoplastic transformation of OSE cells: (a) Testing of OSE cells from women
with genetic predisposition to ovarian cancer, (b) testing of more normal women to understand the basis of variation in response to progesterone; (c) testing of neoplastic OSE cells
to determine whether progesterone responsiveness is retained or lost upon transformation.
24
Title: Epigenetic regulation of mitochondrial complex II
Background:
Inherited gene mutations encoding three of the four subunits of mitochondrial complex II
cause familial predisposition to hereditary paraganglioma (PGL). PGL is characterized by
the development of vascularized tumors, in the head and neck and abdomen, which derive
from oxygen sensing cells. How mitochondrial defects could lead to tumor formation is a
mystery, because mitochondria are primarily involved in energy production. Mutations in
the smallest subunit of complex II, encoded by a gene named SDHD, are the primary cause
of head and neck paragangliomas. Mutations in SDHD cause tumors when they are transmitted from a father to his children, but no tumor development is seen if the mutations are
transmitted from a mother. This phenomenon is known as genomic imprinting. Genomic
imprinting causes differences in the function of genes depending on its parental origin. The
mechanism of imprinting in PGL is unknown. Recently, we have also found that SDHB is
subject to RNA editing in peripheral T lymphocytes. RNA editing changes coding potential of a transcript at the RNA level, while leaving the DNA sequence unchanged. This
research has been funded for five years by National Cancer Institute.
Methods:
The specific aims include determination of molecular signs of genomic imprinting such as
gene expression and DNA methylation differences, which are commonly observed around
other imprinted genes. These molecular signs often distinguish the maternal and paternal
copies of an imprinted gene. We will also study another mechanism of gene control, called
transcript editing, as another means of controlling the amount of mitochondrial complex II
in the cell.
Results:
Although most of the genes in the vicinity of the SDHD gene at chromosome 11q23 show
no evidence of imprinting, we have found a differentially methylated gene at the boundary
of the SDHD domain. We found that RNA editing operates in both normal and neoplastic
cells.
Future Plans:
This research is ongoing and we plan to test for parent-of-origin effects to determine
whether differential-methylation we identified is relevant to genomic imprinting.
Understanding the molecular basis of imprinting in PGL may provide general insights how
expression of a single defective gene leads to disease or normalcy. Also further research is
underway to find the association of RNA editing with T cell activation.
Faculty: Lih-Ching Hsu, Ph.D
Title: Centrosome abnormalities in ovarian cancer
The long-term goal of this research project is to understand the origin and consequence of
centrosome abnormalities in ovarian tumorigenesis and to evaluate the potential clinical
application in diagnosis, prognosis or treatment of ovarian cancer. Centrosome abnormalities have been found in various cancer types including breast, colon, pancreas, and prostate,
and may be involved in early development of cancer and associated with tumor progression.
Centrosome abnormalities have not been evaluated in ovarian cancer. We will determine
whether centrosome dysfunction is involved in ovarian tumorigenesis, and whether it could
be used as an indicator for early detection and/or prognosis of ovarian cancer. Germline
mutation of the BRCA1 gene is a major risk factor for the development of hereditary ovarian cancer. Deficiency of Brca1 leads to centrosome amplification in mouse embryonic
fibroblasts. It is of interest to test whether BRCA1 dysfunction causes centrosome defects
in human ovarian epithelial cells and consequently causes predisposition to ovarian tumorigenesis.
25
Specific Aim 1. Determine whether centrosome abnormalities occur in ovarian tumors.
Specific Aim 2. Determine whether BRCA1-deficiency alone can induce centrosome defects
in ovarian epithelial cells.
Title: Functional interaction between PP1 and BRCA1
Tumor suppressor BRCA1 plays an important role regulating fundamental cellular functions, such as cell cycle progression and DNA repair. The phosphorylation status of
BRCA1 is tightly associated with its functions. Protein kinesis involved in DNA damage
checkpoint control, such as ATM, ATR, and hCds1/Chk2, have been shown to phosphorylate and activate BRCA1 upon DNA damage. We have recently reported for the first time
that a protein phosphatase, protein phosphatase 1n, interacts with and dephosphorylates
BRCA1 phosphorylated by hCds1/Chk2. Protein phosphorylation /dephosphorylation usually serves as an on/off switch to control important cellular events. We hypothesize that
PP1 negatively regulates BRCA1 functions in DNA repair and G2/M checkpoint control
by dephosphorylating BRCA1. We will investigate the detailed mechanisms and functional
consequences of PP1-mediated dephosphorylation of BRCA1. Specific aims are:
1. Test the role of PP1n in the regulation of cell cycle progression and BRCA1
phosphorylation following DNA damage.
2. Determine the functionality of the PP1-binding site in BRCA1.
3. Study how the BRCA1/PP1 complex is regulated.
26
TEACHING PROGRAMS
The division members are dedicated to the education of health care providers. Teaching for
the Division includes the following group of individuals:
1. Gynecologic Oncology fellows
2. Residents in Obstetrics, Gynecology and Reproductive Sciences
3. Chatham College Physician Assistant Program
4. Medical students of the University of Pittsburgh
5. Visiting Surgical Oncology fellows
6. Community education in women’s health
Teaching activities occur in didactic lecture setting, in small problem based learning groups,
in our outpatient offices, the inpatient units, and in the operating room. Education centers
around the diagnosis and treatment of gynecologic and breast malignancies. The faculty
hopes to impart an understanding of the pathophysiology of the disease process as well as
therapeutic interventions. The faculty members emphasize preoperative and postoperative
management as well as surgical technique. An effort is made to expose students to the complexities of outpatient management with patients afflicted with oncologic problems.
Tumor Board
The Division of Gynecologic Oncology sponsors a weekly multi-disciplinary Tumor Board
that focuses on patient management issues and current trends in gynecologic oncology.
Individuals within the subspecialties of gynecologic oncology, medical oncology, radiation
oncology, radiology, pathology, patient care services and social work attend it. Clinical
dilemmas, controversial and unusual patient cases are selected by the attending staff and
discussed by the participants. Radiographic and pathologic findings are correlated with the
clinical findings. The attendees discuss rationale for an approach to the clinical problem.
This Conference allows discussion of different approaches to the problems encountered in
gynecologic oncology. The opportunity to recruit patients within research protocols occurs
during this meeting.
In the past year, the conference has been revamped to include PowerPoint presentations of
all cases, the use of “mini-debates” and the encouragement to discuss patients in a prospective fashion. A didactic lecture series has been started to compliment this important conference.
Didactic Lecture Series in Gynecologic Oncology
A recent addition has been a weekly core lecture series covering topics in the field.
Presentations by the attending staff and colleagues in other subspecialties enhance the educational experience of the attendees. The second and third year residents are assigned a
topic to discuss and an attending faculty mentors them.
Journal Club
Every six weeks a divisional Journal Club is held to discuss timely and controversial topics
in the field of Gynecologic Oncology. The attending staff and/or the house staff choose
topics. An attending physician and senior resident moderate the session.
Ob/Gyn Patient Safety Conference
Under the direction of Dr. Joseph Kelley, an Ob/Gyn Patient Safety Conference has been
established and occurs every 6 weeks during the Thursday morning Core Lecture Series.
The primary goal of the conference is the identification and management of complications
of obstetrical and gynecological care. The house staff are encouraged to identify patient
events of concern. A list is generated of events and presented at the conference. Four to five
cases are discussed in detail with subsequent suggestions from the house staff and attendings.
Fellowship
The Division has an American Board of Obstetrics and Gynecology (ABOG) approved fellowship in gynecologic oncology. We offer one position per year for a three-year fellowship
in Gynecologic Oncology. Fellows will obtain advanced clinical and research training, with
participation in the core Clinical Research Training Program. In addition, a variety of
tracks are available should the fellow wish to pursue a Master of Science in Clinical
Research. Fellows will gain exposure to NIH-funded trials through the Gynecologic
Oncology Group (GOG), Radiation Therapy Oncology Group (RTOC), and many other
ongoing clinical and basic research projects. Clinical training is enhanced by active multidisciplinary collaboration with the Departments of Obstetrics and Gynecology, Radiation
Oncology and Surgical Oncology (at UPMC Shadyside). In January of 2006, the division
underwent an audit from the American Board of Obstetrics and Gynecology and received
continued approval of the program for 3 years.
CLINICAL PROGRAMS
The past year has been one of transition with four faculty joining the division. As rapid
expansion has allowed us to improve access to care for women of Southwestern
Pennsylvania for treatment of gynecologic and breast malignancies. The faculty is energized and dedicated to its mission.
• The cancer program at Magee-Womens Hospital has continued to expand with patients
being diagnosed and/or treated over the past 5 years.1
2000 2001 2002 2003
1362
1632
1745
1875
Geographical Breakdown
2004
1876
2005
2007
• As a large referral center, the hospital provides service to many western Pennsylvania
counties and surrounding states. The 2-year cancer patient population in Allegheny
County equaled 51% in 2003 and 49% in 2004. Out-of-county patient population was
43% in 2003 and 44% in 2004, with Westmoreland, Washington, and Butler counties
referring the largest number of patients for both years. Out-of-state total patient popula
tion was 6% in 2003 and 7% in 2004.1
27
• The total number of patient’s seen in the Gynecologic Oncology outpatient office for the
last 4 years are:
New Patients
Return Patients
Chemotherapy Visits
Consults
FY02
971
4472
656
—
FY03
1168
3353
337*
—
FY04
951
3194
363
341
FY05
702
3564
440
288
FY06
684
4602
851
623
* This number has decreased because we have stopped seeing patients every time they get chemotherapy.
The total estimated charges and payments for the Division for FY06 is as follows:
• Charges . . . . . . . $6,224,530.00
• Payments . . . . . $1,878,548.00
Established clinical initiatives include:
• Ovarian Cancer Assessment and Surveillance Program
• Ovarian Cancer Center of Excellence
• Tissue Procurement Program
• Gynecologic Oncology Fellowship
• Outreach programs to Erie, Uniontown, Moon Township, Cranberry Township, Latrobe
Clinical initiatives that are in the developmental phase include:
• Recruitment of Clinical and Research Staff
• Palliative care program
• Outreach programs to Johnstown and Franklin
• Development of a Clinical Fellowship in Breast Oncology
• Wellness Programs for cancer survivors
• Complimentary Medicine Program for cancer patients
FACULTY LISTING
Joseph L. Kelley, MD
Robert P. Edwards, MD
Associate Professor,
Professor,
Department of Obstetrics,
Gynecology and Women’s Health
Director, Division of Gynecologic Oncology
Vice Chair, Clinical Affairs
Director, Fellowship Program
Director, Gynecologic Oncology Research
Thomas C. Krivak, MD
Assistant Professor
Assistant Professor
Kristin K. Zorn, MD
Assistant Professor,
Department of Obstetrics, Gynecology and Women’s Health
Julie DeLoia, Ph.D
Associate Professor
Dept. of Ob/Gyn
& Women’s Health
Research:
Bora Baysal, MD, Ph.D
Assistant Professor
Dept. of Ob/Gyn
& Women’s Health
Lin-Ching Hsu, Ph.D,
Assistant Professor
Dept. of Ob/Gyn
& Women’s Health
WEBSITE: obgyn.medicine.pitt.edu/oncology
28
DIVISION OF MATERNAL FETAL MEDICINE
OVERVIEW
The primary goals of the Division of Maternal-Fetal Medicine are:
• The conduct of clinical and basic research into the basis and
treatment of diseases affecting pregnant women and their infants.
• The provision of the highest quality clinical care for patients with
complications of pregnancy.
Steve Caritis, MD
Division Director
• The education of private practitioners, fellows in Maternal-Fetal
Medicine, residents, medical students and other healthcare
providers.
RESEARCH PROGRAMS
The research activity of the Division is broad-based and well funded. In fact, the Division
received $3.7 million in federal research grants in 2003-2004, far more than entire departments of OB/GYN, including those at Johns Hopkins, Washington University, Wayne
State, Wake Forest, University of North Carolina and Duke, just to name a few. The
Division of Maternal-Fetal Medicine is composed of seven clinically active specialists; three
of whom direct active research programs. In addition, the Division has five MD or Ph.D
research faculty who are housed at the Magee Womens Research Institute. The clinical faculty who are active in research have appointments in the MWRI. The research foci of the
Division includes, but is not limited to:
· preterm birth – specifically a) the role of infection &inflammation) pharmacology of labor
inhibiting agents and c) gene-environment interactions
· preeclampsia – a) etiologic factors b) preventative therapy and c) predictive factors.
diabetes and pregnancy – a) impact on endothelial cell function, b) cardiovascular risk factors and c) impact on the fetus
· renal disease in pregnancy – specifically, a) the role of renin in regulation of renal blood
flow and b) the impact of immune disorders on renal function
smoking – a) impact on endothelial function and b) interventions for reducing smoking
rates
· maternal-fetal pharmacology – our focus in this area stems from membership in the
NICHD-sponsored Obstetrical-Fetal Pharmacology Research Unit. This group focuses on
drugs, especially their pharmacology in pregnancy.
· Complications of pregnancy - Maternal-Fetal Medicine Units (MFMU) – as a member of
the Network, much of the Divisional research encompasses studies that focus on uncommon problems in pregnancy. The Network represents over 100,000 deliveries enabling
clinical trials to be performed on uncommon diseases affecting pregnant women.
· Disparities in pregnancy outcomes
The Division has been highly successful in obtaining external funding for its research.
These include fundamental and mechanistic studies which are complimented by considerable strength in the clinical arena particularly in the areas of infectious diseases, preterm
labor and preeclampsia. Recent funding by the clinical research faculty includes an NIH
grant to Dr. Steve Caritis to study Maternal Fetal Pharmacology, only four sites being
funded for this new Network. In its third year is an NIH funded grant to MJ Krohn, Steve
Caritis and Hyagriv Simhan to study cytokine polymorphine and environmental factors in
29
preterm birth. Dr. Caritis continues as the longest tenured member of the Maternal-Fetal
Medicine Network. He and Dr. Simhan were awarded a supplementary grant to study
pharmacology of 17-hydroxyprogesterone caproate in twins and triplets.
Dr. Simhan was awarded an NIH-R01 grant to study “Nutrition and the Genetics of
Prematurity. Dr. Simhan recently served on an Institute of Medicine Committee, which
reported on “Understanding Premature Birth and Assuring Healthy Outcomes.”
Dr. Arun Jeyabalan has been selected as a scholar in the NIH funded faculty development
program, Building Interdisciplinary Careers in Womens Health Research (BIRCWH). She
is mentored by Dr. Kirk Conrad and will study the role of matrix metalloproteases in regulating renal blood flow in pregnancy. She is also investigating the role of relaxin in
preeclamptic pregnancies.
Dr. James Roberts heads the largest NIH funded program to study mechanism of
preeclampsia. This Program Project Grant, “Preeclampsia: Mechanisms and Post-pregnancy Implications” includes projects headed by several members of the division. In keeping
with the emerging multidisciplinary focus of the NIH, it also includes faculty from the
schools of Engineering, Nursing and the Graduate School of Public Health as well as
Developmental Biology faculty from the University of California at San Francisco. He also
is working with the NICHD Maternal Fetal Medicine Network heading a clinical trial of
antioxidant therapy jointly funded by the NICHD and the NHLB1 in which 10,000
women will receive Vitamins C and E or placebo from early pregnancy to attempt to prevent preeclampsia. Attached to this study will be the largest longitudinal study of the pathogenesis of preeclampsia ever carried out in which 4,000 women in the study will be examined throughout the pregnancy.
While exploring the role of hypoxia in preeclampsia, Augustine Rajakumar, Ph.D from
the Division of MFM found the placentas from preeclamptic pregnancies contain an overabundance of molecules that act in response to hypoxia to alter cellular function. They also
found that the regulation of these molecules is fundamentally different in placentas from
preeclamptic pregnancies. Their goals are now to determine why this occurs and whether
this abnormality causes the disease.
Several other exciting areas related to maternal health are being explored by members of
the Division of MFM. Arun Jeyabalan, MD., has found evidence that the hormone, relaxin,
is important for the increased renal blood flow that occurs in pregnancy. They are identifying the cellular signaling cascade involved in this response with particular focus on vascular
gelatinase and extending their studies to ask whether relaxin may be the agent responsible
for the general vasodilatation, increased blood flow and arterial compliance that characterizes normal pregnancy, particularly during early stages (also in collaboration with Dr.
Sanjeev Shroff in Bioengineering, University of Pittsburgh). In other pre-clinical studies,
Dr. Conrad and colleagues are evaluating relaxin as a therapeutic agent to combat vasoconstriction and stiff arteries in the non-pregnant population as well as testing the novel concept that relaxin is a vascular-derived, locally acting relaxing and compliance factor (the latter also in collaboration with Laura J. Parry, University of Melbourne, AU). Dr. Conrad
collaborates with John Davidson, MD and Marie Smith, MD of the University of
Newcastle upon Tyne UK on clinical physiology studies related to relaxin.
30
Carl A. Hubel, PhD, focuses on the role of lipid metabolism and free radical reactions in
human health and disease, particularly in regard to the pathogenesis of preeclampsia. He is
the Principal Investigator on two human subject research studies conducted at the MageeWomens Hospital Clinical Research Center (“Lipoprotein Lipase and Preeclampsia”; and
“Endothelial Progenitor Cells and Preeclampsia”). These studies test the hypothesis that
pregnancies complicated by preeclampsia may identify subsets of women at risk of vascular
disease in later life and may provide the opportunity for lifestyle and risk factor modification to alter this vascular disease risk. He has found evidence of altered lipid metabolism,
insulin resistance, and imbalances in angiogenic factors in postpartum women with a history of preeclampsia. Such findings may help to explain the increased cardiovascular risk in
women who have had preeclampsia.
Dr. Hubel is the P.I. on a related project (RO1 HL64144) that focuses on the impact of
lipoprotein lipase (LPL) deficiency on vascular function. Using the LPL knockout mouse,
one aim of this project tests the hypothesis that heterozygous LPL deficiency adversely
affects endothelial cell regulation of blood vessel function, and that pregnancy accentuates
these adverse effects.
Dr. Hubel and colleagues were the first to formally propose that oxidative stress is a key
factor in the progression of preeclampsia (1989). Human and animal studies by Hubel and
colleagues and by other groups have affirmed this link.
Dr. Hubel is the P.I. on newly funded research (R21 HD09453) that tests he hypothesis
that increased mobilization and activity of maternal bone marrow-derived endothelial progenitor cells contributes to the adaptive cardiovascular changes of normal pregnancy and
that dysfunction of these cells contributes to preeclampsia.
Augustine Rajakumar, Ph.D is a co-investigator in the preeclampsia program project
(PO1-HD30367) working with Dr. Conrad to characterize placental hypoxia in order to
better understand the pathology of preeclampsia. Protein degradation machinery in
preeclamptic placentas may be compromised thus resulting in the accumulation of the
hypoxia inducible transcription factors that is a ‘master regulator’ of many other physiologically important genes.
TEACHING PROGRAMS
Division members are active participants in all aspects of teaching including medical students, residents, fellows and private practitioners. Dr. Simhan received the Association of
Professors of Gynecology and Obstetrics (APGO) and Council of Resident Education in
Obstetrics and Gynecology AWARD for EXCELLENCE in resident education. Dr.
Jeyabalan received the Association of Professors of Gynecology and Obstetrics (APGO)
AWARD for EXCELLENCE in medical student education and the annual Residents
Teaching Award for excellence in education.
Medical students - All faculty participate in the Reproductive Biology Course which is
directed by Division member Ashi Daftary, MD. Division members also participate in
numerous other courses for the first and second year medical students. All faculty are
involved in the Problem-Based Learning sessions which are held with students during their
rotation on Obstetrics.
Students are also integrated into the private practice of the Maternal-Fetal Medicine
Division and received bedside teaching in the labor suite and antepartum wards. Teaching
of the medical students throughout their rotation on Obstetrics. Fourth-year students
rotate on Obstetrics and receive supervised training in normal and complicated obstetrics.
Dr. Robert Kaminski provides one-on-one teaching to medical students and residents in
labor and delivery and postpartum units.
Residents - Every resident rotates through the Obstetrics rotation twice annually. They
are in continuous contact with an MFM Division member as three members are on
Obstetrics at any one time. Teaching is not limited to the daytime since a Division member
is in the hospital 24-hours a day, seven days a week. All deliveries are attended by Division
members so teaching occurs continuously. Sign-out conferences are held twice daily at 7
a.m. and 5 p.m. in the labor suite and antepartum rounds are held three times weekly.
31
Formal conferences in Obstetrics are held every Thursday.
Fellows - The fellowship program in Maternal-Fetal Medicine is generally recognized as
one of the strongest nationally and we continue to attract strong candidates. Currently six
fellows are in the program. Next year two new fellows will join us. The fellowship has been
approved since 1975 and was recently reevaluated in 2003 and approved again for five years.
CLINICAL PROGRAMS
The Maternal-Fetal Medicine Division provides high-risk pregnancy services to several categories of patients.
• Private patients of the MFM group – this group results in about 300 deliveries a year.
• Pregnant women with complications who are transferred to Magee for care - this group
accounts for about 425 patients a year
• Resident cases - this group results in approximately 1800 deliveries per year.
• Midwifery patients - the Division provides supervision and consultation to the midwife
practice.
• Consultation services to private physicians – the services provided include ultrasound, fetal
testing, amniocentesis, peri-umbilical blood sampling, chorionic villus sampling and
medical surveillance of women with medical or obstetrical complications of pregnancy.
The Division has established three Centers of Excellence dealing with complications of
pregnancy.
The Center for Diabetes in Pregnancy provides teaching and management of pregnant
women with diabetes. Over 300 patients have been evaluated by the Center over the last
two years making it the largest such center in the region.
Hyagriv Simhan, MD has established a Center for Prematurity that evaluates women with
risk factors for preterm birth or a recent episode of preterm birth. This Center sees more
than 200 women annually.
Arun Jeyabalan, MD has established the Renal and Rheumatological Disorders in
Pregnancy Center along with the divisions of rheumatology and nephrology. This Center
manages women with these pregnancy disorders with subspecialties in the specific diseases.
Each of these Centers provides a rich environment for teaching or residents, medical students and fellows.
The Division supports five certified nurse midwives, Shannon McCabe, CNM, Christina
London, CNM, Tanya Walter, CNM. Carol Washnock, CNM and Emily DeFerrari,
CNM. These certified nurse midwives provide
Care of obstetrical patients of high risk is provided at the following sites:
Magee-Womens Hospital. An outpatient facility for private patients is staffed five days a
week, the resident’s Ambulatory Care Clinic is also staffed by a specialist in Maternal-Fetal
Medicine.
32
FACULTY:
Steve Caritis, MD
Ashi Daftary, MD
Daniel Edelstone, MD
Robin Gandley, Ph.D
Carl Hubel, Ph.D
Arun Jeyabalan, MD
James Roberts, MD
Robert Kaminski, MD
Robert Powers, Ph.D
.Augustine Rajakumar, Ph.D
Margaret Watt-Morse, MD
MFM FELLOWS:
Brenna Anderson, MD
Alison Durica, MD
Hilary Gammill, MD
David Hackney, MD
Carol Lin, MD
Robert C. Moore, MD
Kristiina Parviainen, MD
MIDWIVES:
Emily DeFerrari, CNM
Tina London, CNM
Nicloe Rawson, CNM
Nicole Rawson, CNM
Shannon McCabe, CNM
Tanya Walter, CNM
WEBSITE: http://obgyn.medicine.pitt.edu/maternalfetal
33
34
DIVISION OF REPRODUCTIVE ENDOCRINOLOGY AND FERTILITY
DIVISION OF REPRODUCTIVE ENDOCRINOLOGY AND INFERTILITY
OVERVIEW
Joseph Sanfilippo, MD
Division Director
The Center for Fertility and Reproductive Endocrinology
continues to be a premier program offering all aspects of reproductive health care. The program covers the span of care beginning
with pediatric and adolescent gynecology, proceeding to infertility
evaluation and management, in vitro fertilization, acupuncture and
menopause related care. In addition to patient care, the division
faculty is actively involved with research related to reproductive
health care. Our program has expanded exponentially over the past
several years and continues to provide unprecedented state of the
art care.
The specific services provided include:
• Acupuncture
• Amenorrhea
• Endometriosis
• Hirsutism
• Infertility and Assisted Reproductive Technology
— Ovulation Induction and Intrauterine Insemination
— Stress-induced Infertility
• In Vitro Fertilization
— Preimplantation Genetic Diagnosis
— Assisted Hatching
— Donor Program; Sperm & Oocytes
— Intracytoplasmic Sperm Injection
• Midlife (Menopause) Center
• Minimally Invasive Surgery
• Pediatric and Adolescent Gynecology
• Polycystic Ovarian Syndrome
• Prolactin Disorders
• Pubertal Disorders
• Recurrent Pregnancy Wastage
• Reproductive Tract Abnormalities
RESEARCH PROGRAMS
Basic Science research is conducted in collaboration with the Center for Research in
Reproductive Physiology in association with the Department of Physiology. The Center is
headed by Dr. Tony Plant and Dr. Tony Zeleznik, both of whom hold joint appointments
in our division. Other basic science research includes Dr. Elizabeth McGee who conducts
her work in the Magee-Womens Research Institute. Her area of interest is focused on
ovarian physiology and she has further developed the Program for Fertility in Cancer
Survivors. Dr. Brinda Kalro has been involved with work associated with ovarian cryopreservation in a primate model. This complements work focused on molecular and cellular
avenues critical to fertilization and embryogenesis. Study outcomes related to assisted
reproduction and exploration of molecular and cellular mechanisms mediating infertility,
fertilization and embryogenesis.
Ongoing research includes assessment of pelvic pain in adolescents, new agents for adhesion prevention and alternative stimulation protocols in low responders undergoing con35
trolled ovarian hyper-stimulation as well as in vitro fertilization. The division has been
awarded a number of NIH grants.
Clinical Research is conducted in the Magee Clinical Research Center funded by the satellite mechanism through the GCRC.
The following faculty member’s conduct federally funded clinical research: Drs. Elizabeth
McGee, Tony Plant and Anthony Zeleznik. As noted above, Dr. Plant and Dr Zeleznik
have secondary appointments in the Department. Investigator-initiated research that is
wholly or partially funded by industry is conducted by Drs. Brinda Kalro, Joseph Sanfilippo
and Anthony Wakim.
Research Summaries
Joseph S. Sanfilippo, MD M.B.A.-Professor, Department of Obstetrics, Gynecology and
Reproductive Sciences, The University of Pittsburgh School of Medicine, Vice Chairman
of Reproductive Sciences, Division Director for Reproductive Endocrinology and Infertility
at Magee-Womens Hospital.
Dr. Sanfilippo conducts clinical research focused on adolescent gynecology as well as minimally invasive surgery. Currently he is conducting a Pivotal Clinical Trial to determine the
Safety and Efficacy of Oxiplex Gel for Reduction of Postoperative Adhesions following
Laparoscopic Gynecological Surgery sponsored by Fziomed and a Randomized, multi-center Double Blind Exploratory Study to Evaluate the Efficacy of an Extended Cycle
Combination Oral Contraceptive, DP3-84/10, which utilizes Ethinyl Estradiol during the
usual hormone-free interval compared to placebo for the treatment of Cyclic Pelvic Pain
in Adolescents sponsored by Duramed/Barr Laboratories.
Over the current academic year, Dr. Sanfilippo has served as President of The American
Society for Reproductive Medicine and Scientific Program Chair for the American College
of Obstetricians and Gynecologists annual clinical meeting. He also serves on the Federal
Drug Administration Ob-Gyn New Devices Committee.
Gabriella Gosman, MD Assistant Professor, Obstetrics and Gynecology Residency
Program Director, Department of Obstetrics, Gynecology and Reproductive Sciences.
Dr. Gosman’s clinical practice consists of infertility diagnosis and management including
ovulation induction. She provides care for patients with reproductive endocrine and menstrual disorders such as polycystic ovary syndrome and amenorrhea.
Dr. Gosman is Residency Program Director. Her research focuses on current issues in resident training. She is course director of the Obstetric Crisis Team Training Course at the
WISER Simulation center. Research related to this course focuses on whether team training in obstetric emergencies improves provider performance, process of care and patient
outcomes. Other educational research projects include residency program directors’ experience with resident discipline and Balint Groups’ role in ob/gyn residency training.
Brinda N. Kalro, MD - Assistant Professor, Department of Obstetrics, Gynecology and
Reproductive Sciences.
Dr. Kalro is a clinical researcher and has a 20% research effort to compliment 80% focused
on clinical duties.
36
Dr. Kalro has a growing clinical practice that includes the management of women with
endocrine disorders, menopause, osteoporosis and infertility. Dr. Kalro is also a certified
Medical Acupuncturist having successfully completed the training program in Medical
Acupuncture for Physicians at UCLA in 2004. She offers acupuncture for a wide variety of
medical, gynecologic and endocrine conditions, including infertility, as an adjunct to cur-
rent allopathic treatment options. She has coordinated a program with Dr. Judith Balk
focused on providing acupuncture for infertility patients.
Dr. Kalro also recently completed her basic training in Mind-Body Medicine followed by
advanced training in the Infertility Program, at the Mind Body Medical Institute, Harvard
Medical School. She will start the first series of Mind-Body sessions for infertility patients
in October 2006, to help them deal and cope with the stressors associated with the inability
to conceive.
Given her expertise in menopausal and perimenopausal health related issues, in addition to
the above, Dr. Kalro is now also involved with the Midlife Health Center.
She joined the primate ART program last year under the auspices of Dr. Gerald Schatten at
the PDC, MWRI, her primary role and research focus consisting of providing endocrine
and surgical expertise related to ART.
Elizabeth McGee, MD- Assistant Professor, Department of Obstetrics, Gynecology and
Reproductive Sciences and Department of Cell Biology and Physiology and McGowan
Center for Regenerative Medicine. Dr McGee continues to contribute to understanding
the physiology and pathophysiology of ovarian follicle development. She is funded with
NIH grants RO1 HD 045700 through NICHD focused on preantral follicle development.
Dr. McGee has support from the Pittsburgh Tissue Engineering Initiative allowing her to
pursue research predicated upon in vitro methods of ovarian follicle maturation. She has
received additional support from NIBIB. Ongoing collaboration with Drs. Tony Zeleznik,
Steve Badylak, Mark Nachtigal and Winston Thomas has allowed her to study ovarian
function as part of the Moorehouse College of Medicine and Dalhousie University associated grants.
Dr. McGee maintains a clinical practice focused on the major areas related to Reproductive
Endocrinology and Infertility. She is the attending physician for the Reproductive
Endocrinology Magee-Womens Hospital clinic. Over the past year much progress has been
made regarding the Fertility in Cancer Survivors program which Dr. McGee initiated. The
focus of this program ranges from Andrology, sperm preservation and includes options for
women of reproductive age diagnosed with cancer. The program addresses the current
American Society for Reproductive Medicine (ASRM) recommendations for fertility counseling in patients diagnosed with cancer.
Anthony Wakim, MD- Associate Professor, Department of Obstetrics, Gynecology and
Reproductive Sciences and Director of Assisted Reproductive Technologies.
Dr. Wakim oversees the Assisted Reproductive Technology program. Over the past year,
preimplantation genetic diagnosis (PGD) has expanded to offer the latest technical
advances with respect to quality of care for couples with genetic disorders, recurrent spontaneous abortions and advanced maternal age. Dr. Wakim’s clinical studies are predicated
upon studying the efficacy of GnRH antagonists compared to GnRH agonists in low
responders undergoing stimulation for in vitro fertilization; he is principal investigator in a
randomized clinical trial designed to evaluate GnRH agonists vs. human chorionic
gonadotropin in assisted reproductive technologies. Dr. Wakim has been involved in a
Multi-center, Randomized, Open-Label, Parallel Group study of a Vaginal Micronized
Progesterone Tablet (Endometrin) Compared to Crinone 8% Vaginal Gel in Female
Patients Undergoing In-Vitro Fertilization (IVF). He has also completed a phase IV study
comparing Cetrotide vs. Ganirelix in inhibition of premature LH surge with stimulated
cycles.
37
TEACHING PROGRAMS
The Division continues to conduct a very well received elective for MS-4 students. The
student works one on one with faculty in an office practice setting, actively participates in
surgical procedures performed by division faculty and related REI procedures. In addition
the rotation includes exposure to assisted reproductive technology/in vitro fertilization as
well as involvement in the didactic segment of divisional activities.
Resident Education
Rotations at the PGY 1, PGY 2 and PGY 3 levels occur throughout the academic year.
Resident education is an integral part of divisional activities. Residents work one-on-one
with division faculty in an outpatient setting focused on case management, inpatient related
activities as well as in the operating room. Overall supervision of residents on rotation is
orchestrated by Dr. Gabriella Gosman. An integral part of resident education includes use
of pelvic trainer models, both animate and inanimate aspects. This is supervised by division
faculty and the program is designed to develop and enhance resident technical skills. Dr.
Gosman has participated in national minimally invasive surgical education programs coordinated by the American Association of Gynecologic Laparoscopists. There is a supervised
Reproductive Endocrinology resident clinic conducted under he auspices of Dr. Elizabeth
McGee. Resident education in Minimally Invasive Surgery (MIS) has been expanded to
include a dedicated MIS rotation at the senior PGY level. In addition, a didactic program is
conducted for residents on rotation within the division.
Fellowship
Minimally Invasive Surgery (MIS) is an integral part of the division and is coordinated with
the Division of Gynecologic Specialties. The major area of emphasis is on laparoscopic and
hysteroscopic surgical procedures. A competitive MIS fellowship is offered at one position
annually. The program mandates completion of a MIS-research related project and acquiring advanced endoscopic surgical skills. Fellows completing the MIS program uniformly
proceed into academic focused careers.
CLINICAL PROGRAMS
The clinical activities of the Division of Reproductive Endocrinology and Infertility (REI)
are primarily conducted within the Center for Fertility and Reproductive Endocrinology
(CFRE), which is a discrete clinical area located within Suite 5150 of Magee-Womens
Hospital. The Center houses a most successful Assisted Reproductive Technology-In Vitro
Fertilization program. The CFRE serves as the primary clinical practice site for faculty
members in the Division of REI. Infertility and reproductive services are provided for
referrals throughout western Pennsylvania, eastern Ohio and West Virginia areas.
Patients with reproductive endocrine related diagnoses fall into one of the following four
(4) main categories: infertility, menopause, reproductive endocrinology and those requiring
minimally invasive surgery related to infertility.
The Assisted Reproductive Technologies (ART) program continues to be the premier center in the region. It is currently under the direction of Dr. Anthony Wakim. The ART program focuses on over 260 cycles per year. Over the past academic year we have expanded
the Preimplantation Genetic Diagnosis (PGD) aspect of the program. This technological
advance allows couples with genotypic abnormalities to identify genetically normal embryos
for intrauterine transfer.
38
Over the past academic year, The Midlife Center has expanded the number of new patients
evaluated. This joint venture with the Division of Gynecologic Specialties provides unique
care for women beginning in the peri-menopausal years on up to the elderly. The program
is housed within the CFRE.
Pediatric and Adolescent Gynecology
Care of patients from birth through age 22 is the realm of pediatric and adolescent gynecology. The unique problems in girls prior to reaching puberty require special experience
and expertise. Common problems include vaginal bleeding, abnormal vaginal discharge and
anatomic reproductive tract abnormalities. Each aspect of the delivery of gynecologic care
in these age groups is designed to meet the need of the pediatric or adolescent patient. In
collaboration with the Division of Adolescent Medicine within the Department of
Pediatrics, these patients are provided a unique level of care. The guidelines provided by
The American College of Obstetricians and Gynecologists as well as The North American
Society for Pediatric and Adolescent Gynecology serve to provide recommendations currently followed by the faculty. The program is held at a satellite clinic facility for Children’s
Hospital. The Department of Obstetrics, Gynecology and Reproductive Sciences houses
the one peer review journal focused on gynecologic care in this age group, viz. The Journal
of Pediatric and Adolescent Gynecology.
FACULTY LISTING
Joseph S. Sanfilippo, MD, M.B.A - Division Director
Gabriella G. Gosman, MD – Residency Program Coordinator
Brinda Kalro, MD
Elizabeth McGee, MD
Anthony Wakim, MD – Medical Director of Assisted Reproductive Technology
Tony Plant, Ph.D
Tony Zeleznik, Ph.D
39
40
DIVISION OF REPRODUCTIVE GENETICS
OVERVIEW
The Division of Reproductive Genetics provides genetic counseling and clinical evaluation to individuals who are concerned about
their genetic background and the possible effect it may have on
their health or reproductive future. The Division’s research is
focused in three areas: etiology of recurrent pregnancy loss, noninvasive methods of screening for Down syndrome and other
chromosomal abnormalities in pregnancy, and mechanisms of cancer predisposition.
Brian Clark, Ph.D, MD
Division Director
RECRUITMENT
On July 1, 2006 Dr. Marta Kolthoff joined the Division of Medical
Genetics and Ultrasound as an Assistant Professor in the Department of Obstetrics,
Gynecology and Reproductive Sciences. She comes to us having completed a fellowship in
Medical Genetics at Magee-Womens Hospital through the University of Pittsburgh. She has
particular interests in prenatal diagnosis and bioethics, with an emphasis on the ethical, legal
and social implications of pre-implantation genetic diagnosis.
RESEARCH PROGRAMS
The Division continues to have a focus of research in three specific areas. The first area is
in the etiology of recurrent spontaneous abortion. Previous studies in our Division have
shown a link between non-random X inactivation and recurrent pregnancy loss. Studies are
now underway to better clarify the meaning of the skewed inactivation, and to also assess
the association of recurrent pregnancy loss with various genetic polymorphisms on the X
chromosome and other chromosomes.
The second area of interest is in non-invasive screening for chromosome abnormalities.
Results of a multi-centered study (in which our division and the ultrasound division participated) of first trimester screening using combined ultrasound and serum analytes found that
more than 85% of Down syndrome pregnancies could be detected using this approach.
Studies are now underway to determine the ease with which this form of screening can be
introduced into clinical practice, and to look at additional modifications to enhance the
detection rate and diminish the false positive rate. Likewise, the implications of abnormal
first-trimester screens on other obstetric and genetic complications are being evaluated.
The third area of interest is in the genetic basis of tumor formation. Dr. Hu has been interested in the use of comparative genomic hybridization and expression microarrays to identify candidate molecular markers for the precise diagnosis of ovarian tumor types, and potentially to develop prognostic profiles. Further studies are underway to better define the differentially expressed genes. Likewise, Dr. Latimer is interested in the genetic basis for the
development of breast cancer, and has been able to show abnormalities in DNA repair in
the apparently normal adjacent tissue to that of the tumor. These findings have major
implications for our understanding of how breast cancer develops.
The Division had nine peer-reviewed publications this year.
TEACHING PROGRAMS
The Division is active in resident, medical student and graduate student teaching. Second
year residents (9) in obstetrics and gynecology rotated through the Division as part of their
Ultrasound/Genetics Block. Dr. Hogge is the course director for the 4th year elective in
clinical genetics, and two students rotated through the Division in FY06.
41
Drs. Clark, Kolthoff, Arvon and Turocy were facilitators for the first year class in Molecular
Biology and Genetics.
Dr. Hogge lectured in the 2nd year Reproductive Biology course and in the 1st year
Molecular Biology and Genetics course. Dr. Hogge also gave 6 lectures for the Department
of Human Genetics in the Graduate School of Public Health.
Fellowship
The Department has a two-year fellowship program in Reproductive Genetics and offers
one position per year. The program focuses on methods of fetal diagnosis and therapy, natural history of fetal malformations, and role of heredity in gynecologic cancer. A broad base
of clinical and of laboratory training is offered. Dr. Marta Kolthoff completed her fellowship and has accepted a position as Assistant Professor in the Department of Obstetrics,
Gynecology and Reproductive Sciences at Magee-Womens Hospital, University of
Pittsburgh. She is working for the Department of Genetics and the Department of
Ultrasound. Dr. Regina Arvon is our second year fellow. She completed her residency at
Nassau University Medical Center in East Meadow, New York and has completed a fellowship in Maternal-Fetal Medicine at Jefferson Medical College of Thomas Jefferson
University. Two new fellows are joining our program this year. Dr. John Turocy is a first
year fellow in clinical genetics. He completed his residency at the University of Pittsburgh
in Obstetrics and Gynecology. Dr. Nina Powell is a first year fellow in pediatric genetics.
She completed her residency in pediatrics at Albert Einstein Medical Center.
CLINICAL PROGRAMS
Clinical programs within the Division encompass both direct patient care and laboratory
evaluation. The direct patient care services are as follows:
Prenatal Counseling (including traditional prenatal counseling, pre-conception counseling, and counseling for recurrent pregnancy loss). There were 3509 visits in this category
reflecting a 17% increase over FY05. Much of this increase can be attributed to an
increased emphasis on cystic fibrosis screening, and the introduction as a clinical service of
first-trimester screening for Down Syndrome.
Beginning May FY05 the Pregnancy Screening Laboratory brought all of its testing inhouse for its first trimester screening program.
Pediatrics (patients seen in the Department of Medical Genetics at Children’s Hospital of
Pittsburgh). Beginning July 1, 2006 Dr. Marta Kolthoff sees genetics patients in the
Department of Genetics at Children’s Hospital of Pittsburgh one half day a week.
Fetal Diagnosis and Treatment Center (FDTC) The FDTC coordinates the efforts of
various specialties, including genetics, ultrasound, maternal-fetal medicine, pediatric
surgery, pediatric urology, pediatric neurosurgery, pediatric cardiology, and neonatology to
evaluate and manage pregnancies identified with birth defects. In FY06 there were 658
patient visits through the FDTC, reflecting a 12.5% increase over the previous year.
Adult Genetics (includes cancer genetics) During FY05 a total of 563 patients were seen
in the various adult clinics, which include counseling for cancer risk analysis, adult medical
conditions, and the sickle cell clinic. A total of 721 patients were seen in FY06, an increase
of 28%. This number reflects the arrival of Dr. Clark, whose areas of expertise are cancer
genetics and adult genetic disorders.
Pregnancy Safety Hotline (PSH) The PSH serves as a resource for women and health
professionals who have questions regarding the use of medications, or exposure to environment agents during pregnancy. In this fiscal year 645 calls were handled by the Division.
42
Laboratory services offered by the Division are coordinated under the Center for Medical
Genetics and include:
Pregnancy Screening Laboratory (PSL) The PSL performs on site the Quad Screen
(alpha fetoprotein, human chorionic gonadotropin, unconjugated estriol, and inhibin A),
amniotic fluid AFP measurements, and amniotic fluid acetylcholinesterase. In FY06 technology for performing first trimester screening using nuchal translucency, pregnancy associated plasma protein A and human chorionic gonadotropin was brought in-house under
the direction of Dr. Allen Hogge. In FY05 5612 second trimester screenings were performed and 1312 first trimester screenings were performed.
Pittsburgh Cytogenetic Laboratory (PCL) The PCL serves as the reference laboratory
for all of the UPMC system, and for a number of other hospitals in the tri-state area. It
processes prenatal samples (CVS and amniocentesis), bloods, tissues (especially spontaneous
abortion material) and bone marrow samples. In FY05 there were 10,347 test performed, a
12% increase over the previous year.
FACULTY LISTING:
Brian Clark, MD
W. Allen Hogge, MD
Ji Hu, Ph.D
Jean Latimer, Ph.D
WEBSITE: http://obgyn.medicine.pitt.edu/genetics
43
44
DIVISION OF REPRODUCTIVE INFECTIOUS DISEASES
OVERVIEW
The Division of Reproductive Diseases and Immunology focuses
on infections of the female reproductive tract and their impact on
women’s health. Our division is comprised of internationally-recognized leaders in this field, with expertise in basic and clinical
research as well as clinical care. Unique to an academic obstetrics
and gynecology department, our division is very active with clinical activities, including inpatient and outpatient consultations, as
well as bench, translational, and clinical research activities. Our
multidisciplinary unit is comprised of specialists in clinical infecHarold Wiesenfeld, MD tious diseases, microbiology, immunology, virology, epidemiology,
and molecular biology. Division research includes studies on group
Division Director
B streptococcal infection, infection-mediated preterm birth and
intrauterine growth restriction, intrauterine infection, pelvic inflammatory disease, genital
tract mucosal immune response, reproductive tract microbiology, HIV infection, molecular
diagnostics of sexually transmitted diseases and biosecurity. The Microbicide Trials
Network is based at the Magee-Womens Research Institute and is under the direction of
Sharon Hiller, Ph.D The Microbicide Trials Network is a worldwide collaborative clinical
trials network that evaluates the safety and efficacy of microbicides designed to prevent
HIV transmission. Our division offers a two-year fellowship in Reproductive Infectious
Diseases for physicians completing a residency in Obstetrics and Gynecology.
RESEARCH PROGRAMS
One of the division’s main focus is on clinical and basic research in reproductive infectious
diseases. Investigators in the Division of Reproductive Infectious Diseases and Immunology
are principal investigators of a number of federally-funded research trials. The members of
the division have published extensively in leading peer-reviewed journals and present their
work at national and international meetings. The following are highlights of the ongoing
research programs.
Sharon L. Hillier, Ph.D
“Microbicide Trials Network”
Principal Investigator: Sharon L. Hillier, Ph.D
Agency: NIH/NIAID
The Microbicide Trials Network (MTN) is a worldwide collaborative clinical trials network
evaluating the safety and efficacy of microbicides designed to prevent HIV transmission.
The mission of the MTN is to reduce the sexual transmission of HIV through the evaluation of products which reduce the transmission of HIV when applied topically to mucosal
surfaces. The goal is to conduct scientifically rigorous and ethnically sound clinical trials of
microbicide safety and effectiveness, which will support licensure of these products. The
MTN plans to develop and/or execute 15 separate clinical trials of microbicides between
2006 and 2013.
“Development of NNRTI’s as Combination Microbicides”
Principal Investigator: Sharon L. Hillier, Ph.D
Agency: NIH/NIAID
The proposed studies in this program project grant will develop a combination topical
microbicide containing as non-nucleoside reverse transcriptase inhibitor.
45
“Prevention of Infertility in Women with Subclinical PID”
Principal Investigator: Harold C. Wiesenfeld, MD,C.M.
Co-Investigator: Sharon L. Hillier, Ph.D
Agency: NIH/NIAID
The hypothesis of this study is that women with lower genital tract infection may be suboptimally treated for subclinical upper genital tract infections and therefore at increased risk
for adverse reproductive outcomes. A randomized trial comparing short versus long-term
antibiotic treatments in women at-risk for subclinical PID will be conducted. This study
will examine the effect of longer course antibiotic treatment in the eradication of pathogens
from upper genital tract, resolution of inflammation, and preservation of fertility.
“Prevention of Group B Streptococcal (GBS) Disease”
Co-Investigator: Sharon L. Hillier, Ph.D
Agency: NIH/NIAID
The ultimate goal of this study is to advance understanding of the epidemiology, performance of GBS conjugate vaccines in humans and the immunological responses to vaccination. Study which is designed to evaluate whether vaccination with the type III capsular
polysaccharide conjugated to tetanus toxoid will prevent subsequent colonization by type
III group B Streptococci.
Harold C. Wiesenfeld, MD,C.M.
“Prevention of Infertility in Women with Subclinical PID”
Principal Investigator: Harold C. Wiesenfeld, MD,C.M.
Agency: NIH/NIAID
The goals of this study are to evaluate whether longer course antibiotic therapy for PID for
women at-risk for subclinical PID prevents subsequent infertility better than currently used
short course antibiotic regimens for lower genital tract infections. Subclinical pelvic inflammatory disease (PID) is an important yet overlooked cause of infertility, responsible for
more cases of post-infectious tubal infertility than acute PID. Subclinical PID is present in
25% of women with gonorrhea or chlamydia, and one in seven women with bacterial vaginosis, despite the absence of symptoms of acute PID. Most importantly, there is a doubling
in infertility among women with subclinical PID compared to women without PID.
Current treatment strategies for cervicitis and vaginitis do not address ongoing upper genital tract inflammation. Our hypothesis is that the preservation of fertility is greater among
women with subclinical PID treated with a long-course PID antibiotic regimen compared
to women receiving standard regimens for cervicitis and vaginitis.
Principal Investigator: S. Hillier, Ph.D
Co-investigator: Harold Wiesenfeld, MD,C.M.
Agency: NIH/NIAID
Type: I U19-AI-51661-01 Period: September 30, 2002 to July 31, 2007
The proposed studies in this program project grant will develop a combination topical
microbicide containing as non-nucleoside reverse transcriptase inhibitor.
46
“Treatment of Vulvodynia with Gabapentin: A Randomized Controlled Trial”
Principal Investigator: Harold C. Wiesenfeld MD,C.M. (Co-Invest: Dr. Glenn Updike)
Agency: Pfizer, Inc
This study is a randomized placebo-controlled investigation of gabapentin in the treatment
of vulvodynia. Vulvodynia is a chronic pain disorder that affects women of all ages. The
hypothesis of this study is that the use of gabapentin for 8 weeks will result in a reduction
in the average daily Visual Analog Scale (VAS) pain score in women with vulvodynia.
Thomas Cherpes, MD
“HSV-2 Shedding: Role of Hormonal Contraception and Bacterial Vaginosis”
National Institute of Allergy and Infectious Diseases 1 K23 AI064396-01
An important contributor to the epidemic spread of HSV-2 is its high frequency of asymptomatic shedding in the genital tract, as transmission of the virus usually occurs during
these periods of subclinical reactivation. This research will explore the impact of hormonal
contraceptive use and vaginal microflora on daily genital tract shedding of HSV-2, and the
effects of exogenous sex steroids on the capacity of HSV-specific T lymphocytes to inhibit
HSV reactivation from sensory neurons and subsequent shedding on epithelial surfaces in
an experimental animal model.
Charlene S. Dezzutti, Ph.D
“Development and Characterization of HIV/STD Co-Infection Explant Cultures”
Establishment of an HIV/STD co-infection explant culture is novel. HIV will not reproducibly infect the explant cultures without tissue activation. This project will use non-ulcerative bacterial or parasitic sexually transmitted pathogens along with HIV to infect cervical
explant cultures. Using this culture, we will be able to evaluate parameters such as tissue
toxicity and inflammatory and innate immune factors in a biologically more relevant in
vitro system. The overall objective of this project is to develop a co-infection model to elucidate the process of HIV and STD infection in women. Such understanding will facilitate
the development of new treatment and prevention strategies
“Microbicide Trials Network – Central Laboratory”
Topical microbicides are products designed to be used prior to sexual intercourse to prevent
the transmission of human immunodeficiency virus type 1 (HIV-1) and potentially other
sexually transmitted diseases (see Hillier S above). The Central Laboratory will support the
MTN through 5 core laboratories: Comparative Assessment, Virology, Pharmacology,
Immunology, and Site Support and Diagnostic Training.
Marijane A. Krohn, Ph.D
“The Role of Cytokines and Promoter Genotype in Prematurity”
Principal Investigator: Marijane A. Krohn, Ph.D
NICHD 1 RO1 HD 041663-01A1
“Prevention of Group B Streptococcal (GBS) Disease”
Core Director: Marijane A. Krohn, Ph.D
National Institutes of Allergy and Infectious Diseases 2002-2007
Pregnancy and Drug Metabolizing Enzymes and Transporters
Co-Investigator: Marijane A. Krohn, Ph.D
NIH/NICHD 2004-2009
Development of NNRTI’s as Combination Microbicides
NIH 1 P01 AI-151661 2002-2007
Supplement to the General Clinical Research Center
NIH-3 M01 RR00056-38S1 2003-2008
47
Bernard Moncla, Ph.D
“.Microbicide Trial Network”
Co-investigator, Site Support and Diagnostic Testing Core.
NIH 1PO1AI151661
Core leader (Microbiology): Bernard Moncla, Ph.D
$125,388.
“Testing of Compounds against Lactobacillus”
Conrad MC-030369.
$6,176.
Lisa C. Rohan, Ph.D
“HIV/SIV Intravirion Reverse Transcription and Virucides”
Principal Investigator: Pomerantz, R.J.
Co-Investigator: Lisa C. Rohan 12/04-09/08
National Institutes of Health
“Development of NNRTIs as Combination Microbicides” – Cooperative Agreement
PI: Sharon Hillier
Project 3 Project Leader: Rohan, LC
National Institutes of Health U19- 2002-2007
“Development of a UC-781 Combination Microbicide”
Principal Investigator: Romano, J
Co-Investigator: Rohan, LC,
Biosyn, Inc. 2004-2006
Hyagriv Simhan, MD, M.C.R.
Nutrition and the Genetics of Prematurity
PI: Simhan, HN
1 R01 HD052732-01 4/1/06-3/31/11
NICHD/NIAID
This project addresses gene-environment interactions that contribute to the racial disparity
in preterm birth. We have found that there are specific changes in the lower genital tract
inflammatory milieu early in pregnancy that predispose women to preterm birth. These
alterations in the lower genital tract inflammatory milieu are more common among black
women, and black women are more likely than white women to possess gene polymorphisms related to infection-related preterm birth. Understanding the influence of environment and gene-environment interactions on inflammation is critical to understanding the
racial disparity in preterm birth. Nutritional status’ influence on immunity has both epidemiological and biological plausibility. We posit that biologic responses to nutritional status may affect preterm birth via changes in lower genital tract immunity that predispose to
upper genital tract infection/inflammation. We also hypothesize that inflammatory genotype influences the nature of the lower genital tract inflammation that occurs among
women with an unfavorable nutritional status before and during pregnancy, and that these
effects are further modified by race. We aim to determine if nutritional status periconceptionally and during pregnancy is associated with preterm birth.
48
“Role of Cytokines and Promoter Genotype in Prematurity”
Principal Investigator: Marijane A. Krohn, Ph.D
Co-Investigator: Hyagriv Simhan, MD
NICHD 1 R01 HD41663-01A1
“Adverse Pregnancy Outcomes: Genetic/Environmental Causes”
Principal Investigator: G. Schatten, Ph.D
Co- Investigator: Hyagriv Simhan, MD
NICHD/NIEHS P50 AR 49617-01
TEACHING PROGRAMS
Members of the division are active participants in the teaching of medical students, residents, fellows, postdoctoral students, and other trainees in the health sciences.
Medical Students: All members of the Division participate in the 4th year ILS course on
Reproductive Infectious Diseases. This one-month course is an intensive experience in the
clinical and research of reproductive infections. Students participate in small group discussion, didactic sessions, journal clubs, laboratory sessions, and hands-on clinical experience
at the STD Clinic, the ID Clinics, and the Colposcopy Clinic. Through lectures, studentled group discussions, clinical experience, and laboratory science, students attain excellent
knowledge in reproductive infectious diseases that serves as an important foundation as they
proceed to residency. This course consistently receives outstanding evaluations from the
students. Drs. Wiesenfeld and Simhan are small group facilitators and clinical teachers of
3rd year medical students during their OB/GYN clerkship, Dr. Wiesenfeld is a PBL leader
of the 1st year medical school course “Molecular Pathogenesis of Infectious Diseases” and
serves as a clinical coordinator of this course. Dr. Simhan is the Obstetric director of
Obstetric Emergencies and Crises Simulation Course at the Peter M. Winter Center for
Medical Simulation.
Residents: Every OB/GYN resident rotates through the Infectious Diseases Clinics supervised by Drs. Simhan and Wiesenfeld. During this rotation, residents acquire the skills to
approach and manage basic and complex reproductive infections. Residents also obtain
microscopy skills for the evaluation of vaginal infections. Teaching of residents actively
occurs during obstetric and gynecologic inpatient rotations at all resident levels.
Fellows: The division offers a two-year fellowship in Reproductive Infectious Diseases. The
ID fellow gains a broad experience in reproductive and adult infections diseases, through
clinical rotations at Magee-Womens Hospital, UPMC-Infectious Diseases Service, the
Allegheny County Health Department’s STD program, and the PACT (HIV) Clinic.
Fellows participate in the care of women seeking care via both outpatient and inpatient
consultation. In conjunction with the Graduate School of Public Health at the University
of Pittsburgh, the fellows obtain a Master’s degree in Clinical Research. Our current
Infectious Diseases fellow is Katherine Bunge, MD, M.P.H., a recent graduate from the
OB/GYN residency at Northwestern University, Chicago.
Other Trainees: Members of the division provide training and supervision to postdoctoral
students, graduate students, and other students in the School of the Health Sciences at the
University of Pittsburgh. Drs. Hillier, Moncla, and Rohan provide training in laboratory
and clinical science. Dr. Krohn provides epidemiology training to a number of graduate
students, medical students, residents, and fellows. Division members serve as research mentors for residents in OB/GYN.
CLINICAL PROGRAMS
Specialists in our division provide consultation for women with complex reproductive infectious diseases. Outpatient consultations are provided in the Infectious Diseases Clinic
which takes place three times weekly. Obstetrician-gynecologists, family physicians,
internists, and other healthcare providers are able to seek timely consultation for their
patients with Drs. Wiesenfeld and Simhan. The clinics are complemented by nursing staff
49
devoted to infectious diseases to provide comprehensive care. Fellows, residents and students in the Department of Obstetrics, Gynecology, and Reproductive Sciences rotate at
these clinics to learn the approach and management to complex infectious conditions of the
female reproductive tract. Patients seeking care at the Infectious Diseases clinics are also
provided the opportunity to participate in clinical research trials involving state-of-the-art
diagnostics, novel therapeutics and vaccines, and investigations into the pathogenesis of
reproductive infections.
The division provides 24 hour inpatient consultation for Infectious Disease conditions from
the obstetric and gynecologic services as well as the medical and surgical departments at
Magee-Womens Hospital.
Members of the Division of Reproductive Infectious Diseases provide care to clients at-risk
for reproductive infections at a number of sites throughout our region. The STD clinic is
staffed by our clinical and research team, providing comprehensive STD services to the
community as well as providing the STD clinic clientele the opportunity to participate in
clinical research trials. In collaboration with the Division of Infectious Diseases in the
Department of Medicine, Dr. Wiesenfeld is the gynecologic consultant to the PACT Clinic
under the NIH Prime Agreement No.2 H76 HA00079-10 “OP Early Intervention Services
with Respect to HIV Disease”, and Dr. Simhan coordinates pregnancy care of HIV-positive
women. Research activities are also carried out at a number of ambulatory care sites in
Allegheny County.
50
FACULTY LISTING
Harold C. Wiesenfeld, MD,C.M., Director
Associate Professor of Obstetrics Gynecology, and Reproductive Sciences, and Medicine
Sharon L. Hillier, Ph.D Director of Reproductive Infectious Diseases Research
Professor of Obstetrics, Gynecology, and Reproductive Sciences
Richard Beigi, MD
Assistant Professor of Obstetrics, Gynecology and Reproductive Sciences
Thomas Cherpes,. MD
Assistant Professor of Medicine
Charlene S. Dezzutti, Ph.D
Associate Professor, Obstetrics, Gynecology and Reproductive Sciences, and Molecular
Genetics and Biochemistry, University of Pittsburgh
Marijane A. Krohn, Ph.D
Associate Professor of Obstetrics. Gynecology and Reproductive Sciences and
Epidemiology
Bernard J. Moncla, Ph.D
Associate Professor of Obstetrics, Gynecology, and Reproductive Sciences
Hyagriv Simhan, MD
Assistant Professor of Obstetrics, Gynecology and Reproductive Sciences
WEBSITE: obgyn.medicine.pitt.edu/infectiousdiseases
51
52
DIVISION OF ULTRASOUND
OVERVIEW
The mission of the ultrasound division is to:
Provide quality obstetric and gynecologic ultrasound services in a
timely and cost-effective manner;
• Continue to improve the resident/fellow ultrasound rotation in
order to nurture the development of future obstetric and gynecologic sonologists;
Lyndon M. Hill, MD
Division Director
• Develop an active research program that contributes to the
knowledge of the specialty and provide a stimulus for the academic
growth of young faculty.
Members of the division are recognized locally and nationally for
their expertise in obstetric and gynecologic sonography. Hence,
patients with complicated or abnormal ultrasound examinations are frequently referred for
consultation.
The major success of the ultrasound division is its acknowledged quality in performing
obstetric and gynecologic ultrasound examinations. The goals of the division are to
improve the our services so that patient and referral physician satisfaction is commensurate
with the quality of the service provided.
In 1996, the division was among the first ultrasound facilities to be accredited by the
American Institute of Ultrasound in Medicine for obstetrical and gynecologic ultrasound.
The accrediting process evaluates equipment use and maintenance; report generation; storage of images; and sonographer and physician qualifications. In general, the accreditation
process will improve the quality of ultrasound services. The number of private practices
choosing to perform ultrasound examinations in their offices will inevitably decline. If we
can continue to recruit staff as needed, we will be well positioned to take advantage of this
natural centralization of ultrasound services.
In the next fiscal year our primary goal is to expand the ultrasound services to the
Womancare Centers to the maximum number of days permissible.
The ultrasound division’s patient volumes have increased significantly from 1985 through
2005. This rapid growth is a tribute not only to the members of the division, but also to an
administration that has supported its growth and development. It should be apparent that
the ultimate goal of both the department and the administration – improve patient care – is
the same. The research performed by the division eventually impacts upon patient care.
The teaching of residents and fellows keeps the sonographers and physician staff current
with respect to advances in obstetrics and gynecologic sonography and therefore, also
affects patient care. In the future, the administrative agenda of increasing patient volume
must be balanced with the department’s goals of teaching and research.
RESEARCH PROGRAM
The research interests of the division span the field of obstetrics and gynecologic ultrasound. Recent studies include an assessment of amniotic fluid volume in normal twin gestations; the determination of twin chorionicity and amnionicity; an evaluation of adnexal
masses in pregnancy; and the validity of transabdominal ultrasound in the detection of a
two vessel umbilical cord. Division members have also contributed to a CD/ROM program
on fetal anomalies sponsored by the American College of Obstetricians and Gynecologists,
as well as a CD/ROM program on placental pathology. Ten web programs on the biophysical profile score and oligohyrdramnios, to ectopic pregnancy and the sonographic evalua-
53
tion of leiomyomas and adenomyosis have recently been produced in association with the
Institute of Advanced Medical Education.
This year we have participated in the Combined Antioxidant and Pre-eclampsia Prediction
Studies (CAPPS): A randomized clinical trial of antioxidants to prevent pre-eclampsia. For
this study, uterine artery Doppler measurements are obtained during the 2nd trimester.
TEACHING PROGRAM
The training of residents and fellows is a major commitment of the division. In addition to
obstetric and radiology residents, fellows in Maternal-Fetal Medicine rotate through the
division. The Maternal-Fetal Medicine fellowship rotation has recently been expanded to
5-6 months of hands-on scanning, evaluation of interesting cases and weekly conferences
on fetal anomaly detection.
The obstetric residency training program has also been expanded and now includes both
1st and 2nd year residents. The residents’ training includes a combination of hands-on
training, as well as didactic lectures on specific everyday ultrasound examinations and procedures.
CLINICAL PROGRAM
The ultrasound division performed 50,286 obstetric or gynecologic procedures in 2005.
64% of our volume is derived from obstetric examinations; 21% from gynecologic studies;
and 15% from ultrasound directed procedures.
54
FACULTY LISTING:
Lyndon M. Hill, MD Professor of Obstetrics, Gynecology and Reproductive Sciences
Division Director
Director of OB/Gyn Ultrasound
Co-director Maternal-Fetal Medicine
Jerry G. Martin, MD Assistant Professor of Obstetrics, Gynecology and
Reproductive Sciences
David Kauffman, MD Assistant Professor of Obstetrics, Gynecology and
Bonnie Coyne, MD
Assistant Professor of Obstetrics, Gynecology and
WEBSITE: http://obgyn.medicine.pitt.edu/ultrasound
55
56
DIVISION OF UROGYNECOLOGY AND REPRODUCTIVE PELVIC SURGERY
DIVISION OF UROGYNECOLOGY AND RECONSTRUCTIVE PELVIC SURGERY
OVERVIEW
The mission of the Division of Urogynecology and Reconstructive
Pelvic Surgery (UPRS) is to advance the quality of life of women
with pelvic floor disorders through comprehensive clinical care,
education and research into prevention, diagnosis and treatment.
This past year was notable for numerous changes within the division to better position us for expansion of clinical services, achievment of our educational mission and development of new research
programs. Recruitment efforts were highly successful with the
additional of two faculty and a nurse practitioner. Our fellowship
Halina Zyczynski, MD in Female Pelvic Medicine and Pelvic Reconstructive Surgery was
Division Director
recredentialed by the American Board of Obstetrics and
Gynecology under new directorship from Dr. Pamela Moalli. We successfully competed for
participation in another cycle of the NIH sponsored Urinary Incontinence Treatment
Network and initiated a primate research program to study genetic and hormonal influences on prolapse development.
RESEARCH PROGRAMS
The research program was extremely productive this year with 14 peer review and invited
manuscripts, 10 abstracts at national meetings. We were recipients of $343,118.17 in government, foundation and industry research grants.
The Urogynecology Research Program portfolio includes epidemiologic, randomized clinical trials, and translational laboratory projects (animal model and biomechanical) funded by
the NIH, private foundations and industry. The focus includes prevention, diagnosis and
treatment of childbirth trauma, pelvic organ prolapse, urinary and fecal incontinence. Our
research team is multidisciplinary and extramural. Every member of the division is expected
to be an active contributor to ongoing research projects. In 2005-2006 we were one of
three university medical centers in the United States participating in two National
Institutes of Health clinical trials networks dedicated to pelvic floor dysfunction: the
NIDDK Urinary Incontinence Treatment Network (UITN) and the NICHD Pelvic Floor
Disorders Network (PFDN).
We have utilized the expertise of Pamela A. Moalli MD PhD and for the first time were
able to use objective data obtained from mechanical testing of graft materials to choose
compatible polypropylene slings in our current surgical trial for UITN. Indeed, this testing
protocol has been broadly accepted by Urologists and Urogynecologists at large and has
earned our institution a reputation for expertise in graft materials. As a result, Dr. Moalli
presented a plenary session at the recent Society for Gynecologic Surgeons and will be presenting the most recent results of graft testing at the annual meeting of the American
Urogynecology Society.
57
TRANSLATIONAL LABORATORY RESEARCH
1 R01 HD045590-01
Title: Impact of Menopause on Vaginal Connective Tissue Support
Agency: NIH/NICHD
Period of Grant: 7/1/04 – 6/30/09
Principal Investigator: Pam Moalli
The pelvic floor provides the primary structural support to the pelvic organs and prevents
them from prolapsing into the vagina. The hypothesis of the proposed study is that the
ovarian sex steroids are involved in the regulation of connective tissue remodeling in the
pelvic floor and are required to maintain its integrity. This grant involves an extensive collaborative effort between institutions – Magee Women’s Research Institute (Pamela Moalli),
Center for Biological Imaging (Simon Watkins) and the Musculoskeletal Research Institute
in the School of Engineering (Savio Woo). In addition, there are collaborations for tissue
collection with Northwestern University (Robert Hammer) and University of Connecticut
(Paul Tullikangas). Finally experts in the area of connective tissue remodeling act as active
consultants on the grant including Frederick Woessner (University of Miami), Robert
Kokeneysi (St. Louis University) and Chris Niyibizi (Hershey College of Medicine).
Maternal soft tissue injury resulting from traumatic childbirth is considered the greatest
risk factor for the development of short- and long-term gynecologic complications. Women
with significant birth injury are at increased risk for the development of pelvic organ prolapse, urinary and fecal incontinence and dyspareunia. The lifetime risk for undergoing
surgery to correct pelvic organ prolapse or urinary incontinence is 11%. In spite of the
prevalence of these problems, little is known of the adaptations that are necessary to
achieve delivery of a fetus with minimal maternal injury. Thus no preventative measures
have been developed short of recommending an elective cesarean section prior to the onset
of labor. We have developed a complementary series of experiments in non-human primates to characterize the maternal adaptations of the vaginal and its supportive tissues in
pregnancy and delivery at the ultrastructural, histological, biochemical and biomechanical
level. Once these adaptations are characterized, we will be performing experiments to
exceed or interfere with specific maternal adaptations so as to reproduce mechanisms of
injury.
58
CLINICAL TRIALS
NICHD Pelvic Floor Disorders Network
Principal Investigator: Halina M. Zyczynski, MD
Agency: NIH/NICHD clinical trials network
Type: 1 U01 HD41263
Period: 10/2001 – 9/2006
Interdepartmental Collaboration:Urology, Gastroenterology, and Radiology
Extramural Collaboration: Department of Physical Therapy, Duquesne University
Description: PFDN is a cooperative clinical trials network of investigators from seven clinical centers and a data-coordinating center. The primary goal is to improve the knowledge
about pelvic floor disorders (such as pelvic organ prolapse, urinary incontinence, and fecal
incontinence) in women. Protocols conducted this year included:
CAPS (Childbirth and Pelvic Symptoms) the neuromuscular trauma acquired during childbirth has been implicated as a risk factor in the development of urinary and fecal incontinence as well as sexual dysfunction. This is a descriptive symptom survey based study of
bowel, bladder and sexual function from three cohorts of primiparous women recruited
immediately post-partum: women who experienced anal sphincter disruption compared to
two control groups: vaginal birth without anal injury and cesarean section without labor.
Investigators at the University of Pittsburgh/Magee-Womens Hospital contributed the
greatest number of subjects into theis national trial which was completed in 2005. Analyses
and manuscript submissions are in progress.
CAPS-IS Childbirth and Pelvic Symptoms Imaging Supplementary Study: This study will
correlate the symptom surveys of the CAPS population with MRI and endoanal ultrasonography of the anal sphincter complex. Institutional co-investigators included Dr. Arnold
Wald of the Division of Gastroenterology, who performed the endoanal ultrasounds and
Dr. Christina Hakim of the UPMC Radiology Department who interpreted the pelvic floor
MRI studies for this analysis.
CARE (Colpopexy and Reduction Efforts) Pelvic Organ prolapse and urinary incontinence
share similar risk factors. This RCT demonstrated a significant benefit of an adjuvant
Burch colposuspension in women undergoing abdominal sacral colpopexy for advanced
pelvic organ prolapse who have not yet begun to demonstrate stress urinary incontinence.
Findings were published in the New England Journal of Medicine in April 2006. Long
term follow-up of each cohort continues through 2010.
Pelvic Symptoms And Patient Satisfaction After Colpocleisis In response to the rapidly
expanding population of advanced age women, the PFDN is exploring the acceptability,
morbidity, durability and outcome of the colpocleisis procedure which is an obliterative
procedure of the vaginal canal selected for the treatment of advanced pelvic organ prolapse
in women comfortable with relinquishing coital function. This procedure, which was popularized in the era of significant surgical and anesthetic morbidity, is being rediscovered as a
selectively appropriate, low risk option. Enrollment has ended and subjects are in followup.
ATLAS (Ambulatory Treatments for Leakage Associated with Stress) The goals of this
RCT are to compare patient satisfaction and continence outcomes from two non-surgical
therapies for stress urinary incontinence. Women with stress and mixed (stress predominant) incontinence were randomized to one of three treatment groups: (1) pelvic muscle
training and exercise; (2) incontinence pessary alone; or (3) both. We are in the follow-up
phase of this trial.
59
NIDDK Urinary Incontinence Treatment Network
Principal Investigator: Halina M. Zyczynski, MD
Agency: NIH/NIDDK
Type: 5 U01 DK58225-02
Period: 10/2000 – 9/2010
Interdepartmental Collaboration: Urology,
Extramural Collaboration: Department of Physical Therapy, Duquesne University
Description: The purpose of the Urinary Incontinence Treatment Network is to assess the
long-term outcomes of the most commonly utilized interventions to correct urinary incontinence (both urge and stress urinary incontinence) in adult women. We are currently
involved in three active protocols.
RCT of Burch vs. Sling procedures for the treatment of stress urinary incontinence.
Enrollment of 650 women (64 from University of Pittsburgh/Magee-Womens Hospital)
was completed on June 30th,2004. We will follow these women for 7 years specifically
focusing on continence rates, short and long term complication rates, secondary effects on
pelvic floor support and development of de novo urge incontinence. We hope to gain
insight into selection criteria for these two procedures.
Behavior Enhances Drug Reduction of Incontinence Be-DRI: A randomized control trial of
women with urinary urge incontinence assessing the effect of intensive behavioral interventions to improve treatment success and to facilitate withdrawal from pharmacologic agents,
which are the current standard of care. Enrollment is closed. We completing the followup.
Trial of Mid-Urethral Slings (TOMUS): a RCT comparing outcomes of the originally
described retropubic midurethral sling (“TVT”) to the more recently described transobturator technique in women with stress predominant urinary incotninence.
The Impact of Body Image on Women with Pelvic Floor Disorders
Principal Investigator: Jerry Lowder
Funding Source: Irene McLenahan Young Investigator Research Grant Magee-Womens
Health Foundation
Despite the disfiguring nature of pelvic organ prolapse, no work has been done to assess its
impact on women’s body image. The objective is to assess body image by standardized
questionnaire in women with prolapse and urinary incontinence, and to evaluate women
after surgical treatment to see if body image improves. Women with prolapse and urinary
incontinence will be surveyed by questionnaire, and compared with women without prolapse or incontinence. Women undergoing surgical treatment will complete body image
assessment before and after surgery.
Future Plans: Assuming that body image is affected by prolapse and incontinence, and that
it improves following surgical treatment, this important aspect of quality of life can be
included in future studies of patients’ expectations and satisfaction following surgery.
Role of Apical Support in Vaginal Prolapse
Principal Investigator: Jerry Lowder
Funding Source: Division of Urogynecology
The goal of this prospective observational study of POP-Q exam values will characterize
the contribution of apical vaginal support loss on anterior and posterior vaginal prolapse.
By improving our understanding of the role of apical vaginal prolapse in overall vaginal
prolapse we will better choose surgeries that address the primary site compromised support
thereby reducing failure rates.
60
Weight Reduction And Prolapse Symptoms (WRAPS)
Principal Investigator: James Daucher
Funding Source: Irene McLenahan Young Investigator Research Grant Magee-Womens
Health Foundation
This is an observation study that will assess pelvic organ prolapse, urinary incontinence and
quality of life measures related to sexual function, incontinence (fecal and urinary), prolapse
and general health in women before and after undergoing weight reductive surgery. The
objective of the study is to assess the impact of weight loss on the above mentioned factors.
TEACHING PROGRAMS
Each member of the division is a contributor to the education of fellows, residents and
medical students who rotate through the inpatient service and the offices as well as through
community outreach lectures and organized CME opportunities.
PGY 3 Urogynecology Rotation: Inpatient and outpatient 6 week rotation for third year
residents in Ob/Gyn focused on obtaining targeted histories, office diagnostic testing and
development of a management plan that may include pharmacologic, behavioral, pessary,
physical therapy or surgical options. Exposure to multichannel urodynamics, confirmatory
cystoscopy, ureteral stent placement, vaginal and abdominal incontinence and reconstructive pelvic procedures and post-operative management.
PGY 4 Special Clinics Rotation: Fourth year resident rotation through the Center for
Continence and Pelvic Floor Disorders with a focus on reinforcing targeted histories, physical exams and diagnostic testing. Clinic patients with pelvic floor disorders are brought to
the Center by the residents for concomitant evaluations by the resident and the
Urogynecology faculty. Treatment plans are devised. The Urogynecology faculty staff these
clinic surgical cases as appropriate upon the request of the residents.
Weekly didactic sessions for fellows, residents and medical students are coordinatied by Dr.
Lowder and Ghetti (Fridays 12-1pm). The format follows selected readings from textbooks
and periodicals.
Weekly Conference (Thursday evening 4:30 pm-5:30 pm) alternating Morbidity/Mortality
conference, research updates, Journal club, and multidisciplinary guest lectures.
Introduction to basic laboratory skills: residents, fellows and medical students are offered 6
week to 1 year rotations in our basic science laboratory under the direction of Dr. Moalli.
Students choosing this rotation attend a weekly Work in Progress Conference where the
research of investigators involved in maternal and fetal health is investigated. In addition,
students electing this route attend weekly laboratory meetings with Dr. Moalli.
Fellowship
The fellowship in Female Pelvic Medicine and Reconstructive Surgery at Magee-Womens
Hospital and the University of Pittsburgh is designed as a three-year curriculum for individuals who have completed residency training in obstetrics and gynecology or urology. The
ideal candidate for this fellowship program is an individual with a strong interest in pursing a
career in academic medicine, to include excellence and leadership in education, research and
patient care. All fellows are provided the opportunity to obtain a Master’s degree in Clinical
Research Training. The fellowship has been accredited by the American Board of Obstetrics
and Gynecology (ABOG).
The curriculum is designed to provide training and experience in clinical care and research
for women with pelvic floor disorders. Clinical rotations include in-patient and outpatient
urogynecology, urology, minimally invasive surgery, colorectal surgery, and gastroenterology.
Surgical approaches to pelvic floor disorders include abdominal, vaginal and laparoscopic
61
procedures. Each of the faculty members in our division take a vested interest in the development of each fellow. The environment is designed to be a nurturing one in which each
fellow allowed to take advantage of our well developed infrastructure to perform clinical
outcomes based research or basic science (laboratory) research. We have two weekly conferences dedicated to fellow education. The first, attended by all staff members of the division,
is a forum in which discussion of recent journal articles, presentation of fellows and faculty
research, monthly morbidity and mortality rounds, and outside speaker presentations take
place. The second conference is designed to achieve the educational objectives outlined by
the American Board of Obstetrics and Gynecology and is run by the faculty.
CLINICAL PROGRAM
Clinical services for women with urinary and fecal incontinence as well as pelvic organ prolapse are offered through the Center for Continence and Pelvic Floor Disorders (CCPFD)
at Magee-Womens Hospital of the UPMC. Our evaluation and treatment center offers
comprehensive consultations along with on site cystoscopy, multichannel urodynamics,
endoanal ultrasonography and manometry. Four Urogynecologists and a nurse practitioner
perform 620 new consultations and 2700 total visits annually. The program offers patients
the full breadth of treatment options from pelvic floor muscle rehabilitation (offered by
certified pelvic floor physical therapists), through pessaries, pharmaceuticals, periurethral
bulking agents, and complex reconstructive pelvic surgery. Our clinical research program is
administrated through the immediately adjacent clinical research center which facilitates
vigilant monitoring of over 400 subjects in our numerous clinical trials. Our patients have
the opportunity to enjoy access to investigational pharmaceuticals, behavioral interventions
and surgical procedure under the supervision of the local human investigation committee
and National Institutes of Health data safety and monitoring boards.
62
FACULTY LISTING
Chiara Ghetti, MD
Pamela Moalli, MD Ph.D
Anne Weber, MD
Halina Zyczynski, MD
WEBSITE: http://obgyn.medicine.pitt.edu/urogynecology
63
64
MAGEE-WOMENS RESEARC INSTITUTE (MWRI)
MAGEE-WOMENS RESEARCH INSTITUTE (MWRI)
OVERVIEW
Research continues as a major strength of the Department of
Obstetrics Gynecology and Reproductive Sciences. This year total
funding for the department from all sources was $25.4 million and
for NIH sources was $17.5 million. This results in the Department
once again being the in the first three leading NIH funded
Obstetrics and Gynecology Department in the country. Total
funding over the duration of all grants is $92 million.
Several programs in the department continue to be recognized as
premier worldwide. Dr. Hillier was recently awarded NIH funding
to direct a very large program to develop and test microbicides to
James Roberts, MD
protect women against HIV infection. The Microbicide Trials
Professor and
Network based in Pittsburgh will include centers from around the
Vice Chair, Research
world with the goal of developing an approach to HIV prevention
that can be instituted by women to protect themselves. Dr. Schatten and his colleagues’
studies on primate cloning, stems cell research and ART are matched nowhere in the US.
The group has an NIH Program Project Grant to study stem cells, “Pluripotential stem
cells in development and disease.” Dr. Creinin heads one of the nations only Centers for
Contraceptive Research and Research Training while Dr. Roberts and his group have the
only PPG in the nation to study mechanisms of the pregnancy complication, preeclampsia.
The Department of Obstetrics and Gynecology and Reproductive Sciences continues as a
member of the NICHD Maternal Fetal Medicine Network for Clinical Trials. The Magee
program, headed by Dr Steve Caritis is the only center that has been part of this program
since its inception 20 years ago. The Department also is a member of the NIH sponsored
Incontinence Collaborative Treatment Network and the Gynecological Oncology Group
for clinical trials. Dr Caritis and his colleagues in this department and other departments in
the medical school were selected to participate as one of four centers in the Network of
Obstetrical-Fetal Pharmacology Research Units
The department also has funded training grants for fellows and young investigators. These
include a program for Epidemiology Training for Obstetricians and Gynecologists and the
Contraceptive Research training program. The Department is also quite active in the
University of Pittsburgh Center for Building Interdisciplinary Research Careers in
Women’s Health. Dr. Roberts is PI and several faculty serve on the Steering Committee.
We also are proud to have one of our faculty Dr. Aletha Akers, selected for the prestigious
NIH roadmap generated training grant, the Clinical Research Scholars Program (CRSP) a
multidisciplinary career development program.
The coming year also brings some exciting new programs and collaborations. Dr David
Peters joins the faculty to head the Genetics Research Program. Dr. Peters major interest
in translational research attempting to identify novel markers for intrauterine diagnoses.
The Magee/RAND Women’s Health Initiative has formed several working groups to study
health services aspects of contraception, perinatal care and breast diseases. The Women’s
Cancer Research Program continues to grow and a major recruitment is in process to
attract an ovarian cancer investigator of world renown.
Other emerging programs include Dr. Simhan’s and his colleagues work on premature birth
that are addressing mechanisms including nutrition and reasons for the increased risk of
preterm birth for African-Americans. Dr. Moali is conducting seminal research on mecha-
65
nisms responsible for pelvic floor dysfunction while Dr. Orwig is examining sperm stem cell
biology with the eventual goal of providing opportunities for reproductive capability for
boys who lose their ability to produce sperm due to cancer treatment. Behavioral and complementary research is addressing issues such as cancer related fatigue and its alleviation by
acupuncture and methods to improve physician patient communication.
The Research Program is diverse and extensive but in always directed in a translational
manner at improving health including reproductive capacity.
66
PITTSBURGH DEVELOPMENT CENTER
DIVISION OF DEVELOPMENT AND REGENERATIVE MEDICINE
PITTSBURGH DEVELOPMENT CENTER
DIVISION OF DEVELOPMENT AND REGENERATIVE MEDICINE
Gerald Schatten,
MD, Ph.D
OVERVIEW
The Department of Obstetrics, Gynecology, and Reproductive
Sciences established the Division of Development and
Regenerative Medicine in 2004, with Gerald Schatten, Ph.D, as
Division Director. The Department’s DDRM is devoted to the
clinical, translational, and fundamental research and education
encompassing developmental and reproductive biology, especially
Assisted Reproductive Technologies (ART), Prenatal Medicine,
and Stem Cells for Regenerative Medicine. Its research, teaching,
and outreach activities are performed largely within the Pittsburgh
Development Center.
The Pittsburgh Development Center (PDC) established in May
2001, is focused exclusively on the confluence of developmental biology and molecular
medicine. The PDC is a center with in the auspices of the Magee-Womens Research
Institute – the research arm of the Magee-Womens Health Corporation – a non-profit
women’s health institution. All PDC faculty are professors at the University of Pittsburgh
School of Medicine with appointments in the Departments of Obstetrics, Gynecology and
Reproductive Science, as well as other Departments including Cell Biology-Physiology,
Molecular Biology-Genetics.
The Division of Development and Regenerative Medicine with the Department of ObGyn-RS at the University of Pittsburgh School of Medicine investigates urgent and important biomedical issues. Consistent with our mission statement ‘Biology Enhancing
Molecular Medicine,’ the PDC is actively researching contemporary topics of national
importance including: the pluripotency of embryonic stem cells (ES cells) using nonhuman
primates; feasibilities of transgenic approaches for disease modeling using primates, outcomes of Assisted Reproductive Technologies (ART); and cloning in non-human primates,
either for production of identical research models or to evaluate ‘therapeutic’ cloning. The
PDC is housed directly on the University of Pittsburgh Campus, which itself is contiguous
with Carnegie-Mellon University and other academic centers. In fact and in spirit, the
PDC is at the biomedical heart of the University of Pittsburgh’s Health Sciences Center
and its Director, Dr. Gerald Schatten, is involved in several leadership positions within the
biomedical community.
Building on the Divisional faculty’s recent successes, including the births of the first nonhuman primate through embryo-splitting, Tetra and the first genetically-modified nonhuman primate ANDi, the PDC plans to accelerate discoveries on stem cell potentials;
improved disease models including genetically identical, as well as genetically modified primates; infertility treatments; reproductive aging; testing functional genomic models; and
evaluation and optimization of gene and cell therapies.
The six scientific pillars of the PDC are reproduction, stem cells, cloning, transgenesis,
non-invasive imaging, and childhood development, exclusive of research infrastructure.
Assisted Reproductive Technology (ART) research is vital to ensure that the most innovative infertility therapies are as safe and effective as possible. The combination of transgenics
and cloning may result in the generation of identical sets of non-human primates for disease models. Our publications attest to our strengths in reproductive and developmental
biology using a variety of systems, especially nonhuman primates. Understanding the therapeutic potentials of embryonic and adult stem cells is of critical importance to provide a
more solid scientific foundation for the ethical and social conversations regarding human
embryonic stem (ES) cells.
67
Research at the Division of Development and Regenerative Medicine is moving forward
rapidly. Scientifically, our intellectual scope is crystallizing to focus on the confluence of
developmental biology and molecular medicine. While laboratory space continues to be
challenging – including our fourth move into yet a third building location within the past
two years and a projected upcoming move– we retain optimism that adequate modern facilities will indeed be constructed in a timely fashion.
In the last year we solidified our position as among the handful of leading centers in stem
cell biomedicine – including in the areas of research, mentoring, training, as well as fostering conversations regarding the ethics with the awarding for a significant NIH program
grant. We will now build on the foundation that it provides to push the forefront of science
and innovation in our field. This year, we are acknowledged as only the nine Universities
and Institutions with major NIH sponsorship for stem cell research. The Division’s scientific reputation results in favorable reviews of its many research, program project, research
center and training grants. The following is a partial list of its current sponsorship, and
every faculty member of the division (i.e. Drs. D Carlisle, L. Hewitson, K Orwig, C
Navara, C Simerly and G Schatten) shares credit for these successes:
NIH (MERIT) Egg-Mediated Motility during Fertilization
$ 3,715,046
NIH (P50) Adverse Pregnancy Outcomes: Genetics & Epigenetics $ 5,943,892
Competing Continuation pending
NIH (R24) Rhesus Propagation by Cloning
$ 6,955,903
NIH (MERIT) Human Embryonic Stem Cell Supplement
$ 225,000
NIH (T15) Frontiers in Human Embryonic Stem Cells
$ 449,808
Competing Continuation funded
$ 588,507
NIH (G20) Infrastructure Improvements
$ 311,147
NIH (G20) Infrastructure Improvements
$ 640,000
NIH (Indo-US Joint Working Group) Transgenic Primates
$ 150,000
NIH MARC Mentor for Carlos Castro: Prenatal Imaging
$ 448,400
NIH (F32) Mentor for Ahmi Ben-Yehudah: ?-Islets from ESCs
$ 140,000
NIH (ADRC) Alzheimer’s disease Modeling In Stem Cells
$ 950,000
NIH (P01) Pluripotent Stem Cells in Development & Disease
$ 19,937,980
7/97-9/07
9/02-8/07
9/07-8/12
7/03-6/08
8/03-7/05
4/03-3/06
4/06-3/09
8/03-7/04
4/05-3/07
4/05-3/08
7/05-6/07
4/05-3/07
4/05-3/10
7/05-6/10
Furthermore, we continue to build our scientific and technological links to clinical research
strengths here at Pitt as well as at Carnegie-Mellon University.
68
MAGEE-WOMENS RESEARCH INSTITUTE
RESEARCH GRANTS AND CONTRACTS
FEDERAL CONTRACTS
PI NAME
Balk
Baysal
AWARD NUMBER & STUDY TITLE
DATE
TOTAL AWARD
1R21CA098659-01A2
A Pilot Study of Acupuncture for Cancer Related Fatigue NCI
8/1/05-7/331/07
$359,480
1R01CA112364-01
Epigenetic Regulation of Mitochondrial Complex II
NCI
2/1/05-1/31/10
$955,144
NIDDK
7/1/05-6/30/07
$98,224
5U10HD21410-19
Multicenter Network of Maternal-Fetal-Medicine
Units
NICHD
4/1/91-3/31/06
$1,936,467
1U10HD047905-01
Obstetrics-Fetal Pharmacology Research Units
Network
NICHD
7/1/04-4/30/09
$2,875,000
1K08HS013913-1A1
Patient-Provider Communication on Partner Volence
AHRQ
5/1/06-4/30/10
$499,940
1K23AI064396-01
HSV-2 Shedding: Role of Hormonal
Contraception and BV
NIAID
5/1/05-4/30/10
$632,570
5R01DK63321-13
Mechanisms of Vasodilation in Pregnancy
NIDDK
9/1/02-3/31/06
$1,121,766
5R01HL67937-03
Relaxin: The ‘Elusive’ Vasodilator of Pregnancy
NHLBI
8/20/01-7/31/05
$726,540
5T32HD40673-04
Ob-Gyn Fellowships in Epidemiology and
Clinical Trials
NICHD
6/27/01-4/30/06
$817,528
HHSN275200403372I
Female Contraceptive Clinical Trial:
A Randomized Controlled
Study of the Efficacy, Safety and Acceptability
of C31G
NICHD
4/1/04-9/30/07
$1,084,791
HHSN275200403372I
Core Task (Female Topic Area): Protocol
Review, Protocol
Development and Informal Consultation
NICHD
4/1/04-3/31/11
$289,836
NCI
9/4/02-8/31/05
$24,675
NIAID
9/30/02-7/31/07
$7,990,717
DOD
9/30/04-10/29/06
$114,000
Ben-Yehudah 1F32DK070424-01
Driving B-Cell Differentiation from
Embryonic Stem Cells
Caritis
Caritis
Chang
Cherpes
Conrad
Conrad
Creinin
Creinin
Creinin
Hillier
Hillier
Hogge
263-MQ-216781
Measurement of Cervical Inflammation
from Pap Slides
5U19AI051661-03
Development of NNRTI’s as
Combination Microbicides
W81XWH-04-1-0685
Identification of Stem Cells in a Novel Human
Mammary Epithelial Culture HMEC System that
Reproducibly Demonstrates Ductal Organotopic
Architecture in 3 Weeks
AGENCY
69
Hogge
Hillier
Hsu
Hubel
Krohn
McGee
Moalli
Orwig
Orwig
Patrick
Ramirez
Roberts
a)Conrad
b)Roberts
c)Gandley
d)Roberts
e)Roberts
Roberts
Schatten
Schatten
Schatten
70
W81XWH-04-1-0686
Genetic Analysis of DNA Repair Deficiency in
in Novel Non-Tumor Adjacent and Tumor Cell Line
Suggests a New Paradigm of Breast Cancer Etiology
DOD
9/30/04-10/29/06
$114,000
DHHS
9/30/05-9/29/08
$75,000
NCI
7/1/05-4/30/09
$770,499
1R21HD049453-01
Maternal Endothelial Progenitor Cells
and Preeclampsia
NICHD
6/1/05-5/31/07
$303,879
5R01HD041663-03
Role of Cytokines and Promoter Genotype
in Prematurity
NICHD
4/14/03-3/31/08
$1,599,556
5R01HD045700-02
Regulation of Preantral Follicles
NICHD
7/1/04-4/30/09
$1,368,000
5R01HD045590-02
Impact of Menopause on Vaginal Connective
Tissue Support
NICHD
6/1/04-3/31/09
$1,465,482
5R01RR018500-02
Male Germline Modification in Rats
NCRR
9/15/03-6/30/08
$1,895,000
1R01AG024992-01
Aging of Male Germline Stem Cells
NIA
9/30/04-7/31/09
$1,623,171
NINR
9/5/00-5/31/05
$1,675,530
5R01HL64144-06
Lipoprotein Lipase and Preeclampsia
(Minority Supplement)
NHLBI
2/1/02-1/31/06
$257,456
5P01HD30367-12
Preeclampsia—Mechanisms and
Post Pregnancy Implications
5P01HD30367-12 Project 2
5P01HD30367-12 Administrative Core
3P01HD030367-12S1 Supplement
NICHD
NICHD
NICHD
NICHD
NICHD
NICHD
6/14/02-1/31/07
6/14/02-1/31/07
6/14/02-1/31/07
6/14/02-1/31/07
6/14/02-1/31/07
2/1/05-1/31/07
$1,088,113
$1,083,618
$1,001,302
$224,915
$261,886
5K12HD43441-03
Building Interdisciplinary Research Careers
in Women’s Health
NICHD
9/26/02-7/31/07
$2,244,978
5R37HD12913-23
Egg-Mediated Motility During Fertilization
NICHD
8/1/97-7/31/07
$2,736,619
3R37HD012913-23
Egg-Mediated Motility During Fertilization
(Supplement to MERIT Award)
NICHD
8/1/03-7/31/05
$228,000
NCRR
9/30/98-6/30/08
$6,350,667
1AFCWH050003-01-00
National Centers of Excellence in
Women’s Health (COE)
5R01CA111436-02
Regulation of BRCA1 Function by Protein
Phosphatase 1
5R01NR05275-05
Exercise Intervention to Reduce Recurrent
Preeclampsia
5R24RR13632-07
Rhesus Propagation by Intracytoplasmic
Nuclear Injection
Schatten
Schatten
Schatten
Schatten
Schatten
Schatten
Simhan
Wiesenfeld
Zyczynski
Zyczynski
Zyczynski
3R24RR013632-08S1
Rhesus Propagation by Intracytoplasmic
Nuclear Injection -Supplement
NCRR
7/25/05-6/30/08
$155,762
1G20RR018338-01
Improvement of Institutional Animal Resources
NCRR
9/15/03-9/14/05
$311,147
5P50ES12359-03
Adverse Pregnancy Outcomes:
Genetic/Environmental Causes
NIEHS
9/30/02-7/31/07
$5,923,564
5T15HL074353-03
Frontiers in Human Embryonic Stem Cells
NHLBI
4/23/03-3/31/06
$485,793
1G20RR021610-01
Improving PDC/MWRI Institutional
Animal Resources
NCRR
8/10/05-7/31/06
$640,000
1P01HD0476775-01A1
Pluripotent Stem cells in Development
and Desease
NICHD
8/30/05-5/31/10
16,095,841
1R01HD052732-01
Nutrition and the Genetics of Prematurity
NICHD
5/1/06-2/28/11
$2,770,941
5R01AI41624-08
Prevention of Infertility in Women with
Subclinical PID
NIAID
5/1/98-1/31/08
$2,614,312
5U10HD41263-05
Pittsburgh Collaborative Reconstructive
Pelvic Surgery Program
NICHD
9/1/01-6/30/06
$2,309,376
5U01DK58225-05
Pittsburgh Incontinence Collaborative
Treatment Program
NIDDK
9/30/00-6/30/06
$1,141,218
3U01DK058225-05S1
Pittsburgh Incontinence Collaborative
Treatment Program
NIDDK
7/1/05--6/30/06
$478,525
TOTAL OB GYN FEDERAL GRANTS
$79,505,022
FEDERAL SUBCONTRACTS
Balk
Capuano
Clark
Comerci
5M01RR000056-44
Suppliment to the General Clinical
Research Center (Univ. of Pittsburgh)
NCRR
3/1/99-3/31/09
$2,676,539
5R01HL075845-02
Latent and Reactivation Tuberculosis
(Univ. of Pittsburgh)
NHLBI
9/19/03-8/31/08
$313,116
HRSA
9/1/02-5/31/08
$83,784
NCI
9/1/03-8/31/08
$91,697
2H46MC00255-04
Western PA Sicle Cell network: An Integrated System
of Care of the Enhancement of Newborn Screening
Follow-up (Children’s Hospital of Pittsburgh)
1U54CA104677-01
Optical Spectroscopy for Management of
Cancer Treatment (Univ. of Pittsburgh)
71
Creinin
DeLoia
Edwards
Edwards
Edwards
Guido
Hillier
a)Hillier
b)Krohn
Hillier
a)Hillier
b)Krohn
Hillier
Hillier
Kalro
Kauffman
Kelley
Krivak
72
EVMS#280010 (PSA-06-04)
Single Dose and 14-Day Once or Twice-Daily
Pharmacokinetic Study the Vaginal Microbicide
Agent 1% Tenofir Gel (CONRAD/EVMS)
CONRAD
4/1/06-3/31/07
$110,123
3P50CA083591-06
Admixture Mapping for Ovarian Cancer
Susceptibility Genes
(Univ. of Alabama at Birmingham)
NCI
9/30/03-9/29/05
$50,000
W81XWH-05-2-0005
Gynecological Disease Program
DOD
10/20/04-11/30/06
$586,970
1R01CA111786-01A1
Novel Targets for Protection of T Cells
from Tumor-Induced Dysfunction
NCI
7/1/05-4/30/10
$107,328
DAMD17-02-1-0669
Novel Risk Factors and Potential Early
Detection Markers for Ovian Cancer
DOD
8/1/04-7/31/08
$18,567
N02-CP-11003
NCI Silent markers Pilot Study
NCI
12/15/05-12/31/06
$60,513
NIAID
9/30/02-9/28/07
NIAID
9/30/02-9/28/07
$2,073,803
NIAID
9/30/97-9/29/05
$636,880
NIAID
9/30/02-9/28/07
NIAID
9/30/02-9/28/07
$2,073,803
NIAID
9/30/02-9/28/07
$929,585
N01-A146745-05S1
Sexually Transmitted Diseases Prevention-Primate
Unit/Protocal 1a: Effects of Topical Biomedical
Products on the Cervicovaginal Environment
(Univ. of Washington)
NIAID
9/24/99-9/23/06
$525,780
HHSN266200400073C
Sexually Transmitted Infections Clinical Trials
Group (Univ. of Alabama at Birmingham)
NIAID
2/1/05-9/28/11
$112,513
NIH
3/15/93-3/14/06
$1,653,301
NICHD
9/24/01-5/31/06
$125,550
5R01CA095023-03
Inflammation and Ovarian Cancer
NCI
5/12/03-4/30/08
$102,294
Not Applicable
Dr. Thomas C. Krivak Research Funds
(Henry M. Jackson Foundation)
DOD
3/7/06-3/7/06
$25,000
N01-AI-25495
Prevention of Group B Streptococcal (GBS)
Disease (Bingham and Women’s Hospital)
N01-A1-225495
Clinical and Laboratory Component
N01-AI-75326
Data Management Core
N01-AI-25495
Prevention of Group B Streptococcal
(GBS) Disease (Brigham and Women’s Hospital)
N01-AI-25495
Clinical and Laboratory Component
N01-AI-25495
Data Management Component
N01-WH-3-2112
Women’s Health Initiative (Univ. of Pittsburgh)
7R01HD41149-04
Twin-Twin Transfusion Syndrome Study
(The Children’s Hospital Medical Center - Cincinnati)
Lain
McGee
Powers
Roberts
Roberts
Rohan
Rohan
Schatten
Schatten
Simhan
Simhan
Wiesenfeld
5R01MH060335-05
Antidepressant Use during Pregnancy
NIMH
4/1/04-7/31/05
$73,460
1R21EB004065-01A2
Bioreactor Actuated Ovarian Development
NIBIB
9/15/05-8/31/07
$60,382
1R01HL076532-01A1
Fetal Growth restrictions and Maternal
Cardiovascular Risk (Univ. of Pittsburgh)
NHLBI
8/15/05-7/31/10
$259,149
5R01HL067052-02
CVD Risk Factors and Sexual Identity in Women
NHLBI
3/5/03-2/28/07
$235,224
1R01ES012059-01A2
Pesticides and Infant Neuropsychological Development
NIEHS
9/1/04-8/31/05
$84,202
2R44AI052629-02
Development of UC-781 Combination Microbicides
(Biosyn, Inc.)
NIAID
2/15/04-3/31/06
$200,222
1U19A1065430-01
CV-N Secreting Lactobaccilli and Retrocyclin
Microbicides
NIAID
7/10/05-6/30/09
$741,091
5D43TW000671-10
Reproductive Biology Research Training for Latin
America-an Americas Fellowship
(Univ. of Pennsylvania)
NICHD
8/1/03-4/30/05
$86,400
NIA
7/15/05-3/31/10
$190,000
5U01AI46383-05
Adult AIDS Clinical Trials Unit (Univ. of Pittsburgh)
NIAID
1/1/01-12/31/04
$42,629
5H12HA23029-05-00
Ryan White Title IV Program (Univ. of Pittsburgh)
HRSA
8/1/01-7/31/05
$81,912
5H76HA00079-12
OP Early Intervention Services with Respect to HIV
HRSA
9/30/94-12/31/06
$91,269
2P50AG005133-22
Alzheimer’s Disease Research Center
TOTAL OB GYN FEDERAL SUBCONTRACTS
$12,953,731
NON-FEDERAL GRANTS
Baysal
Carlisle
Carlisle
ObGyn
Gene Targeting for Paraganglioma Mouse Model
(Pennsylvania Dept. of Health)
ObGyn
The Role of Nicotine in COPD Progression
(Flight Attendant Medical research Institute)
ObGyn
Alterations in Airway Cell Differention in Response
to Nicotine (Pennsylvania Dept. of Health)
Comm of PA
1/1/06-12/31/06
$12,604
FAMRI
7/1/05-6/30/08
$325,500
Comm of PA
1/1/06-12/31/06
$199,722
73
Chang
Chang
Conrad
Creinin
Creinin
Creinin
Creinin/
Schreiber
Creinin
Creinin
/Reeves
Creinin
/Lohr
Csoka
DeLoia
Dezzutti
Edington
74
ObGyn
Improving Patient-Provider Communication of
Behavior Risks and Issues in Obstetrics
APGO
8/1/05-10/31/07
$15,000
ObGyn
Scaife Intimate Partner Violence Project
(Scaife Family Foundation)
Scaife
12/1/00-11/30/06
$336,175
ObGyn
Relaxin: A Vascular-Derived Relaxing and
Compliance Factor (State of Pennsylvania Tobacco
Settlement Grant)
State of PA
1/1/05-12/31/05
$224,747
ObGyn
Fellowship in Family Planning and Contraception
(Anonymous
Foundation)
9/1/93-6/30/05
$1,270,545
FHI
2/1/01-12/31/05
$100,000
ObGyn
Mifepristone and Misoprostol for Abortion through
63 Days’ Gestation: A Multicenter, Randomized
Comparison of Misoprostol 6 to 8 Hours vs.
24 Hours Following Mifepristone
(Anonymous
Foundation)
3/11/02-12/31/05
$614,149
ObGyn
A Multicenter, Randomized Comparison of
Mifepristone and Misoprostol Administered
Simultaneously versus 24 Hours Apart for Abortion
through 63 Days Gestation
(Anonymous
Foundation)
5/1/04-4/30/06
$153,215
ObGyn
A Multicenter, Randomized Comparison of
Mifepristone and Misoprostol Administered
Simultaneously versus 24 Hours Apart for
Abortion through 63 Days Gestation
(Anonymous
Foundation)
5/1/04-4/30/06
$602,861
ObGyn
Serum Levels of Doxycycline at the Time of Abortion (Anonymous
with Two Dosing Regiments
Foundation)
4/1/05-3/31/06
$13,041
ObGyn
Oral Mifepristone and Buccal Mifoprostal
Administered Simultaneously for Abortion
through 63 Days Gestation
(Anonymous
Foundation)
3/1/06-2/28/07
$48,998
State of PA
5/1/04-4/30/05
$116,003
ObGyn
The Role of Pharmacogenetics in Development of
Individualized Chemotherapy for Women with
Advanced Ovarian Cancer (The Pittsburgh Foundation) PghFdn
7/1/03-6/30/05
$150,000
ObGyn
Development and Characterization of HIV/STD
Co-Infection Explant Cultures
Comm of PA
1/1/06-12/31/06
$104,164
PghFdn
3/1/04-2/28/06
$123,650
ObGyn
Design and Testing of Inhibitors of Human
Chorionic Gonadotropin (Family Health International)
ObGyn
A Transgenic Mouse Model of Hutchinson-Gilford
Progeria Syndrome (State of Pennsylvania
Tobacco Settlement Grant)
ObGyn
Intramammary Ductoscopy for the Early Detection
and Treatment of Breast Cancer
(The Pittsburgh Foundation)
Edwards
Edwards
Edwards
Hewitson
Hewitson
Hillier
Hillier
Hogge
Hogge
Hsu
Hubel
Kelley
Moncla
Powers
Rohan
ObGyn
Genetic Determinants of Ovarian Cancer Development
in BRCA 1 an BRCA 2 Mutation Carriers
(Univ. of Pittsburgh Cancer Institute)
UPCI
7/1/03-6/30/06
$180,000
ObGyn
Ovarian Cancer Surveillance Program
(Scaife family Foundation)
Scaife
1/1/06-12/31/10
$200,000
ObGyn
Research Pilot Projects in Ovarian Cancer
Scaife
1/1/06-12/31/09
$450,000
ObGyn
Autism in Primates: Genetics vs. Environment
(National Alliance for Autism Research Award)
NAAR
7/1/03-6/30/05
$118,825
ObGyn
A Primate Model of Gut, Immune, and Central
Nervous System Interaction in Response to Childhood
Vaccines: A Controlled Exploratory Study
(Visceral Foundation)
Visceral
5/1/04-4/30/06
$842,433
CONRAD
9/1/02-7/10/05
$59,048
ObGyn
Gram Stain Evaluation for the ACIDFORM and
BufferGel Phase I Study (CONRAD Program/EVMS) CONRAD
8/1/04-6/30/05
$6,427
ObGyn
Quantitative Fluorescence - Polymerase Chain
Reaction (QF-PRC) for the Rapid Diagnosis of
Fetal Aneuploidy (The CROWN Foundation)
CROWN
10/1/05-6/30/06
$12,877
Comm of PA
4/1/03-3/31/06
$262,515
CMRF
7/1/03-6/30/06
$25,000
ObGyn
Maternal Endothelial Progenitor Cells and
Preeclampsia (State of Pennsylvania Tobacco
Settlement Grant)
Comm of PA
5/1/04-4/30/05
$87,868
ObGyn
Ovarian Cancer Research (Oppenheimer Funds
Legacy Program)
Oppenheimer
8/1/03-7/31/05
$66,442
CONRAD
12/1/03-11/30/05
$18,818
Comm of PA
1/1/06-12/31/06
$98,770
Pendleton
91/05-8/31/06
$149,000
ObGyn
Vaginal Cultures and Gram Stain Analysis for
Protocols #A01-068, #A02-074 and #A02-077
(CONRAD Program/EVMS)
ObGyn
Genetic Disease Services Testing and Counseling
(Pennsylvania Dept. of Health: ME-02308)
ObGyn
Centrosome Abnormalities in Ovarian Cancer
(UPMC Competitive Medical Research Fund)
ObGyn
Testing of Compounds Against Lactobacillus
(CONRAD Program/EVMS)
ObGyn
Effect of Leptin on Placental Amino Acid Transport
to Fetal Growth (Pennsylvania Dept. of Health))
ObGyn
Development of a Vaginal Drug Delivery System
for PSC-RANTES
(James B. Pendleton Charitable Trust)
75
Rohan
Schreiber
ObGyn
Lymph Node Mapping in Cervical Cancer
ObGyn
Mifepristone and Misoprostol for the Treatment of
Early Pregnancy Failure: A Pilot Clinical Trial
Scaife
12/1/00-11/30/06
$200,000
(Anonymous
Foundation)
12/1/04-11/30/05
$24,197
TOTAL OB GYN NON-FEDERAL
$7,558,473
NON-FEDERAL SUBCONTRACTS
Gooch
Wiesenfeld
ObGyn
Reproductive Health Program for Women with
Diabetes Across the Lifespan (UPMC Adult Clinical
Services Division, Univ. of Pittsburgh Diabetes Inst.)
UPMC
7/1/05-6/30/06
$39,000
ObGyn
A Multicenter, Randomized, Double-Blind,
Vehicle-Controlled Study to Evaluate Maintenance
Therapy with 0.75% Metronidazolee Vaginal Gel to
Prevent Recurrent Bacterial Vaginosis (Wayne State
Univ. thru 3M Pharmaceuticals)
3M
8/28/00-1/31/05
$27,108
TOTAL OB GYN NON-FEDERAL SUBCONTRACTS
$66,108
INDUSTRY SUPPORT
Creinin
Creinin
Creinin
Edwards
Edwards
ObGyn
A Multi Center, Open Label, Uncontrolled Study to
Investigate the Efficacy and Safety of a 4-phasic Oral
Contraceptive SH T00658ID Estradiol,
Valerate/Dienogest in a 28-Day Regimen for 13 Cycles
in 240 Healthy Female Volunteers (Berlex, Inc.)
Berlex
4/12/05-5/31/07
$12,242
Organon
5/1/05-10/31/06
$514,930
Althenium
11/1/05-5/31/08
$2,820
Unither
4/1/03-3/31/08
$18,525
ObGyn
A Phase 3 Randomized Study of TLK286 (Telcyta )
in Combination with Carboplatin (Paraplatin ) versus
Liposomal Doxorubicin (Doxil ) as Second-Line
Therapy in Platinum Refractory or Resistance Ovarian
Cancer (Telik, Inc.)
Telik
8/1/05-4/30/06
$30,400
ObGyn
Describing the Psychosocial Burden of Illness Among
Women Experiencing HPV-Related Illness or
Screening Interventions (Merck & Co., Inc.)
Merck
12/9/04-5/31/06
$19,889
ObGyn
An Open-Label, Randomized, Multi-Center Trial to
Evaluate Continuation Rates, Side Effects and
Acceptability of NuvaRing versus OrthoEvra
(Organon Pharmaceuticals USA, Inc.)
ObGyn
Mifepristone and Vaginal Misoprostol Treatment
of Early Pregnancy Failure in a Clinical Setting
(Athenium Pharmaceuticals, LLC)
ObGyn
OVA-Gy-17 Study (Unither Pharmaceuticals, LLC)
™
™
®
Edwards
76
Edwards
Edwards
Guido
Harwood
Harwood
Hillier
Kelley
Kelley
Kelley
Kelley
ObGyn
A Phase III, Double-Blind, Randomized, Controlled
Study to Evaluate the Safety, Immunogenicity and
Efficacy of GlaxoSmithKline Biologicals’
HPV-16/18L1/AS 04 Vaccine Administered
Intramuscularly According to a Three-Dose Schedule
in Healthy Female Subjects Aged 26 Years and Above
(GlaxoSmithKline)
GSK
4/3/06-4/2/07
$2,000
ObGyn
A Non-Interventional Prospective Study of the Accuracy
of the Precision Therapeutics, Inc. ChemoResponse
Assay in Patients with Recurrent Epithelial Ovarian,
Peritoneal or Fallopian Tube Cancer (Precision
Therapeutics, Inc.)
PTI
8/15/05-8/14/07
$4,810
ObGyn
Clinical Study Protocol 1547-851B
(3M Innovative Properties Co. through
3M Pharmaceuticals)
3M
5/16/06-6/30/09
$6,258
Organon
1/1/04-6/30/05
$23,726
Warner Chil.
4/13/04-6/30/06
$39,759
ObGyn
Gram Stain Evaluations for T-500 Phase III Study
(Presutti Laboratories, LLC)
Presutti
2/7/05-2/28/06
$8,119
ObGyn
A Randomized, Worldwide, Placebo-Controlled,
Double-Blind Study to Investigate the Safety,
Immunogenicity and Efficacy on the Incidence
of HPV16/18-Related CIN 2/3 or Worse of the
Quadrivalent HPV (Types 6,11,16,18) L1 Virus-Like
Particle (VLP) Vaccine in Consistency Lots for 16 to
23 Year Old Women (Merck & Co., Inc.)
Merck
7/1/02-8/31/07
$211,253
ObGyn
Actimmune in Combination with Chemotherapy for
First-Line Therapy of Advanced Ovarian or Primary
Peritoneal Carcinoma (INTERMUNE, Inc.)
Intermune
2/14/02-2/14/10
$41,923
ObGyn
A Phase II Trial of the Impact of CYP3A
and MDR1 Genotypes on Docetaxel Clearance in
Patients with Advanced Epithelial Ovarian Carcinoma
or Primary Peritoneal Carcinoma Treated with
Intravenous Docetaxel and Carboplatin
(Aventis Pharmaceuticals, Inc.)
Aventis
5/1/04-4/30/06
$283,890
4/27/05-4/30/08
$20,451
ObGyn
Evaluation of NuvaRing for the Treatment of
Abnormal Bleeding Patterns in the Perimenopause
(Organon Pharmaceuticals, Inc.)
ObGyn
Protocol 10503 - An Open Label Study of the
Contraceptive Efficacy and Safety of Norethindrone
Acetate 1mg/Ethinyl Estradiol 0.005, 0.030, and
0.035mg Oral Tablets Administered for 24 Days of a
28-Day Cycle (Warner Chilcott, Inc.)
ObGyn
A Phase 3 Randomized Study of TLK286 versus Doxil /
CAELYX Alone in Subjects with Advanced Relapsed
Ovarian Cancer (Johnson & Johnson Pharmaceutical
Research & Development, LLC
J&JPRD
®
®
77
Roberts
Sanfilippo
Wakim
ObGyn
Remote Site Collection Center
(National Disease Research Interchange)
NDRI
8/1/02-7/31/06
$76,563
ObGyn
A Randomized, Multicenter, Double-Blind Exploratory
Study to Evaluate the Efficacy of an Extended Cycle
Combination Oral Contraceptive, DP3-84/10 which
Utilizes Ethinyl Estradiol During the Usual HormoneFree Interval, Compared to Placebo for the Treatment
of Cyclic Pelvic Pain in Adolescents
(Duramed Research, Inc.)
Duramed
12/1/05-11/30/06
$15,000
ObGyn
A Multi-Center, Randomized, Open-Label, Parallel
Group Study of a Vaginal Micronized Progesterone
Tablet (Endomeetrin ) Compared to Crinone 8%
Vaginal Gel in Female Patiens Undergoing IVF
(Ferring Pharmaceuticals, Inc.)
Ferring
9/30/05-1/31/05
$70,485
Pfizer
4/1/04-3/31/05
$49,985
ObGyn
A Phase 3 Randomized, Multi-Center, Double-Blind,
Double-Dummy Placebo Controlled Treatment Trial
of Bacterial Vaginosis with Tinidazole Oral Tablets
(Presutti Laboratories, LLC),
Presutti
1/18/05-1/31/06
$65,370
ObGyn
The Evaluation of an In Vitro Diagnostic Test for
Vaginal Yeast Infection (Savyon Diagnostics Ltd.)
Savyon
3/1/06-4/30/07
$1,480
ObGyn
BE-DRI Study of the Urinary Incontinence
Treatment Network (New England Research Institutes,
Inc. under Pfizer Grant CTA-DK-04-0068)
NERI
7/1/05-9/30/06
$6,400
®
Wiesenfeld
Wiesenfeld
Wiesenfeld
Zyczynski
ObGyn
Treatment of Vulvodynia with Gabapentin:
A Randomized Controlled Trial (Pfizer, Inc.)
TOTAL OB GYN INDUSTRY SUPPORT
$1,532,578
INTRAMURAL AWARDS
THE IRENE McLENAHAN YOUNG INVESTIGATOR RESEARCH FUND 2003
Henry
Pediatrics
Cardiomegaly and Cardiac Function in Low Birth
Weight Infants
IMYIRF
1/1/03-12/31/06
$2,000
Bodnar
Zhang
78
ObGyn
Periconceptional Dietary Intake and Disorders of
Implantation
IMYIRF
1/1/04-12/31/06
$2,000
ObGyn
Epidemiological Study of Seroprevalance Rates of
VP1/VP2 Antibodies to Human Parvovirus B19
Among Patients with Preeclampsia
IMYIRF
1/1/04-12/31/05
$2,000
Chen
Lowder
ObGyn
Prospective Comparison of Clean Catch and
Catheterized Urine Specimens for Determination of
Protein/Creatinine Ratio in Evaluation of Preeclampsia IMYIRF
1/1/05-6/30/06
$2,500
ObGyn
Body Image in Women with Pelvic Organ Prolapse
1/1/05-7/31/06
$2,500
IMYIRF
Daucher
McClure
ObGyn
The Prevalence of Pelvic Organ Prolapse and Stress
Urinary Incontinence Following Weight Reduction
IMYIRF
1/1/06-12/31/06
$2,500
Centers for Rehab
Breast Cancer Recovery Program, Efficacy for
Women with Unilatera Upper Extremity
Lymphedema Following Breast Cancer Surgery
IMYIRF
1/106-12/31/06
$2,479
TOTAL IRENE McLENAHAN YOUNG INVESTIGATOR AWARDS
$14,000
79
80
PUBLICATIONS
PUBLICATIONS
Abner, S.R., Guenthner, P.C., Guarner, J.,
Hancock, K.A., Cummins, Jr., J.E., Fink, A.,
Gilmore, G.T., Staley, C., Ward, A., Ali, O.,
Binderow, S., Cohen, S., Grohskopf, L.A.,
Paxton, L., Hart, C.E., and Dezzutti, C.S. A
human colorectal explant culture to evaluate
topical microbicides for the prevention of HIV
infection. J. Infect. Dis. 192:1545-1556, 2005.
ACOG Committee on Practice Bulletins (Hill
LM) et al. Clinical Management Guidelines for
Obstetrician-Gynecologists. ACOG Practice
Bulletin 104;6:1449-1458, December 2004.
Achilles SL, Amortegui AJ, Wiesenfeld HC.
Endometrial plasma cells: do they indicate subclinical pelvic inflammatory disease? Sex Transm
Dis. 2005;32(3)185-188.
Agatisa, PK; Ness, RN; Roberts, JM;
Costantino, JP; Kuller, LH; McLaughlin, MK:
Impairment of endothelial function in women
with a history of preeclampsia: an indicator of
cardiovascular risk: Am J Physiol Heart Circ,
286, H1389-93, 2004.
Ahrens ET, Srinivas M, Capuano S, Simhan
HN, Schatten GP. Magnetic resonance imaging
of embryonic and fetal development in model
systems. Methods Mol Med. 2006, 124:87-101.
Amundson NR, Flores AE, Hillier SL, Baker
CJ, Ferrieri P. DNA macrorestriction analysis of
nontypeable group B streptococcal isolates: clonal evolution of nontypeable and type V isolates. J
Clin Microbiol 2005; 43: 572-576.
Anderson BL, Simhan HN, Landers DV.
Improving Universal Prenatal Screening for
Human Immunodeficiency Virus. Infectious
Diseases in Obstetrics and Gynecology.
2004;12(3/4):115-120
Anderson BL, Sherman FS, Simhan HN. Fetal
Echocardiogram Findings Are Not Predictive Of
Death in Twin-Twin Transfusion Syndrome.
Journal of Ultrasound in Medicine, 2006;
25(4):455-9.
Augustine Rajakumar, Heather M. Brandon,
Premeela A. Rajakumar, Eiji Shibata, Carl A.
Hubel, Ananth Karumanchi, Ravi Thadhani,
Myles Wolfe, Gail Harger, Nina Markovic.
Extra-placental Expression of Vascular
Endothelial Growth Factor Receptor-1, (Flt-1)
and soluble Flt-1, (sFlt-1) by Peripheral Blood
Mononuclear Cells (PBMCs) in Normotensive
and Preeclamptic Pregnant Women. Placenta
2005, 26 (7), p 563-573
Augustine Rajakumar, Heather M. Brandon,
Ashi Daftary, Roberta Ness and Kirk P.
Conrad. Evidence for the functional activity of
hypoxia inducible transcription factors over
expressed in preeclamptic placentae. Placenta
(2004 ) 25 (10) 763-769.
Augustine Rajakumar, Ketah Doty, Ashi
Daftary, Nina Markovic and Kirk P. Conrad.
Expression of von Hippel Lindau (pVHL) protein in placentae from normal pregnant women
and women with preeclampsia. Placenta 2006,
27(4-5) p 411-421.
Augustine Rajakumar, Shanthie Thamotharan,
Nupur Raychaudhuri, Ram Menon, and Sherin
U. Devaskar. Trans-activators Regulating
Neuronal Glucose Transporter Isoform-3 Gene
Expression in Mammalian Neurons.J. Biol
Chem. (2004) 279 (25) p 26768-26779.
Ault KA, Giuliano AR, Edwards RP, Tamms G,
Kim LL, Smith JF, Jansen KU, Allende M,
Taddeo FJ, Skulsky DM, Barr E. A Phase I
Study to Evaluate a Human Papillomavirus
(HPV) Type 18 L1 VLP Vaccine. Vaccine
2004;22:3004-3007.
Austin MN, Beigi RH, Meyn LA, Hillier SL.
Microbiologic response to treatment of bacterial
vaginosis with topical clindamycin or metronidazole. J Clin Microbiol 2005; 43: 4492-4497.
Antonio MAD, Rabe LK, Hillier SL.
Colonization of the rectum by Lactobacillus
species and decreased risk of bacterial vaginosis.
J Infect Dis 2005; 192: 394-8.
Bahado-Singh RO, Wapner R, Thom E,
Zachary J, Platt L, Mahoney MJ, Johnson A,
Silver RK, Pergament E, Filkins K, Hogge WA,
Wilson RD, Jackson LG; First Trimester
Maternal Serum Biochemistry and Fetal Nuchal
Translucency Screening Study Group. Elevated
first-trimester nuchal translucency increases the
risk of congenital heart defects. Am J Obstet
Gynecol 2005 May;192(5): 1357-61.
Ahrens ET, Srinivas M, Capuano S, Simhan
HN, Schatten GP. Magnetic resonance imaging of embryonic and fetal development in
model systems. Methods Mol Med. 124:87-101
(2006).
Baysal BE, Willett-Brozick JE, Bacanu SA,
Detera-Wadleigh S and Nimgaonkar VL.
Common variations in ALG9 are not associated
with bipolar I disorder: a family based study.
Behav Brain Funct. 2006 Jul 21;2(1):25
81
Baysal BE, DeLoia JA, Willett-Brozick JE,
Goodman MT, Brady MF, Modugno F, Lynch
HT, Conley YP, Watson P, Gallion HH. Analysis
of CHEK2 gene for ovarian cancer susceptibility
Gynecol Oncol. 2004 Oct;95(1):62-9.
Baysal BE, Willett-Brozick JE, Filho PA,
Lawrence EC, Myers EN, Ferrell RE. An Alumediated partial SDHC deletion causes familial
and sporadic paraganglioma. J Med Genet. 2004
Sep;41(9):703-9.
Baysal BE, Willett-Brozick JE, Andrade P,
Lawrence EC, Ferrell RE. An Alu-mediated partial SDHC deletion causes familial and sporadic
paraganglioma J Med Genet 2004; 41: 703-9.
Baysal BE. Genomic imprinting and environment in hereditary paraganglioma Am J Med
Genet C Semin Med Genet. 2004 Aug
15;129(1):85-90.
Baysal BE. Krebs cycle enzymes as tumor suppressors. Drug Discovery Today: Disease
Mechanisms (2005) 2(2): 247-254.
Beer, B.E., Doncel, G.F., Krebs, F., Shattock, R.,
Fletcher, P., Buckheit, R., Watson, K., Dezzutti,
C.S., Cummins, Jr., J.E., Bromley, E.,
Richardson-Harman, N., Pallansch, L.,
Lackman-Smith, C., Osterling, C., Mankowski,
M., Miller, S.R., Catalone, B.J., Welsh, P.A.,
Howett, H.K., Wigdahl, B., Turpin, J.A., and
Reichelderfer, P. Multisite comparison of
nonoxynol 9 toxicity in vitro. Antimicrob.
Agents Chemother. 50:713-723, 2006.
Beigi RH, Austin MN, Meyn LA, Krohn MA,
Hillier SL. Antimicrobial resistance with the
treatment of bacterial vaginosis. Am J Obstet
Gynecol 2004; 191: 1124-9.
Beigi RH, Meyn, LA, Hillier SL. Vaginal yeast
colonization in non-pregnant women: a longitudinal study. Obstet Gynecol 2004; 104: 926-30.
Beigi RH, Wiesenfeld, HW, Hillier SL, Straw
T, Krohn MA. Bacterial vaginosis and lactobacilli. Factors associated with absence of H2O2producing Lactobacillus among women with
bacterial vaginosis. J Infect Dis 2005; 191: 924-9.
Beigi RB, Wiesenfeld HC. Enoxaparin for postpartum ovarian vein thrombosis-a case report. J
Reprod Med 2004;49:55-57.
82
Ben-Yehudah A, Witchel SF, Hyun SH, Chaillet
JR, Schatten G. Can diabetes be cured by therapeutic cloning? Pediatr Diabetes 2004;5 Suppl
2:79-87.
Ben-Yehudah A, Reinhart B, Navara C, Kotzuk
J, Witchel S, Schatten G, Chaillet JR. Specific
dynamic and noninvasive labeling of pancreatic
beta cells in reporter mice. Genesis. 2005 Dec;
43(4): 166-74.
Berghella V, Iams JD, Newman, RB,
MacPherson C, Goldenberg RL, MuellerHeubach E, Caritis SN, Dombrowski MP, for
the NICHD Network of Maternal-Fetal
Medicine Units Network. Frequency of uterine
contractions in asymptomatic pregnant women
with or without a short cervix on transvaginal
ultrasound. Am J Obstet & Gynecol 191:125356, 2004.
Beriwal S, Gerszten K, Kelley JL, Edwards RP.
Intensity-modulated radiotherapy for the treatment of vulvar carcinoma: A comparative dosimetric study with early clinical outcome. Int J
of Radiation Oncology Biol Phys 64:1395-1400,
2006.
Beriwal S, Jain S, Heron D, Kim H, Gerszten K,
Edwards RP, Kelley JL. Clinical outcome with
adjuvant treatment of endometrial carcinoma
using intensity-modulated radiation therapy.
Gynecologic Oncology 102:195-199, 2006.
Boggess KA, Trevett TN, Madianos PN, Rabe
L, Hillier SL, Beck J, Ofenbacher, S. Use of
DNA hybridization to detect vaginal pathogens
associated with bacterial vaginosis among asymptomatic pregnant women. Am J Obstet Gynecol
2005; 193: 752-6.
Bower, W., Culver, D.H., Castor, D., Wu, Y.,
James, V.N., Hammer, S., Kuhnert, W.L.,
Williams, I.T., Bell, B.P., Vlahov, D., and
Dezzutti, C.S. Suppression of HIV RNA titers
with HAART results in elevated HCV RNA
titers in HIV/HCV coinfected patients. J. AIDS
42:293-297, 2006.
Boyd MA, Antonio MAD, Hillier SL.
Comparison of API 50 CH strips to whole-chromosomal DNA probes for the identification of
Lactobacillus species. J Clin Microbiol 2005;
43:5309-5311.
Beigi RH, Austin MN, Meyn LA, Krohn MA,
Hillier SL. Antimicrobial resistance associa-ted
with the treatment of bacterial vaginosis. Am J
Obstet Gynecol. 2004 Oct;191(4):1124-9.
Buageaw A, Sukhwani M, Ben-Yehudah A,
Ehmcke J, Rawe VY, Pholpramool C, Orwig
KE, Schlatt S. 2005. GDNF family receptor
alpha1 phenotype of spermatogonial stem cells
in immature mouse testes. Biol. Reprod. 2005;
73:1011-1016.
Beigi RH, Meyn LA, Moore DM, Krohn MA,
Hillier SL. Vaginal yeast colonization in nonpregnant women: a longitudinal study. Obstet
Gynecol. 2004 Nov;104(5):926-30.
Burrows LJ, Howden NLS, Meyn L, Weber
AM. Surgical procedures for urethral diverticula
in women in the United States, 1979-1997. Int J
Urogyn 2005; 16: 158-161.
PUBLICATIONS
Burrows LJ, Howden NL, Meyn L, Weber AM.
Maternal morbidity associated with vaginal versus cesarean delivery. Obstet Gynecol 2004; 103:
907-12.
Burrows LJ, Meyn L, Walters MD, Weber AM.
Pelvic symptoms in women with pelvic organ
prolapse. Obstet Gynecol 2004; 104: 982-988.
Canavan TP, Simhan HN, Caritis SN. An
Evidence-Based Approach to the Evaluation and
Treatment of Premature Rupture of Membranes:
Part I. Obstetrical and Gynecological Survey.
2004; 59(9): 669-677.
Canavan TP, Simhan HN, Caritis SN. An
Evidence-Based Approach to the Evaluation and
Treatment of Premature Rupture of Membranes:
Part II. Obstetrical and Gynecological Survey.
2004; 59(9): 678-689.
Caritis S: Adverse effects of tocolytic therapy.
Br J Obstet & Gynecol, 112:Suppl 1, pp.1-5,
2004.
Carlisle, D.L., Hopkins, T.M., Gaither-Davis,
A., Silhanek, M.J., Luketich, J.D., Christie, N.,
Siegfried, J.M. (2004) Nicotine signals through
muscle-type and neuronal nicotinic acetylcholine
receptors in both human bronchial epithelial
cells and airway fibroblasts. Res. Research.
5(27)1-16.
Castle P, McIntyre-Seltman K, Guido RS.
Smoking is a risk factor for cervical intraepithelial neoplasia grade 3 among oncogenic HPV
DNA positive women with equivocal or mildly
abnormal cytology. Cancer Epidemiol
Biomarkers Prev 2005;14(5):1165-70.
Chang JC, Cluss PA, Ranieri L, Hawker L,
Buranosky R, Dado D, McNeil M, Scholle SH.
Healthcare Interventions For Intimate Partner
Violence: What Women Want Women’s Health
Issues, 2005;15(1): 21-30.
Chang JC, Decker M, Moracco KE, Martin SL,
Petersen R, Frasier PY. Asking About Intimate
Partner Violence: Advice from Female Survivors
to Health Care Providers. Patient Education and
Counseling. 2005;59(2): 141-147
Cherpes TL, Melan MA, Kant JA, Cosentino
LA, Meyn LA, Hillier SL. Genital tract shedding of herpes simplex virus type 2 in women:
effects of hormonal contraception, bacterial
vaginosis, and vaginal Group B Streptococcus
colonization. Clin infect Dis 2005; 40: 1422-8.
Cherpes TL, Meyn LA, Hillier SL.
Cunnilingus and vaginal intercourse are risk factors for herpes simplex virus type 1 acquisition
in women. Sex Transm Dis 2005; 32: 84-89.
Cherpes, TA, Wiesenfeld, HC, Melan MA,
Kant JA, Cosentino LA, Meyn LA, Hillier SL.
The associations between pelvic inflammatory
disease, trichomonas vaginalis infection, and positive Herpes Simplex Virus Type 2 serology. Sex
Transm Dis. 2006; 33.
Connor V, Apgar BS, Creinin M, Wysocki S.
Current options in contraception: Help your
patient choose wisely for satisfaction and adherence. J Fam Pract 2006;55:1-8.
Conrad KP, Debrah, DO, Novak J, Danielson
LA, Shroff SG. Relaxin modifies systemic arterial resistance and compliance in conscious, nonpregnant rats. Endocrinology 145:3289-3296,
2004.
Constantinescu, D, Csoka, A, and Schatten, G.
Lamin A/C expression is an Early Marker of
Mouse and Human Embryonic Stem Cell
Differentiation. Stem Cells (1):177-85 (2006).
Cook, RL, Comer DM, Wiesenfeld HC,
Chang CC, Tarter R, Lave JR, Clark DB.
Alcohol and drug use and related disorders: An
under recognized health issue among adolescents
and young adults attending sexually transmitted
disease clinics. Sex Transm Dis 2006; Mar 27
(EPub).
Corey L, Wald A, Patel R, and the Valacyclovir
HSV Transmission Study Group (Wiesenfeld
HC). Once-daily valacyclovir to reduce the risk
of transmission of genital herpes. N Engl J Med.
2004;350:11-20.
Costoya JA, Hobbs RM, Barna M, Cattoretti G,
Manova K, Sukhwani M, Orwig KE,
Wolgemuth DJ, Pandolfi PP. 2004. Essential
role of Plzf in maintenance of spermatogonial
stem cells. Nature Genetics 36: 653-659.
Creinin MD, Fox MC, Teal S, Chen A, Schaff
EA, Meyn LA, MOD Study Trial Group
(Harwood B). A randomized comparison of
misoprostol 6 to 8 hours versus 24 hours after
mifepristone for abortion. Obstetrics and
Gynecology 103 (5 pt 1):851-9, 2004.
Creinin MD, Harwood B, Guido RS, Fox
MC, Zhang J, NICHD Management of Early
Pregnancy Failure Trial Group. Endometrial
thickness after misoprostol use for early pregnancy failure. International Journal of
Gynaecology and Obstetrics 86(1):22-6, 2004.
Creinin MD, Shore E, Balusubramanian B,
Harwood B. The true cost differential between
mifepristone and misoprostol compared to misoprostol alone for medical abortion.
Contraception 2005;71:26-30.
83
Creinin MD, Fox MC, Teal S, Chen A, Schaff
EA, Meyn LA, MOD Study Trial Group. A multicenter, randomized comparison of misoprostol
6 to 8 hours versus 24 hours following mifepristone for abortion through 63 days gestation.
Obstet Gynecol 2004;103:851-9.
Creinin MD, Harwood B, Guido RS, Fox
MC, Zhang J, NICHD Management of Early
Pregnancy Failure Trial group. Endometrial
thickness after misoprostol use for early pregnancy failure. Int J Gynecol Obstet 2004;86:22-6.
Creinin MD, Keverline S, Meyn LA. How regular is regular? An analysis of menstrual cycle
regularity. Contraception 2004;70:289-92.
Dezzutti, C.S., Astemborski, J., Thomas, D.L.,
Marshall, J.H., Cabrera, T., Purdy M., Vlahov,
D., and Garfein, R.S. Human Immunodeficiency
Virus (HIV) and the Occurrence of
Cryoglobulinemia among Hepatitis C Virus
(HCV) Coinfected Injection Drug Users. J.
Clin. Virol. 31:210-214, 2004.
Creinin MD, Huang X, Westhoff C, Barnhart
K, Gilles JM, Zhang J. Factors related to successful misoprostol treatment for early pregnancy failure. Obstet Gynecol 2006;107:901-7.
Dezzutti, C.S., James, V.N., Ramos, A.,
Sullivan, S.T., Siddig, A., Bush, T.A., Grohskopf,
L.A., Paxton, L., Subbarao, S., Hart, C.E. In
Vitro Comparison of Topical Microbicides for
the Prevention of HIV Transmission.
Antimicrob. Agents Chemother. 48:3834-3844,
2004.
Csoka AB, English SB, Simkevich CP,
Ginzinger DG, Butte AJ, Schatten GP,
Rothman FG, Sedivy JM.Genome-scale expression profiling of Hutchinson-Gilford progeria
syndrome reveals widespread transcriptional
misregulation leading to mesodermal/mesenchymal defects and accelerated atherosclerosis.
Aging Cell. 2004; 3:235-43.
Dombrowski MP, Schatz M, Wise R, Momirova,
M, Landon M, Mabie W, Newman R, McNellis
D, Hauth J, Lindheimer M, Caritis S, Leveno
K, Meis P, Miodovnik M, Wapner R, Paul R,
Varner M, O’Sullivan M, Thurnau G, Conway
D for The NICHD Maternal-Fetal Medicine
Units Network, and The NHLBI. Asthma
During Pregnancy. Obstet Gynecol, 103(1): 512, 2004.
Csoka AB, Cao H, Sammak PJ, Constantinescu
D, Schatten GP, Hegele RA. Novel lamin A/C
gene (LMNA) mutations in atypical progeroid
syndromes. J Med Genet. 2004 Apr;41(4):304-8.
Dombrowski M, Schatz M, Wise R, Thom E,
Landon M, Mabie W, Newman R, McNellis D,
Hauth J, Lindheimer M, Caritis S, Leveno K,
Meis P, Miodovnik M, Wapner R, Varner M,
O’Sullivan M, Conway D, for the NICHD
Maternal-Fetal Medicine Units Network and
The NHLBI. Randomized trial of inhaled
beclomethasone dipropionate versus theophylline for moderate asthma during pregnancy.
Am J Obstet & Gynecol 190(3):737-44, 2004.
Cummins, Jr., J.E, Christensen, L.L., Switzer,
W.M., Boneva, R.S., Heneine, W., Folks, T.M.,
Chapman, L.E., Sandstrom, P.A., Dezzutti, C.S.
Mucosal Antibody Responses in Humans
Occupationally Infected with SFVcpz. J. Virol.
79:13186-13189, 2005.
Cummins, Jr., J.E., Christensen, L., Lennox,
J.L., Bush, T.J., Wu, Z., Malamud, D., EvansStrickfaden, T., Siddig, A., Caliendo, A.M.,
Hart, C.E., and Dezzutti, C.S. Mucosal innate
immune factors in the female genital tract are
associated with vaginal HIV-1 shedding independent of plasma viral load. AIDS Res. Hum.
Retroviruses 22:788-795, 2006.
Davis AR, Robilotto CM, Westhoff CL, Forman
S, Zhang J, NICHD Management of Early
Pregnancy Failure Trial group (…Creinin
MD…). Bleeding patterns after vaginal misoprostol for treatment of early pregnancy failure.
Human Reprod 2004;19:1655-8.
84
DeLoia, JA, W.C. Zamboni, J. Jones, H.H.
Gallion Expression and function of taxane-metobolizing enzymes in ovarian tumors; a potentially novel mechanism of taxane resistance. Society
for Gynecologic Oncology, 2004.
DeLoia JA, Zamboni W, Jones J. Variable
expression and activity of taxane-metabolizing
enzymes in ovarian tumors as a potential mechanism of taxane-resistance. American Society of
Human Genetics, October 2005.
Donnenberg VS, Popovic AM, Gallion HH,
DeLoia JA, Donnenberg AD. Suppression of
immune effector responses in ovarian cancer
ascites. American Association of Cancer
Research, 2004.
Donnenberg VS, Luketich JD, DeLoia JA,
Brufsky AM, Romoff JA, Donnenberg AD.
Constitutive Multiple Drug Resistance in Tumor
Stem Cells, American Association of Cancer
Research, 2005.
Donovan, M., Miles, T.D., Latimer, J.J., Grant,
S., Talbott, E., Sasco, A.J., and Davis, D.L.
(2006). Association between biomarkers ofenvironmental exposure and increased risk of breast
cancer. Nature Reviews Cancer 6(8):c1[reply
6(8): c2].
Eckert LO, Thwin SS, Hillier SL, Kiviat NB,
Eschenbach DA. The antimicrobial treatment of
sub-acute endometritis: a proof of concept study.
Am J Obstet Gynecol 2004; 190: 305-13.
PUBLICATIONS
Eid GM, Cottam DR, Velcu LM, Mattar SG,
Korytowski MT, Gosman G, Hindi P, Schauer
PR. Effective treatment of polycystic ovarian
syndrome with Roux-en-Y gastric bypass. Surg
Obes Relat Dis. 2005; 1(2)77-80.
Eiji Shibata, Augustine Rajakumar, Robert W.
Powers, Robert W. Larkin, Carol Gilmour, Lisa
M. Bodnar, William R. Crombleholme, Roberta
B. Ness, James M. Roberts, and Carl A.
Hubel. Soluble fms-like Tyrosine Kinase 1 (sFlt1) is increased in Preeclampsia but not in IUGR
Pregnancies Without Preeclampsia: Relationship
to Circulating Placental Growth Factor (PlGF).
JCEM 2005 90 (8), 4895-4903.
Eiji Shibata, Robert W. Powers, Augustine
Rajakumar, Frauke von Versen-Hoynck, Marcia
J. Gallegher, David L. Lykins, James M.
Roberts, and Carl A. Hubel. Angiotensin II
decreases system A amino acid transporter activity in human villous fragments through AT1
receptor activation. Am J Physiol Endocrinol
Metab June 20 2006, doi: 10.1152/ajpendo.
00134.2006.
Ferrieri P, Baker CJ, Hillier SL, Flores AE.
Diversity of surface protein expression in group
B streptococcal colonizing & invasive isolates.
Indian J Med Res 2004; 119 (Suppl): 191-196.
Ferrieri P, Hillier SL, Moore D, Paoletti LC,
Flores AE. Characterization of vaginal & rectal
colonization with multiple serotypes of group B
streptococci using multiple conoly picks. Indian
J Med Res 2004; (Suppl); 208-212.
Gandley RE, Tyurin VA, Huang W, Arroyo A,
Daftary A, Harger G, Jiang G, Pitt B, Taylor
RN, Hubel CA, Kagan VE. S-nitroso-albumin–mediated relaxation is enhanced by ascorbate and copper: implications for impaired vascular function in preeclampsia. Hypertension,
2005 Jan;45(1):21-7.
Gerszten K, Selvaraj RN, Kelley JL, Faul CM.
Preoperative chemo-radiation for locally
advanced carcinoma of the vulva. Gynecologic
Oncology 2005;99:640-644.
Ghetti C, Chang J, Gosman G. Teaching
Empathy: Incorporating Balint Training in the
Obstetrics and Gynecology Residency 2006
CREOG & APGO Annual Meeting Grande
Lakes Orlando, Orlando, Florida, March 2 - 5,
2006.
Gilles JM, Creinin MD, Barnhart K, Westhoff
C, Frederick MM, Zhang J, NICHD
Management of Early Pregnancy Failure Trial
Group (….Harwood B…). A randomized trial of
saline solution-moistened misoprostol versus dry
misoprostol for first-trimester pregnancy failure.
American Journal of Obstetrics and Gynecology
190(2):389-94, 2004.
Gold MA, Huh WK, Cestero RM, Garcia FA,
Guido RM, Alvarez RD, McIntyre-Seltman K,
De Santis T, Harper DM, Sundborg M,
Holschneider C, Blank S, Edwards RP, Felix
JC, Ferris DG, Walker JL. Optical detection of
cervical neoplasia: Results from a randomized,
dual-arm, multi-center clinical trial. Society of
Gynecologic Oncologists, San Diego, California,
February 2004. (Gynecol Oncol 2004;92:397398).
Gopalani S, Krohn M, Meyn L, Crombleholme
WR. Contermporary management of preterm
premature rupture of membranes: Determinants
of latency and neonatal outcome. Am J Perinat
2004, 21 (4): 183-190.
Gordon AN, Schultes BC, Gallion H, Edwards
RP, Whiteside TL, Cermak JM, Nicodemus CF.
CA125 and tumor-specific T-cell responses correlate with prolonged survival in oregovomabtreated recurrent ovarian cancer patients.
Gynecol Oncol 2004;94:340-351.
Gosman GG, Simhan HN, Guido RS, Lee
TT, Mansuria SM, Sanfilippo JS. Focused
assessment of surgical performance: difficulty
with faculty compliance. Am J Obstet Gynecol
2005;193(5);1811-6.
Gosman GG, Katcher HI, Legro RS. Obesity
and the role of gut and adipose hormones in
female reproduction. Human Reproduction
Update. 2006;12(5):585-601.
Guenthner, P.C., Secor, W.E., and Dezzutti,
C.S. Trichomonas vaginalis-induced epithelial
monolayer destruction and HIV-1 replication:
implications for the sexual transmission of HIV1. Infect. Immun. 73:4155-4160, 2005.
Guido RS, Abdul-Mbacke, Meyn L. Vasopressin
injection during vaginal hysterectomy: A randomized, placebo-controlled trial. Obstet
Gynecol 2004;103(4):3s.
Ghetti C, Gregory WT, Edwards SR, Clark AL.
Severity of Pelvic Organ Prolapse is Associated
with Measurements of Genital Hiatus. Int
Urogynecol J Pelvic Floor Dysfunct. 2005 NovDec;16(6):432-6.
Guido RS, McIntyre-Seltman K, Walker JL,
Huh WK, Garcia FA, Cestero RM. Optical
detection of cervical Neoplasia: Results from a
randomized, duel-arm, multicenter trial. Obstet
Gynecol 2004;103(4):57s.
Ghetti C, Guise JM. Responses of Portland
Obstetricians to Patient Requested Cesarean
Delivery. Birth. 2004 Dec;31(4):280-4.
Guido RS. J Ped Adolesc Gyne. “Guidelines for
Screening and Treatment of Cervical Disease in
the Adolescent,”October 2004. Vol 17:5.
85
Guido RS, Jeronimo J, Schiffman M, Solomon
D, for the ALTS Group. The distribution of
neoplasia arising on the cervix: Am J Obstet
Gynecol 2005;193.1331-7.
Haggerty CL, Hillier SL, Bass DC, Ness RB.
Bacterial vaginosis and anaerobic bacteria are
associated with endometritis. Clin Infect Dis
2004; 39: 990-5.
Guido RS, English A. ACOG Committee
Opinion. Evaluation and management of abnormal cervical cytology and histology in the adolescent. Number 330, April 2006. Obstet
Gynecol. 2006 Apr;107(4):963-8. Review.
Haggerty CL, Peipert JF, Weitzen S, Hendrix
SL, Holley RL, Nelson DB, Randall H, Soper
DE, Wiesenfeld HC, Ness RB, and for the PID
Evaluation and clinical Health (PEACH) Study
Investigators. Predictors of chronic pelvic pain
in an urban population of women with symptoms and signs of pelvic inflammatory disease.
Sex Transm Dis 2005;32:293.
Gupta, P, Dampf, D., Patterson, BK, Rohan, L,
Parniak, M, Isaacs, CE, Hillier, SL. Use of
Frozen-thawed Cervical Tissues in the Organ
Culture System to Measure Antiviral Activities
of Microbicides Across the Mucosa. AIDS
Research & Human Retroviruses. 22(5):419-24,
2006 May.
Gupta P, Ratner D, Patterson BK, Caruso L,
Kulka K, Rohan LC, Parniak MA, Isaacs CE,
Hillier S. Use of frozen-thawed cervical tissues
in the organ culture system to measure anti-HIV
activities of candidate microbicides. AIDS
Research and Human Retroviruses 2006; 22:
419-424.
Ferrieri P, Hillier SL, Krohn MA, Moore D,
Paoletti LC, Flores AE. Characterization of
vaginal & rectal colonization with multiple
serotypes of group B streptococci using multiple
colony picks. Indian J Med Res. 2004 May;119
Suppl:208-12.
Fox MC, Creinin MD, Mayn LA, Murthy AS,
Harwood B, MOD Study Trial Group
Ultrasound appearance of the endometrium after
medical abortion. Association of Reproductive
Healthcare Professionals Annual Meeting,
September 2004, oral presentation
(Contraception 2004;70:261).
Forest, JC, Girouard, J, Masse, J; Moutquin, JM,
Kharfi, A, Ness, RB, Roberts, JM, Giguere, Y.
Early occurrence of metabolic syndrome after
hypertension in pregnancy. Amer Journ of Obst
& Gyn, 105; 1373-80; 2005.
GEAR-UP (Graduate Education And Research
at the University of Pittsburgh) A Program for
Educating Students about Pharmaceutical
Research. Poloyac, SM., Rohan, LC, Janjic,
JM, Gibbs, RB, Kroboth, PD Smith, RB.
American Journal of Pharmaceutical Education.
2005; 69(5).
Haggerty CL, Ferrell, RE, Hubel CA, Markovic
N, Harger G, Ness RB. Association between
allelic variants in cytokine genes and preeclampsia. Am J Obstet Gynecol, 2005; 193:209-215.
86
Haggerty CL, Hillier SL, Bass DC, Ness RB.
Bacterial vaginosis and anaerobic bacteria are
associated with endometritis. Am J Epidemiol
2004; 159 (11): S593.
Hamilton SH, Weber AM, Meyn L.
Ambulatory procedures for incontinence in the
United States, 1994-1996. Am J Obstet Gynecol
2004; 190: 33-36.
Harper DM. Huh WW, Guido RS, McIntyreSeltman K, Schomacker K. The effect of the
menstrual cycle phases on the optical algorithms
developed from diffuse reflectance. Obstet
Gynecol 2004;103(4):22s.
Harville E, Schramm M, Watt-Morse M,
Chautala K, Anderson J, Hertz-Picciotto I.
Calcium intake during pregnancy among white
and African-American pregnant women in the
United States. Journal of the American College
of Nutrition. Feb; 23(1): 43-50. 2004.
Helm CW, Martin III RS, Metzinger DS,
Edwards RP. Secondary surgical cytoreduction
and hyperthermic intraperitoneal chemotherapy
(SSC-HIPEC) for recurrent ovarian and
endometrial cancer. International Gynecologic
Cancer Society, Edinburgh, October 2004.
(International Journal of Gynecological Cancer,
Vol. 14, Suppl. 1, 2004:167).
Henderl I, Goldenberg RL, Mercer BM, Iams
JD, Meis PJ, Moawad AH, MacPherson CA,
Caritis SN, Miodovnik M, Menard KM,
Thurnau GR, Sorokin Y: the Preterm Prediction
Study: Association between maternal body mass
index and spontaneous and indicated preterm
birth. Am J Obstet Gynecol 192(3): 882-6, 2005.
Heron DE, Axtell A, Gerszten K, Amortegui A,
Kelley J, Comerci J, and Edwards RP.
Villoglandular adenocarcinoma of the cervix
recurrent in an episiotomy scar: A case report in
a 32-year-old female. International Journal of
Gynecologic Cancer 15:366-371, 2005.
Hewitson L. Primate models for assisted reproductive technologies. Reproduction. 2004 Sep;
128(3):293-9.
Hillier SL, Moench T. Shattock R, Black R,
Reichelderfer P, Veronese F. In vitro and in vivo:
the story of nonoxynol 9. J Acquire Immune
Defic Syndr 2005; 49: 1-8.
PUBLICATIONS
How HY. Sibai B. Lindheimer M. Caritis S.
Hauth J. Klebanoff M. Macpherson C. Van
Dorsten P. Miodovnik M. Landon M. Paul R.
Meis P. Thurnau G. Dombrowski M. Roberts
JM. Is early-pregnancy proteinuria associated
with an increased rate of preeclampsia in women
with pregestational diabetes mellitus? American
Journal of Obstetrics & Gynecology. 190(3):7758, 2004.
Howden NL, Weber AM, Meyn L. Episiotomy
use by residents and faculty compared to private
practitioners. Obstet Gynecol 2004; 103: 114118.
Hu J, Rao UN, Jasani S, Khanna V, Yaw K,
Surti U. Loss of DNA copy number of 10q is
associated with aggressive behavior of
leiomyosarcomas: a comparative genomic
hybridization study. Cancer Genet Cytogenet
2005;Aug:161(1):20-7.
Hu J, Shekhter-Levin S, Shaw PH, Bay C,
Kochmar S, Surti U. A case of myelodysplastic
syndrome with acquired monosomy 7 in a child
with a constitutional t(1;19) and a mosaicism for
trisomy 21. Cancer Genet Cytogenet 2005;Jan
1:156(1):62-7.
Hubel, CA; Bodnar, LM; Many, A; Harger, G;
Ness, R B; Roberts, JM: Nonglycosylated
Ferritin Predominates in the Circulation of
Women with Preeclampsia but Not Intrauterine
Growth Restriction, Clinical Chemistry, 948-51,
2004.
Hubel CA, Bodnar LM, Many A, Harger G,
Ness RB, Roberts JM. Non-glycosylated ferritin predominates in serum of women with
preeclampsia but not in intrauterine growth
restriction. Clin Chem 2004;50(5):948-51.
Hubel CA, *Wolf M, Lam C, Sampson M,
Ecker JL, Ness RB, Rajakumar A, Daftary A,
Shakir ASM, Seely EW, Roberts JM, Sukhatme
VK, Karumanchi SA, Thadhani R. Preeclampsia
and future cardiovascular disease: Potential role
of altered angiogenesis and insulin resistance. J
Clin Endocrinol Metab 2004;89:6239-43. *(equal
contributors).
*Hubel CA, *Ramirez RJJ, Novak J, DiCianno
JR, Kagan VE, and Gandley RE. Moderate
ascorbic acid deficiency increases myogenic reactivity of arteries from pregnant but not virgin
ascorbate-dependent rats. Hypertension
2006;47(3):454-60. (*equal contributors).
Huh WK, Gold MA, Walker JL, Garcia FA,
Cestero RM, Harper DM, Guido RM,
McIntyre-Seltman K, Sundborg M,
Holschneider C, Blank S, Edwards R, De Santis
T, Ferris DG, Felix JC, Alvarez RD. Optical
detection of cervical neoplasia: Final results from
a randomized, dual-arm, multi-center clinical
trial. International Gynecologic Cancer Society,
Edinburgh, October 2004. (International Journal
of Gynecological Cancer, Vol. 14, Suppl. 1,
2004:12).
Huh KW, Cestero RM, Garcia FA, Guido RS,
et al. Optical detection of high-grade cervical
intraaepithelial neoplasia in vivo: Results of a
604-patient study. Am J Obstet Gynecol 2004;
190 (5):1249-57.
Hsu, Lih-Ching, Ph.D, Julie A. DeLoia,
Ph.D, and Holly H. Gallion, MD Centrosome
abnormalities in ovarian cancer. Society for
Gynecologic Oncology, 2004.
Hsu, L.-C., Lee, R.M., and White, R.L. The
HPV16 E6/E7 oncogene sensitizes human ovarian surface epithelial cells to low-dose but not
high-dose 5-FU and 5-FUdR. Biochem.
Biophys. Res. Commun. 320, 249-255, 2004.
Hsu, L.-C., Kapali, M., DeLoia, J.A., and
Gallion, H.H. Centrosome defects in ovarian
tumorigenesis. Proc. American Association for
Cancer Research, volume 45, March 2004.
Hsu, L.-C., Kapali, M., DeLoia, J.A., and
Gallion, H.H. Centrosome abnormalities in
ovarian cancer. Int. J. Cancer 113, 746-751,
2005.
Hsu, L.-C., Huang, X., and Gollin, S.M. Gene
amplification and overexpression of protein
phosphatase 1a in oral squamous cell carcinoma
(OSCC) cell lines. Proc. American Association
for Cancer Research, volume 46, April 2005.
Hwang WS, Roh SI, Lee BC Kang SK, Kwon
DK, Kim S, Kim SJ, Park SW, Kwon HS, Lee
CK, Lee JB, Kim JM, Ahn C, Paek SH, Chang
SS, Koo JJ, Yoon HS, Hwang JH, Hwang YY,
Park YS, Oh SK, Kim HS, Park JH, Moon SY,
Schatten GP. Patient-specific embryonic stem
cells derived from human SCNT blastocysts.
Science. 2005 Jun 17;308(5729):1777-83.
Retraction in: Science 20;311(5759:335 (2006).
Isaacs, C E, Rohan, L C, Xu, W, Jia, J H,
Mietzner, T, Hillier, SL. Inactivation of Herpes
Simplex Virus Clinical Isolates Using a
Combination Microbicide. Antimicrobial Agents
and Chemotherapy, March 2006, p. 1063-1066.
Jari SD, Fraer LM, Hogge WA. Association of
undetectable unconjugated estriol on multiple
marker screening with steroid sulfatase deficiency. Fetal Diagn Ther. 2004 Jan-Feb;19(1):43-8.
87
Jazaeri A, Awtrey C, Chandramouli G, Chuang
T, Khan J, Sotiriou C, Apelikova O, Yee C,
Zorn K, Birrer M, Barrett J, Body J. Gene
expression profiles associated with response to
chemotheraopy in epithelial ovarian cancers.
Clinical Cancer Research 11(17):6300-10, 2005.
Jeyabalan A, Novak J, Danielson LA, Kerchner
LJ, Opett SL, Conrad KP. Essential role for vascular gelatinase activity in relaxin-induced renal
vasodilation, hyperfiltration, and reduced myogenic reactivity of small arteries. Circulation
Research 2003; 93:1249-1257.
Jeyabalan A, Kerchner LJ, Fisher MC,
McGuane JT, Doty KD, Conrad KP. Matrix
metalloproteinase-2 activity, protein, mRNA and
tissue inhibitors in small arteries from pregnant
and relaxin-treated nonpregnant rats. Journal of
Applied Physiology 2006;100(6):1955-63.
John JC, Ramalho-Santos J, Gray HL, Petrosko
P, Rawe VY, Navara CS, Simerly CR, Schatten
GP. The expression of mitochondrial DNA
transcription factors during early cardiomyocyte
in vitro differentiation from human embryonic
stem cells. Cloning Stem Cells 7(3): 141-53
(2005).
Johnson JM, Latimer JJ. Analysis of DNA
repair using transfection-based host cell reactivation. Methods Mol Biol 2005;291:321-35.
Kalro BN and Berga SL. Bleeding problems in
mid-life. Gynecology and Obstetrics, Ed:
Kaunitz A. Lippincott Williams and Wilkins.
Text Book on CD-ROM, 2004 Edition, Volume
5, Chapter 23.
Kelly CM, Latimer JJ. Unscheduled DNA synthesis: a functional assay for global genomic
nucleotide excision repair. Methods Mol Biol
2005;291:303-20.
Klebanoff MA, Hillier SL, Nugent RP,
MacPherson CA, Hauth JC, Carey JC, Harper
M, Wapner RJ, Trout W, Moawad A, Leveno
KJ, Miodovnik M, Sibai BM, Vandorsten JP,
Dombrowski MP, O’Sullivan MJ, Varner M,
Langer O. Is bacterial vaginosis a stronger risk
factor for preterm birth when it is diagnosed
earlier in gestation? Am J Obstet Gynecol 2005;
192: 470-7.
Klebanoff M, Hillier S, Nugent R, Macpherson
C, Hauth J, Carey J, Ernest J, Wapner R, Trout
W, Moawad a, Leveno K, Miodovnik M and the
NICHD Maternal-Fetal Medicine Units
Network (Carirtis S). Is bacterial vaginosis a
stronger risk factor for preterm birth when it is
diagnosed earlier in gestation? Am J Obstet &
Gynecol 192:470-7, 2005.
88
Kolthof MC, Wiesenfeld HC. Placenta accreta
requiring hysterectomy following endometrial
ablation. Female Patient 2006;31:21-6.
Krantz D, Goetzel L, Simpson JL, Thom E,
Zachary J, Hallahan TW, Silver R, Pergament
E, Platt LD, Filkins K, Johnson A, Mahoney M,
Hogge WA, Wilson RD, Mohide P, Hershey D,
Wapner R; First Trimester Maternal Serum
Biochemistry and Fetal Nuchal Translucency
Screening (BUN) Study Group. Association of
extreme first-trimester free human chorionic
gonadotropin-beta, pregnancy-associated plasma
protein A, and nuchal translucency with
intrauterine growth restriction and other adverse
pregnancy outcomes. Am J Obstet Gynecol
2004; Oct;191(4):1452-8.
Knudtson EJ. Smith K. Mercer BM. Miodovnik
M. Thurnau GR. Goldenberg RL. Meis PJ.
Moawad AH. Vandorsten JP. Sorokin Y. Roberts
JM. Das A. National Institutes of Child Health
and Human Development Maternal-Fetal
Medicine Units Network. Serum homocysteine
levels after preterm premature rupture of the
membranes. Amer Journ of Obst & Gyn.
191(2):537-41, 2004.
Kreimer AR, Guido RS, Solomon D, Schiffman
M, Wacholder S, Jeronimo J, Wheeler C, Castle
PE for the ALTS Group. Human papillomavirus
testing following loop electrosurgical excision
procedure identifies women at risk for posttreatment cervical intraepithelial neoplasia grade 2 or
3 disease. Cancer Epidemiol Biomarkers Prev.
2006 May;15(5):908-14.
Krivak TC, Cooksey C, Propst AM. Tubo-ovarian abscess: diagnosis, medical and surgical management. Comp Ther, 2004;30(2):93-100.
Krivak TC, Elkas JC, Rose GS, Sundborg M,
Winter WE, Carlson J, MacKoul PJ. The utility
of hand-assisted laparoscopy in ovarian cancer.
Gynecol Oncol, 2005;96(1):72-76.
Kwon S, Whitehead W, Visco A, for the Pelvic
Floor Disorders Network.(A. Weber) Validity
and reliability of the Modified Manchester
Health Questionnaire. Dis Colon Rectum 2005;
48: 323-31; discussion 331-334.
Landers DV, Wiesenfeld HC, Heine RP,
Krohn MA, Hillier SL. Predictive value of the
clinical diagnosis of lower genital tract infection
in women. Am J Obstet Gynecol
2004;190:1004-10.
Lain KY, Luppi P, Roberts JM, McGonigal S,
DeLoia JA. Intercellular adhesion molecule
concentrations in women who smoke during
pregnancy. Obstet Gynec, 107:588-594, 2006.
Lain KY, Krohn MA, Roberts JM. Second
pregnancy outcomes following preeclampsia in a
first pregnancy. Hypertens Pregnancy.
2005;24(2):159-69.
PUBLICATIONS
Laivuori H, Gallaher MJ, Collura L,
Crombleholme WR, Markovic N, Rajakumar
A, Hubel CA, Roberts JM and Powers RW.
Relationships between maternal plasma leptin,
placental leptin mRNA and protein in normal
pregnancy, pre-eclampsia and intrauterine
growth restriction without pre-eclampsia. Mol
Hum Reprod 2006 July 26 (Epub ahead of
print).
Luppi P, Tse H, Lain KY, Markovic N, Piganelli
J DeLoia JA. Preeclampsia activates circulating
immune cells with engagement of the NF-kB
pathway, Am J Reprod Immunol. 56:135-44,
2006.
Lampe, ML, Rohan, LC, Skinner, MC, Stamm,
WE. Susceptibility of Chlamydia trachomatis to
Excipients Commonly Used in Topical
Microbicide Formulations Antimicrobial Agents
and Chemotherapy. 2004, 48(8): 3200-3202.
Malina, A; Laivouri, H; Agatisa, P;
Crombleholme, W; Sims, C; Collura, L,
Roberts, JM: The Trp64Arg polymorphism of
the B3-adrenergic receptor is not increased in
women with preeclampsia. Amer J Obstet &
Gynecol 190(3); 779-83, 2004.
Landers DV, Weisenfeld HC, Heine RP,
Krohn MA, Hillier SL. Predictive value of the
clincial diagnosis of lower genital tract infection
in women. Am J Obstet Gynecol 2004; 190:
1004-1009.
Landon MB, Hauth JC, Leveno MD, Spong CY,
Leindecker MS, Varner MW, Moawad AH,
Caritis SN, Harper M, Wapner RJ, Sorokin Y,
Miodovnik M, Carpenter M, Peaceman AM,
O’Sullivan MJ, Sibai B, Conway D, Thorp JM,
Ramin SM, Mercer BM, Gabbe SG. The
MFMU Cesarean Registry: Maternal and perinatal outcome in women undergoing trial of
labor after cesarean delivery. New Engl J Med
351:2581-89, 2004.
Latimer JJ, Rubinstein WS, Johnson JM,
Kanbour-Shakir A, Vogel VG, Grant SG.
Haploinsufficiency for BRCA1 is associated with
normal levels of DNA nucleotide excision repair
in breast tissue and blood lymphocytes. BMC
Med Genet 2005 June 14;6(1):26.
Latimer JJ, Johnson JM, Kelly CM, Grant SG,
Vogel VG, Brufsky AM, and Kelley J. (2004)
Human breast cancer tumors manifest both
hereditary deficiency and somatic loss of DNA
(nucleotide excision) repair. Presented at the
2004 meeting of the Environmental Mutagen
Society, Pittsburgh, Pennsylvania. Environmental
and Molecular Mutagenesis 44: 211,2004.
Lee BC, Kim MK, Jang G, Oh HJ, Yuda F, Kim
HJ, Shamim MH, Kim JJ, Kang SK, Schatten
G. Hwang, WS. Dogs cloned from adult somatic
cells. Nature. 2005 Aug 4;436(7051):641.
Luppi P, Irwin T, Simhan H, DeLoia JA.
Cd11b expression on circulating leukocytes
increases in preparation for parturition.
American Journal of Reproductive Immunology,
52: 323-329, 2004.
Luppi P, DeLoia JA. Monocytes of preeclamptic
women spontaneously synthesize pro-inflammatory cytokines. Clin Imm, 118:268-75, 2006.
Makhlouf MA, Simhan HN. Effect of tocolytics
on interleukin-8 production by human amniotic
and decidual cells. Journal of Reproductive
Immunology. 2006; 69:1-7.
Malina, AN, Daftary A, Crombleholme W,
Markovic N, Roberts, JM: Placental system A
transporter mRNA is not different in preeclampsia, normal pregnancy, or pregnancies with small
for gestational age infants: Hypertension in
Pregnancy, 24: 65-74, 2005.
Mansuria S. and Sanfilippo J. “Laparoscopy in
the Pediatrics and Adolescent Population” In
Obstetrics and Gynecologic Clinics of North
America. 2004;31(3):469-84.
Marrazzo JM, Wiesenfeld HC, Murray PJ,
Busse B, Meyn L, Krohn M, Hillier SL. Risk
factors for cervicitis among women with bacterial vaginosis. J Infect Dis 2006;193:617-24.
Mauck CK, Creinin MD, Rountree W,
Callahan MM, Hillier SL. Lea’s Shield: colposcopic and microbiological testing during 8
weeks of use. Elsevier 2005; 72: 53-59.
Mauck CK, Weiner DH, Ballagh SA, Creinin
MD, Archer DF, Schwartz JL, et al. Single and
multiple exposure tolerance study of polystyrene
sulfonate gel: a phase I safety and colposcopy
study. Contraception 2004;70:77-83.
Mauck CK, Creinin MD, Barnhart KT, Ballagh
SA, Archer DF, Callahan M, et al. A phase I
comparative post-coital testing study of three
concentrations of C31G. Contraception
2004;70:227-31.
Mauck CK, Weiner DH, Creinin MD, Barnhart
KT, Callahan M, Bax R. A randomized phase I
vaginal safety study of three concentrations of
C31G vs. Extra-Strength Gynol II.
Menon R, Velez DR, Simhan H, Ryckman KB,
Jiang L, Thorsen P, et al. Multilocus interactions
at maternal tumor necrosis factor-a, tumor
necrosis factor receptors, interleukin-6 and
interleukin-6 receptor genes predict spontaneous
preterm labor in European-American women.
American Journal of Obstetrics & Gynecology
2006;194:1616-1624.
89
Mauck CK, Weiner DH, Creinin MD, Archer
DA, Schwartz JL, Pymar HC, et al. FemCap‰
with removal strap: Ease of removal, safety, and
acceptability. Contraception 2006;73:59-64.
McBroom JW, Acs G, Rose GS, Krivak TC,
Mohyeldin A, Bell A. Erythropoeitin receptor
function and expression in epithelial ovarian carcinoma. Gynecol Oncol 2005;99:1405-1409.
McGee EA. Ovarian Diseases. In: Larry
Jameson (ed). Textbook of Molecular Medicine
2nd edition, Humana Press, 2005.
Murthy A, Creinin MD, Harwood B, Schreiber
CA. Medical abortion with simultaneous administration of mifepristone and vaginal misoprostol
through 49 days gestation. Contraception
2005;71:333-6.
McIntyre-Seltman K, Castle PE, Guido R, et
al: Smoking is a risk factor for cervical intraepithelial neoplasia grade 3 among oncogenic
human papillomavirus DNA-positive women
with equivocal or mildly abnormal cytology.
Cancer Epid Biomarkers Prev 2005;14:1165-70.
Murthy AS, Creinin MD, Harwood B,
Schreiber CA. Same day initiation of the transdermal hormonal delivery system (contraceptive
patch) versus traditional initiation methods.
Menon R, Velez DR, Simhan H, Ryckman KB,
Jiang L, Thorsen P, et al. Multilocus interactions
at maternal tumor necrosis factor-a, tumor
necrosis factor receptors, interleukin-6 and
interleukin-6 receptor genes predict spontaneous
preterm labor in European-American women.
2006;194:1616-1624.
Myles Wolf, Carl A. Hubel, Chun Lam,
Marybeth Sampson, Jeffrey L. Ecker, Roberta
B. Ness, Augustine Rajakumar, Ashi Daftary,
Ellen W. Seely, James M. Roberts, S. Ananth
Karumanchi, and Ravi Thadhani. Preeclampsia
Clin Endocrinol Metab. 2004 Dec; 89 (12):
6239-43.
Miller D, Dunn J, Darlrymple J, Krivak TC.
Pelvic sidewall adenocarcinoma after definitive
therapy for cervical adenocarcinoma in situ.
Gynecol Oncol 2005;99:489-492.
Moalli PA, Howden NS, Lowder JL, Navarro J,
Debes KM, Abramowitch SD, Woo S L-Y. “A
Rat Model to study the structural properties of
the vagina and its supportive tissues.” American
Journal of Obstetrics & Gynecology. 192(1): 8088, January 2005.
Moncla BJ, Hillier SL. Why nonoxynol-9 may
have failed to prevent acquisition of Neisseria
gonorrhoeae in clinical trials. Sex Transm Dis
2005;32:491-494.
Moracco KE, Brown CL, Martin SL, Chang
JC, Dulli L, Loucks-Sorrel MB, Turner T, BouSaada I, Starsoneck L. Intimate Partner Violence
and Mental Health: Results from a Statewide
Survey of Domestic Violence Programs in North
Carolina. Psychiatric Services, 2004;55(9):10361040.
Moracco KE, Brown CL, Martin SL, Chang
JC, Dulli L, Loucks-Sorrel MB, Turner T, BouSaada I, Starsoneck L. Intimate Partner Violence
and Mental Health: Results from a Statewide
Survey of Domestic Violence Programs in North
Carolina. Psychiatric Services, 2004;55(9):10361040.
90
Murthy AS, Creinin MD, Harwood B,
Schreiber C. Mifepristone and misoprostol
administered at the same time for abortion up to
49 days of gestation. Association of Reproductive
Healthcare Professionals Annual Meeting,
September 2004, oral presentation
(Contraception 2004;70:254).
Moreno RD, Palomino J, Schatten G. Assembly
of spermatid acrosome depends on microtubule
organization during mammalian spermiogenesis.
Dev Biol. 293(1):218-27 (2006).
Nathanson K, Baysal BE, Drovdlic C,
Komminoth P, Neumann HP. Familial paraganglioma-pheochromocytoma syndromes caused
by SDHB, SDHC and SDHD mutations. WHO
Classification of Tumours. Pathology and
Genetics. Tumours of Endocrine Organs
pp.238-242. Edited by DeLellis RA, Lloyd RV,
Heitz PU Eng, C. IARC press, Lyon 2004.
Navara, C.S., Simerly, C.R., Hyun, SangHwan, and Schatten, G. Hurdles to therapeutic
cloning. In Stem Cells: From Bench to Bedside.
A. Bongso, editor. World Scientific Publishing,
Singapore. 2005.
Navara, C.S., The spleen tyrosine kinase (Syk)
in human disease, implications for design of
tyrosine kinase inhibitor based therapy. Curr.
Pharm. Des. 10:1739-1744. 2004.
Navara, CS, Simerly, C, Hyun, SH Schatten,
G. Hurdles to Improving the Efficiency of
Therapeutic Cloning. In ‘Human Embryonic
Stem Cells Research’ by A. Bongso (2005).
Neiswanger K, Hohler PM, Hively-Thomas LB,
McPherson EW, Hogge WA, Surti U. Variable
outcomes in mosaic trisomy 16: five case reports
and literature analysis. Prenat Diagn 2006
Mar;26: 454-461.
Neshat Rowgani, Matthew Heise, Richard
Koepsel, Dan McKeel, EA. McGee, Alan
Russell. Maintenance of morphology and growth
of ovarian follicles in suspension culture. Tissue
engineering 2004 Mar-Apr;10(3-4):545-52.
PUBLICATIONS
Ness RB, Hillier SL, Kip KE, Richter HE,
Soper DE, Stamm CA, McGregor JA, Bass DC,
Rice P, Sweet RL. Douching, pelvic inflammatory disease, and incident gonococcal and chlamydial genital infection in a chort of high-risk
women. Am J Epidemiol 2005; 161: 186-195.
Ness RB, Hillier SL, Kip KE, Soper DE,
Stamm CA, McGregor JA, Bass DC, Sweet RL,
Rice P, Richter HE. Bacterial vaginosis and risk
of pelvic inflammatory disease. Obstet Gynecol
2004; 104: 761-9.
Ness RB, Hillier SL, Richter HE, Stamm C,
Bass DC, Sweet RL, Rice P. Does bacterial vaginosis (BV) increase the risk of gonococcal/
chlamydial (GC/CT) cervicitis and pelvic
inflammatory disease (PID)? Am J Epidemiol
2004; 159 (11): S100.
Ness RB, Kip KE, Hillier SL, Soper DE,
Stamm CA, Sweet RL, Rice P, Richter HE. A
cluster analysis of bacterial vaginosis-associated
microflora and pelvic inflammatory disease. Am J
Epidemiol 2005; 162: 585-590.
Ness RB, Kip KE, Soper DE, Hillier SL,
Stamm CA, Sweet RL, Ice P, Richter HE.
Bacterial vaginosis (BV) and the risk of incident
gonococcal or chlamydial genital infection in a
predominantly black population. Sex Transm Dis
2005; 32: 413-417.
Novak J, Rajakumar A., Miles TM., and
Conrad KP. Nitric oxide synthase isoforms in
the rat kidney during pregnancy. (2004) Jnl Soc
Gyn Inves. Vol 11/5 pp280-288.
Nygaard IE. McCreery R. Brubaker L. Connolly
A. Cundiff G. Weber AM. Zyczynski HM.
Pelvic Floor Disorders Network. Abdominal
sacrocolpopexy: a comprehensive review.
Obstetrics & Gynecology. 104(4):805-23, 2004
Oct.
Orwig KE and Schlatt S. 2005. Cryopreservation
and transplantation of spermatogonia and testicular tissue for preservation of male fertility.
Journal of the National Cancer Institute
Monographs. 34:51-56.
Patrick TE. Powers RW. Daftary AR. Ness
RB. Roberts JM. Homocysteine and folic acid
are inversely related in black women with
preeclampsia. [Journal Article] Hypertension.
43(6):1279-82, 2004 Jun.
Patrick TE, R.W. Powers, A.R. Daftary, R.B.
Ness, and J.M. Roberts. (2004) Homocysteine
and folic acid are inversely related in black
women with preeclampsia. Hypertension. 43:1-4.
Patrick TE, Hubel CA, Roberts JM.
Evidence of increased oxidative stress, unexplained by lipid changes, is present in nulliparous black women from early gestation.
Hypertension Pregnancy 2004; 23(1): 91-100.
Patton DL, Sweeney YC, Cummings PK, Meyn
L, Rabe LK, Hillier SL. Safety and efficacy
evaluations for vaginal and rectal use of
BufferGel‘ in the macaque model. Sex Transm
Dis 2004; 31: 290-61.
Patton DL, Sweeney YG, Tsai CC, Hillier SL.
Macaca fascicularis vs. Macaca nemestrina as a
model for topical microbicide safety studies. J
Med Primatol 2004; 33: 105-108.
Patton DL, Cosgrove-Sweeney YT, McCarthy
TD, Hillier SL. Preclinical safety and efficacy
assessments of Dendrimer-based (SPL7013)
microbicide gel formulations in a nonhuman primate model. Antimicrobiol Agents and
Chemotherapy 2006; 50: 1696-1700.
Patrick TE, Hubel CA, Roberts JM. Evidence
of increased oxidative stress, unexplained by lipid
changes, is present in nulliparous black women
from early gestation. Hypertension Pregnancy
2004;23(1):91-100.
Peters DG, Kudla DM, DeLoia JA, Chu TJ,
Fairfull L, Edwards RP, Ferrell RE.
Comparative gene expression analysis of ovarian
carcinoma and normal ovarian epithelium by
serial analysis of gene expression. Cancer
Epidemiology, Biomarkers & Prevention 14:
1717-1723, July 2005.
Petrek J, Naughton M,Case D, Paskett E,
Naftalis E, Singletary E, Sukumvanich, P
Incidence, Time Course, and Determinants of
Menstral Bleeding After Breast Cancer
Treatment: A Prospective Study. Journal of
Clinical Oncology 2006;24:1045.
Phadke SM, Deslouches B, Hileman SE,
Montelaro RC, Wiesenfeld HC, Mietzner TA.
Antimicrobial peptides in mucosal secretions: the
importance of local secretions in mitigating
infection. J Nutr 2005; 135: 1289-1293.
Pinter R. Hogge WA, McPherson E. Infant
with severe penicillamine embryopathy born to a
woman with Wilson disease. Am J Med Genet A,
2004July 30;128(3):294-8.
Platt LD, Greene N, Johnson A, Zachary J,
Thom E, Krantz D, Simpson JL, Silver RK,
Snijders RJ, Goetzl L, Pergament E, Filkins K,
Mahoney MJ, Hogge WA, Wilson RD, Mohide
P, Hershey D, MacGregor S, Bahado-Singh R,
Jackson LG, Wapner R; First Trimester
Maternal Serum Biochemistry and Fetal Nuchal
Translucency Screening (BUN) Study Group.
Sequential pathways of testing after firsttrimester screening for trisomy 21. Obstet
Gynecol 2004 Oct;104(4):661-6.
91
Powers, R.W., Bodnar, L.M., Ness, R.B.,
Cooper, K.M., M.J. Gallaher, M.J., Frank, M.P.,
Daftary, A.R., Roberts, J.M. (2006) Uric acid
concentrations are increased throughout pregnancy among women with gestational hyperuricemia at delivery. American Journal of
Obstetrics and Gynecology. 194:161-168.
Powers, R.W., Majors, A.K., Kerchner, L.J.,
and Conrad, K.P. (2004) Renal Handling of
Maternal Homocysteine During Normal
Pregnancy and Preeclampsia. Journal of the
Society for Gynecologic Investigation. 11 (1):
45-50.
Powers, R.W., Gandley, R.E., Lykins, D.L.,
and Roberts, J.M. (2004) Moderate
Hyperhomo-cysteinemia Decreases Endothelialdependent Vasorelaxation in Pregnant but not
Nonpregnant Mice. Hypertension. 44: 327-333.
Powers, R.W., Dunbar, M.S., Laivuori, H.M.
Harger, G.F., Lykins, D.L., and Roberts, J.M.
(2005) Maternal Plasma Homocysteine Concentrations are not increased in Twin Pregnancies.
Hypertension in Pregnancy. 24:49-58.
Powers, R.W., Roberts, J.M., Cooper, K.M.,
Gallaher, M.J., Frank, M.P., Harger, G.F., and
Ness, R.B. (2005) Maternal serum sFlt-1 concentrations are not increased in early pregnancy
and decrease more slowly postpartum in women
who develop preeclampsia. American Journal of
Obstetrics and Gynecology. 193: 185-91.
Pymar HC, Creinin MD, Vallejo MC.
Prospective randomized controlled study of
postoperative pain after titanium silicone rubber
clip or silastic ring tubal occlusion.
Ramalho-Santos J, Schatten G. Presence of Nethyl maleimide sensitive factor (NSF) on the
acrosome of mammalian sperm. Arch Androl.
2004 May-Jun;50(3):163-8.
Randall-Whitis L, Helm CW, Toler CR, Martin
RS, Metzinger DS, Edwards RP. Secondary
surgical cytoreduction and hyperthermic
intraperitoneal chemoperfusion (SSC-HIPEC)
for recurrent gynecologic malignancies.
American Society for Clinical Oncology, New
Orleans, Louisiana, June 2004. (ASCO Annual
Meeting Proceedings 2004;23:471).
92
Rajakumar Augustine, Heather M. Brandon,
Eiji Shibata, Carl A. Hubel, Ananth
Karumanchi, Ravi Thadhani, Myles Wolfe, Gail
Harger, Nina Markovic. Extra-placental
Expression of Vascular Endothelial Growth
Factor Receptor-1, (flt-1) and soluble Flt-1,
(sFlt-1) by Peripheral Blood Mononuclear Cells
(PBMCs) in Normotensive and Preeclamptic
Pregnant Women. Placenta 2005, 26 (7), p 563573.
Rajakumar Augustine, Shanthie Thamotharan,
Nupur Raychaudhuri, Ram Menon, and Sherin
U. Devaskar. Trans-activators Regulating
Neuronal Glucose Transporter Isoform-3 Gene
Expression in Mammalian Neurons.J. Biol
Chem. (2004) 279 (25) p 26768-26779.
Ramalho-Santos J, Schatten G. Presence of Nethyl maleimide sensitive factor (NSF) on the
acrosome of mammalian sperm. Arch Androl.
50(3): 163-8 (2004).
Rawe, V.Y., Payne, C., Navara, C.S., and
Schatten, G. WAVE1 intranuclear trafficking is
essential for genomic and cytoskeletal dynamics
during fertilization: cell-cycle-dependent shuttling between M-phase and interphase nuclei.
Dev. Biol. 276:253-267.
Rawe, VY, Payne, C, and Schatten, G. Profilin
and actin-related proteins regulate microfilament
dynamics during early mammalian embryogenesis. Hum Reprod. 21(5):1143-53 (2006).
Ray BK, Vallejo MC, Creinin MD, Shannon
KT, Mandell GL, Kaul B, et al. Amniotic fluid
embolism with second trimester pregnancy termination: a case report. Can J Anesth
2004;51:139-44.
Raymond EG, Chen PL, Luoto J, the
Spermicide Trial Group (…Creinin MD…).
Contraceptive effectiveness and safety of five
Nonoxynol-9 spermicides: A randomized trial.
Obstet Gynecol 2004;103:430-9.
Raymond EG, Chen PL, Pierre-Louis B, Luoto
J, Barnhart KT, Bradley L, Creinin MD, et al.
Contraceptive effectiveness and safety of five
Nonoxynol-9 spermicides: Participant withdrawals from a large randomized trial of spermicide effectiveness. BMC Med Res Methodol
2004;4:23.
Raymond EG, Chen PL, Condon S, Luoto J,
Barnhart KT, Creinin MD, et al. Acceptability
of Five Nonoxynol-9 Spermicides. Contraception 2005;71:438-42.
Reeves M, Harwood B, Creinin M. Cost-effectiveness of presumptively medically treating
women at risk for ectopic pregnancy compared
with first performing a dilatation and curettage
(letter). Fertil Steril 2005;84:543.
Rohan LC, Ratner D, McCullough K, Hillier
SL, Gupta P. Measurement of anti-HIV activity
of marketed vaginal products and excipients
using a PBMC-based in vitro assay. Sex Transm
Dis 2004; 31: 143-148.
Roberts, J.M., Bodnar, L.M., Lain, K.Y.,
Hubel, C.A., Markovic, N., Ness, R.B., and
Powers, R.W. (2005) Uric acid is as important
as proteinuria in identifying fetal risk in women
with gestational hypertension. Hypertension. 46:
1263-1269.
PUBLICATIONS
Roberts, JM, Speer, P: Antioxidant Therapy to
Prevent Preeclampsia. Seminars in Nephrology,
24: 557-564, 2004.
Rossi B, Creinin MD, Meyn LA. The ability of
the clinician and patient to predict the outcome
of mifepristone and misoprostol medical abortion. Contraception 2004;70:313-7.
Rouse DJ, Landon M, Leveno KJ, Leindecker S,
Varner MW, Caritis SN, O’Sullivan MJ,
Wapner RJ, Meis PJ, Miodovnik M, Sorokin Y,
Moawad AH, Mabie W, Conway D, Gabbe S,
Spong CY for the NICHD Maternal-Fetal
Medicine Units Network. Chorioamnionitis and
its duration: Relationship to maternal and
neonatal outcomes at term. Am J Obstet
Gynecol 191:211-6, 2004.
Rubinstein, W.S., Latimer, J.J., Sumkin, J.,
Huerbin, M.B.. Grant, S.G. and, Vogel, V. G.
(2006) Prospective screening study of 0.5 Tesla
dedicated magnetic resonance imaging for the
detection of breast cancer in young high-risk
women, BMC Women’s Health 6(10) online.
Ryu BY, Orwig KE, Kubota H, Avarbock MR,
Brinster RL. 2004. Phenotypic and functional
characteristics of spermatogonial stem cells in
rats. Dev. Biol. 274:158-170.
Ryu, B.-Y., Orwig, K.E., Oatley, J.M.,
Avarbock, M.R., Brinster, R.L. Effects of Aging
and Niche Microenvironment on
Spermatogonial Stem Cell Self-Renewal. Stem
Cells 2006; 24(6):1505-11.
Sackett, G., Ruppenthal, G., Hewitson, L.,
Simerly, C. and Schatten, G. Neonatal behavior and infant cognitive development in rhesus
macaques produced by assisted reproductive
technologies. Dev Psychobiol. 2006
Apr;48(3):243-65.
Sanfilippo JS, Mansuria SM. Surgical
Problems in the Pediatric Patient. Clinical
Gynecology Textbook. Eric Bieber, MD, Joseph
Sanfilippo, MD, MBA and Ira Horowitz, ed.
Elsevier. 2006;33:513-526.
Sanfilippo A, Mansuria S. Microperforate
hymen resulting in pelvic abscess. J Ped Adol
Gynecol 2006;19:95-8.
Sassi AB, McCullough KD, Cost MR, Hillier
SL, Rohan LC. Permeability of tritiated water
through human cervical and vaginal tissue. J
Pharmaceutical Sci 2004; 93: 2009-2016.
Schafer IA, Stein J, Hyland JC, Clark BA.
Gene symbol: COL1A1. Disease: Osteogenesis
imperfecta type I. Human Genetics 11(4):404,
March, 2004.
Schafer IA, Stein J, Hyland JC, Clark BA. Gene
symbol: COL1A1. Disease: Osteogenesis imperfecta type I. Human Genetics 11(4):404, March,
2004.
Schatten G, Donovan P. Embryology: plane
talk. Nature. 2004 Jul 15;430(6997):301-2.
Schatten, G., Smith, J., Navara, C.S., Park,
J.H., Pedersen, R. Culturing Human Embryonic
Stem Cells. Nature Methods 2:455-463 2005.
Schatz M, Dombrowski MP, Wise R, Momirova
V, Landon M, Mabie W, Newman RB, Hauth
JC, Lindheimer M, Caritis SN, Leveno KJ,
Meis P, Miodovnik M. Wapner RJ, Paul RH,
Varner MW, O’Sullivan M, Thurnau GR,
Conway DL, for the NICHD Maternal Fetal
Medicine Units Network. The relationship of
asthma medication use to perinatal outcomes. J
Allergy Clin Immunol 113:1040-5, 2004.
Schatten, G, Smith, J, Navara, C, Park, JH,
Pedersen, RA. Human Embryonic Stem Cell
Research: Culture, Maintenance, SubPassaging, Cryopreservation, Quality Control,
and Experimental Preparations. Nature Methods
(6): 455-63 (2005).
Schatz M, Dombrowski MP, Wise R, Momirova
V, Landon M, Mabie W, Newman RB, Hauth
JC, Lindheimer M, Caritis SN, Leveno KJ,
Meis P, Miodovnik M. Wapner RJ, Paul RH,
Varner MW, O’Sullivan M, Thurnau GR,
Conway DL, for the NICHD Maternal Fetal
Medicine Units Network. The relationship of
asthma medication use to perinatal outcomes. J
Allergy Clin Immunol 113:1040-5, 2004.
Schiavi F, Boedeker CC, Bausch B, Peczkowska
M, Gomez CF, Strassburg T, Pawlu C, Buchta
M, Salzmann M, Hoffmann MM, Berlis A, Brink
I, Cybulla M, Muresan M, Walter MA, Forrer F,
Valimaki M, Kawecki A, Szutkowski Z, Schipper
J, Walz MK, Pigny P, Bauters C, Willet-Brozick
JE, Baysal BE, Januszewicz A, Eng C, Opocher
G, Neumann HP; European-American Paraganglioma Study Group. Predictors and prevalence
of paraganglioma syndrome associated with
mutations of the SDHC gene. JAMA. (2005);
294(16):2057-63.
Scholle SH, Chang JC, Harman J, McNeil M.
Characteristics of patients seen and services provided in primary care visits in Obstetrics/
Gynecology: Data from the NAMCS and
NHAMCS. Am j Obstet Gynecol 2004:190:
1119-27.
Schreiber CA, Creinin MD, Harwood B,
Murthy AS. A pilot study of mifepristone and
misoprostol administered at the same time for
abortion in women with gestation from 50 to 63
days. Contraception 2005;70:447-450.
Schreiber CA, Harwood BJ, Switzer GE,
Creinin MD, Reeves MF, Ness RB.
Contraceptive knowledge and attitudes of graduating resident physicians: the implications for
public health. Contraception 2006;73:618-22.
93
Schreiber CA, Meyn L, Creinin MD, Barnhart
KT, Hillier SL. The effects of long-term use of
nonoxynol-9 on vaginal flora. Obstet Gynecol
2006;107:136-43.
Schreiber C, Creinin MD, Harwood B,
Murthy AS. Mifepristone and misoprostol
administered at the same time for abortion from
50 to 63 days gestation. Association of
Reproductive Healthcare Professionals Annual
Meeting, September 2004, oral presentation
(Contraception 2004;70:254-5).
Schwartz JL, Mauck C, Lai J-J, Creinin MD,
Brache V, Ballagh SA, et al. Fourteen-day safety
and acceptability study of 6% cellulose sulfate
gel: A randomized double-blind phase I safety
study. Contraception 2006;74:133-40.
Shibata, E., Rajakumar, A., Powers, R.W.,
Larkin, R.W., Gilmour, C., Bodnar, L.M.,
Crombleholme, W.R., Ness, R.B., Roberts,
J.M., and Hubel, C.A. Soluble fms-like
Tyrosine Kinase 1 (sFlt-1) is Increased in
Preeclampsia but not in Normotensive
Pregnancies with Small For Gestational Age
Neonates: Relationship to Circulating Placental
Growth Factor (PlGF). (2005) Journal of
Clinical Endocrinology and Metabolism. 90:
4895-4903.
Scholle SH, Chang JC, Harman J, McNeil M.
Characteristics of Patients Seen and Services
Provided in Primary Care Visits in
Obstetrcs/Gynecology: Data from the NAMCS
and NHAMCS, American Journal of Obstetrics
and Gynecology, 2004: 190: 1119-27.
94
Simerly, C., Navara, C.#, Hyun, S.H., Lee,
B.C., Kang, S.K., Capuano, S., Gosman, G.,
Dominko, T., Chong, K., Compton, D., Hwang,
W., and Schatten G. Embryogenesis and blastocyst development after somatic cell nuclear
transfer in nonhuman primates: overcoming
defects caused by meiotic spindle extraction.
Dev. Biol. 2004 276:237-252 # The first three
authors contributed equally to this manuscript.
Simhan HN, Caritis SN, Krohn MA, Hillier
SL. The vaginal inflammatory milieu and the
risk of early premature preterm rupture of membranes. Am J Obstet Gynecol 2005; 192: 213-8.
Simhan H, Krohn M, Heine RP. Obstetric rectal injury: risk factors and the role of physician
experience. J Matern Fetal Neonatal Med. 2004
Nov;16(5):271-4.
Simhan HN, Caritis CN, Hillier SL, Krohn
MA. Cervical anti-infoammatory cytokine concentrations among first-trimester pregnant
smokers. Am J Obstet Gynecol 2006; 193: 19992003.
Simhan HN, Chura JC, Rauk PN. The effect of
the anti-inflammatory cytokines interleukin-4
and interleukin-10 on lipopolysaccharide-stimulated production of prostaglandin E(2) by cultured human decidual cells. J Reprod Immunol
2004;64:1-7.
Simhan HN, Canavan TP. Preterm premature
rupture of membranes: diagnosis, evaluation and
management strategies. Bjog 2005;112 Suppl
1:32-7.
Simhan HN. Serum biomarkers of spontaneous
preterm birth. Acta Obstet Gynecol Scand.
2005; 84:545-6.
Schreiber CA, Meyn LA, Creinin MD,
Barnhart KT, Hillier SL. The effects of longterm use of nonoxynol-9 on vagina flora. Obstet
Gynecol 2006; 107:136-143.
Simhan HN, Bodnar LM. Prepregnancy Body
Mass Index, Vaginal Inflammation, and the
Racial Disparity in Preterm Birth. American
Journal of Epidemiology. 2006;163: 459-466.
Schwartz JL, Mauck C, Lai JJ, Hillier SL.
Fourteen-day safety and acceptability study of
6% cellulose sulfate gel: a randomized doubleblind phase 1 safety study. Contraception 2006;
74:133-40.
Simhan HN, Anderson BL, Krohn MA, Heine
RP, de Tejada BM, Landers DV, Hillier SL.
Host immune consequences of asymptomatic
Trichomonas vaginalis infection in pregnancy.
2006, accepted and in press.
Shibata E, Powers RW, Rajakumar A, von
Versen-Höynck F, Gallaher MJ, Lykins DL,
Roberts JM, Hubel CA. Angiotensin II
decreases system A amino acid transporter activity in human placental villous fragments through
AT1 receptor activation. Am J Physiol
(Endocrinol Metab) Epub ahead of press, June
20, 2006.
Sit A., Kelley J., Gallion HH., Kunschner A.,
Edwards R., Paclitaxel and Carboplatin for
Recurrent or Persistent Cancer of the Cervix.
Cancer Investigation, 2004;22:1-6.
Sit ASY, Kelley JL, Gallion HH, Kunschner AJ,
Edwards RP. Paclitaxel and Carboplatin for
Recurrent or Persistent Cancer of the Cervix.
Cancer Investigation 22:368-373, 2004.
PUBLICATIONS
Sit ASY, Modugno F, Hill LM, Martin J,
Weissfeld JL. Transvaginal Ultrasound
Measurement of Endometrial Thickness as a
Biomarker for Estrogen Exposure. Cancer
Epidemiol Biomarkers Prev 2004;13(9),
September 2004.
Petrek J, Naughton M,Case D, Paskett E,
Naftalis E, Singletary E, Sukumvanich,P
Incidence, Time Course, and Determinants of
Menstral Bleeding After Breast Cancer
Treatment: A Prospective Study. Journal of
Clinical Oncology 2006;24:1045.
Sobel JD, Wiesenfeld HC, Martens M, Danna
P, Hooton TM, Rompalo a, Sperling M,
Livengood C, Horowitz B, Von Thron J,
Edwards L, Panzer H, Chu TC. Maintenance
fluconazole therapy for recurrent vulvovaginal
candidiasis. N Engl J Med 2004;351:876-83.
Surti U, Hill LM, Dunn J, Prosen T, Hoffner L.
Twin pregnancy with a chimeric androgenetic
and giparental placenta in one twin displaying
placental mesenchymal dysplasia phenotype.
Prenatal Diagn 2005;25:1048-1056.
Sobel JD, Ferris D, Schwebke J, Nyirjesy P,
Wiesenfeld HC, Peipert J, et al. Suppressive
antibacterial therapy with 0.75% metronidazole
vaginal gel to prevent recurrent bacterial vaginosis. Am J Obstet Gynecol 2006;194:1283-9.
Sobel JD, Wiesenfeld HC, Martens M, Danna
P, Hooton TM, Rompalo a, Sperling M,
Livengood C, Horowitz B, Von Thron J,
Edwards L, Panzer H, Chu TC. Maintenance
fluconazole therapy for recurrent vulvovaginal
candidiasis. N Engl J Med 2004;351:876-83.
Solnick JM, Guido RS, Sanfilippo JS, Krohn
MA. The impact of endometrial ablation technique at a large university women’s hospital. Am
J Obstet Gynecol. 2005: Jul;193(1):98-102.
Solnik J, Guido RS, Sanfilippo JS, Gosman
GG, Lee T. A Prospective, Randomized,
Masked Trial Comparing Laparoscopic
Peritoneal Excision with Electrocautery versus
Bipolar Fulguration and Subsequent Adhesion
Formation in the White Zealand Rabbit. J Am
Assoc Gynecol Laparosc 11(3) Suppl:20 Aug
2004.
St. John, J.C., Ramalho-Santos, J., Gray, H.L.,
Petrosko, P., Rawe, V.Y., Navara, C.S., Simerly,
C.R. and Schatten, G.P. The expression of
mitochondrial DNA transcription factors during
early cardiomyocyte in vitro differentiation from
human embryonic stem cells. Cloning and Stem
Cells 7:141-153 2005.
St. John, J. and Schatten, G. Paternal mitochondrial DNA transmission during primate
nuclear transfer. Genetics, 167(2): 897-905
(2004).
Sutkin G, Krohn MA, Heine RP, Sweet RL.
Antibiotic prophylaxis and non-group B streptococcal neonatal sepsis. Obstet Gynecol. 2005
Mar;105(3):581-6.
Speer, P, Roberts, JM: Aspirin did not prevent
pre-eclampsia in women with abnormal uterine
artery Doppler results (Commentary): Evidence
Based Obstetrics and Gynecology, Vol 6, 54-55,
2004.
St. John JC, Schatten G. Paternal mitochondrial
DNA transmission during nonhuman primate
nuclear transfer. Genetics. 2004 Jun;167(2):897905.
Stoner KA, Rabe LK, Hillier SL. The effect of
transport time, temperature, and concentration
on the survival of group B Streptococcus (GBS)
in amies transport media. J Clin Microbiol 2004;
42: 5385-5387.
Swamy GK, Simhan HN, Gammill HS, Heine
RP. Clinical Utility of Fetal Fibronectin for
Predicting Preterm Birth. Journal of
Reproductive Medicine. 2005; 50(11): 851-6.
Swords, W.E., Guenthner, P.C., Birkness, K.A.,
Lal, R.B., Dezzutti, C.S., Quinn, F.D.
Mycobacterium xenopi multiplies within human
macrophages and enhances HIV replication during co-infection in human PBMC. Microbial
Pathol. 40:41-47, 2006.
Taylor DD, Edwards RP, Case CR, GercelTaylor C. Modulation of CD3-zeta as a marker
of clinical response to IL-2 therapy in ovarian
cancer patients. Gynecol Oncol 2004;94:54-60.
Sukumvanich P, DesMarais V, Wang, Y,
Sarmiento C, Condeelis J. Neural-WiskottAldrich Syndrome Protein Activation and
Localization in Metastatic Breast Cancer Cells.
Cell Motility and Cytoskeleton 2004;59:141.
Telfer, EE, Gosden RG, Byskov AG, Spears, N,
Albertini, D, Andersen, D, Braw-Tal, D Clarke,
H Gougeon, A Hsueh, A, McLaughlin, M,
McLaren, A, McNatty, K, Schatten, G Silber, S,
Tsafriri, A. On Regenerating the Ovary and
Generating Controversy. On regenerating the
ovary and generating controversy. Cell Sep 23;
122(6):821-2. (2005).
Sukumvanich P, Einstein M, Wagner B, Gucalp
R, Goldberg GL. Recurrent Small Cell Lung
Cancer Presenting as Bilateral Adnexal Masses.
Gynecologic Oncology 2005;96:232.
Teppa, RJ, Roberts, JM: The uriscreen® test to
detect significant asymptomatic bacteriuria during pregnancy. Journal of Society for Gynec
Investigation. Vol 12(1); 50-3, 2005.
95
Tereda Y, Nakamura S, Simerly C, Hewitson
L, Murakami T, Yaegashi N, Okamura K,
Schatten G. Centrosomal function assessment
in human sperm using heterologous ICSI with
rabbit eggs: a new male factor infertility assay.
Mol Reprod Dev. 2004 Mar; 67(3):360-5.
Thrall M, Gallion HH, Kapali M, Armstrong
DK, Kryscio R, DeLoia JA,. BRCA1 expression
in a large series of sporadic ovarian carcinomas:
a Gynecologic Oncology Group study. Int J of
Gynec Cancer, 16 Suppl 1:166-171, 2006.
Updike GM, Wiesenfeld HC. Insight into the
management of vulvar pain: a survey of clinicians. Am J Obstet Gynecol. 2005; 193:1404-9.
Warrino DE, Olson WC, Knapp WT, Scarrow
MI, Guido RS, et al. Disease-Stage Variance in
Functional CD4+T Cell Responses Against
Novel Pan-HLA-DR Presented HPV-16 E17.
Epitopes. Clin Can Res, May 2004.
Watts DH, Fazarri M, Minkoff H, Hillier SL,
Sha B, Glesby M, Levine AM, Burk R, Palefsky
JM, Moxley M, Ahdieh-Grant L, Strickler HD.
Effects of bacterial vaginosis and other genital
infections on human papillomavirus natural history among HIV-infected and uninfected
women. JID 2005; 191: 1129-39.
Weber AM, Buchsbaum GM, Chen B, Clark
AL, Damaser MS, Daneshgari F, Davis G,
DeLancey JOL, Kenton K, Weidner AC, Word
RA. Basic science and translational research in
female pelvic floor disorders: Proceedings of an
NIH-sponsored meeting. Neurourol Urodyn
2004; 23: 288-301.
Whiteside JL, Meyn L, Weber AM, Walters
MD. Risk factors for recurrent pelvic organ prolapse. Am J Obstet Gynecol 2004; 191: 1533-1538.
Wiesenfeld HC, Hillier SL, Krohn MA,
Sweet RL. Comparison of acute and subclinical
PID. Sex Transm Dis 2005; 32: 400-405.
Wiesenfeld HC, Dennard-Hall K, Ashton MR,
Krohn MA, Zamborsky T, Cook RL.
Knowledge about sexually transmitted diseases
in women among primary care physicians. Sex
Transm Dis 2005;32:649-53.
Wiesenfeld HC, Sweet RL, Ness RB, Krohn
MA, Amortegui AJ, Hillier SL. Comparison of
acute and subclinical pelvic inflammatory disease. Sex Transm Dis 2005;32:400-5.
Wilcox CB, Baysal BE, Gallion HH, Strange
MA, DeLoia JA. High resolution analysis of
BRCA1 promoter methylation in ovarian
tumors. Cancer Genetics and Cytogenetics, 159:
114-122, 2005.
Winter WE III, Seidman JD, Krivak TC,
Chauhan S, Carlson JW, Rose GS, Birrer MJ.
Clinicopathologic analysis of c-kit expression in
96
carcinosarcomas and leiomyosarcomas of the
uterine corpus. Gynecol Oncol, 2003;91:3-8.
Wolf Myles, Carl A. Hubel, Chun Lam,
Marybeth Sampson, Jeffrey L. Ecker, Roberta B.
Ness, Augustine Rajakumar, Ashi Daftary,
Ellen W. Seely, James M. Roberts, S. Ananth
Karumanchi, and Ravi Thadhani. Preeclampsia
Clin Endocrinol Metab. 2004 Dec; 89(12): 623943.
Wren PA, Janz N, Brubaker L, FitzGerald MP,
Weber AM, Laporte F, Wei JT for the Pelvic
Floor Disorders Network. Reliability of healthrelated quality of life measures one year following pelvic floor surgery. Am J Obstet Gynecol
2005; 192: 780-788.
Yanowitz TD. Baker RW. Roberts JM.
Brozanski BS. Low blood pressure among verylow-birth-weight infants with fetal vessel inflammation. Journal of Perinatology. 24(5):299-304,
2004 May.
Yanowitz, T, Roberts, JM: Asymmetry of
Cerebral Blood Flow Velocity in Low Birth
Weight Infants. Biology of the Neonate, Vol
87:3; 145-151, 2005.
Yost NP, Owen J, Berghella V, MacPherson C,
Swain M, Dildy GA, Miodovnik M, Langer O,
Sibai B, for the NICHD Maternal Fetal
Medicine Units Network.(Caritis S).
Midtrimester cervical sonography: Features
other than cervical length for the prediction of
spontaneous preterm birth. Am J Obstet &
Gynecol 191:241-6, 2004.
You W, Dainty LA, Rose GS, Krivak TC,
McHale MT, Olsen CH, Elkas JC. The epidemiology of gynecologic malignancies in
women <25 years of age. Obstet Gynecol,
2005;105(6) 1405-1409.
Zhang J, Gilles JM, Barnhart K, Creinin MD,
Westhoff C, Frederick MM. Medical management with misoprostol for early pregnancy failure. New Engl J Med 2005;353:761-9.
Zlupko R, Sanfilippo JS. Endocrine Aspects of
Reproductive Aging in Men and Women.
Androgens & Reproductive Aging Textbook.
Taylor & Francis Books, Ltd. 2006;3:17-27.
Zorn K, Bonome T, Gangi L, Chandramouli G,
Awtrey C, Gardner G, Barrett J, Birrer M.
Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and
endometrial cancer. Clinical Cancer Research
11(18):6422-30, 2005.
PRESENTATIONS AND INVITED LECTURES
PRESENTATIONS
REGINA ARVON, MD —
BORA E. BAYSAL, MD, Ph.D —
Airoldi, J, Arvon, R, Berghella, V. Subsequent
Pregnancy outcomes after transabdominal cerclage. Poster Presentation, The American
College of Obstetricians and Gynecologists 52nd
Annual Clinical Meeting, San Francisco, Ca,
May 2005.
Sequence analysis of Succinate Dehydrogenase
Subunit A Gene (SDHA) for paraganglioma
tumor susceptibility. American Society of
Human Genetics 54th Annual meeting, October
26-30, 2004, Toronto, Canada.
STEVE CARITIS, MD —
Arvon, R, O’Neill, M, Wood, D, Weiner, S.
Ductus Venosus Size in Four Fetuses with Intraabdominal Masses. Poster Presentation, The
International Society of Ultrasound in Obstetrics
and Gynecology, 15th World Congress,
Vancouver, Canada, September 2005.
Wood, D, Done, E, Ness, A, Airoldi, J, Arvon,
R, Berghella, V. Librizzi, R, Weiner, S. Ductus
venous dimensions during gestation. Poster
Presentation, The International Society of
Ultrasound in Obstetrics and Gynecology, 15th
World Congress, Vancouver, Canada, September
2005.
Predictors of Preterm Birth. Grand
Rounds.Duke University Medical Center,
Durham, NC. March 2004
Pathophysiology of Adverse Events with
Tocolysis. Preterm Labor Conference, Geneva,
Switzerland. Sept 2004.
DIANE CARLISLE, Ph.D —
Nicotine promotes survival of non-small cell
lung cancer cells in the presence of anti-tumor
agents. American Association for Cancer
Research. Anaheim, CA. April 2005.
Arvon, R, O’Neill, M, Bega, G, Weiner, S. What
is the color under the fetal head? Oral
Presentation, The International Society of
Ultrasound in Obstetrics and Gynecology, 15th
World Congress, Vancouver, Canada, September
2005.
- Ghetti C, Romm, J. Balint Groups: A Tool for
Addressing Burnout in the Obstetrician
Gynecologist, APGO Faculty Development
Seminar, Phoenix, Phoenix, Arizona. January 710, 2006. Workshop leader.
Arvon, R, Pelham, J, Bega, G, Weiner, S. Is
Pallister-Killian Syndrome associated with
advanced-maternal age; a review of the Genzyme
genetics database. Poster Presentation, The
American Society of Human Genetics, Salt Lake
City, Ut, October 2005.
Ghetti C, Gregory WT, Edwards SR, Hamilton
S, Smith V, Gold R, Clark AL. Risk Factors for
Surgically Managed Pelvic Organ Prolapse and
Urinary Incontinence. American
Urogynecologic Society 26th Scientific Meeting.
Atlanta, GA September 15-17,2005. Oral presentation.
Arvon, R, Turocy, J, Clark, B, Hill, L. Outcome
of Chromosomally Normal Fetuses with
Elevated Nuchal Translucency Measurements.
Poster Presentation, The International Society
of Ultrasound in Obstetrics and gynecology, 16th
World Congress, London, United Kingdom,
September 2006.
Urinary Incontinence: Evaluation and
Management. Women’s Health Seminar
Series. Division of General Internal Medicine,
Montefiore Hospital, Pittsburgh, PA. 4/2005.
Genetics Education Conference, Department of
Obstetrics and Gynecology, Drexel University
College of Medicine Philadelphia, PA .January
2004 “Advanced Paternal Age”.
Romm J, Ghetti C. The Patient and Her
Doctor: A Workshop Introducing the Balint
Method to NASPOG Members. 32nd Annual
Meeting The North American Society for
Psychosocial Obstetrics and Gynecology.
February 10-12, 2005. Workshop leader.
Research Day, Department of Obstetrics and
Gynecology, Thomas Jefferson University,
Philadelphia, PA. June 2005, “Post-Partum
Weight Retention in an Urban Obstetrical
Population”.
Pelvic Organ Descent and the Perception of
Prolapse. American Urogynecologic Society
25th Annual Scientific Meeting. San Diego, CA
July 27-31, 2004. Oral presentation.
97
Incontinence and the Female Patient. Oregon
Health and Science University, Department
Family Medicine, sponsored by the Oregon
Geriatric Education Center 2/2004.
JUDY CHANG, MD —
Gender Differences In Residents’ Strategies For
Establishing Mentoring Relationships, Poster
Presentation, Society for General Internal
Medicine 28th Annual Meeting, New Orleans,
May 2005.
Intimate Partner Violence: A Research Update,
Panel presentation, Domestic Violence Task
Forces Lunch N’ Learn, Magee Womens
Hospital, Pittsburgh, PA May 2005.
Violence and the Obstetric Patient,
Presentation, Women’s Mental Health Interest
Group Seminar Series, University of Pittsburgh,
PA Jan 2005.
The Ups and Downs of Violence: Mapping the
Process of Change, Oral Presentation, National
Conference on Health Care and Domestic
Violence, Boston, MA Oct 2004.
Planting A Seed: The Process Of Change For
Victims Of Intimate Partner Violence Oral
Presentation, National Conference on Health
Care and Domestic Violence, Boston, MA Oct
2004.
Provider Perspectives On Addressing Intimate
Partner Violence, Poster Presentation, National
Conference on Health Care and Domestic
Violence, Boston, MA Oct 2004.
Creating a Health Care Intervention for
Intimate Partner Violence: Community-based
Participatory Research with Patients and Health
Care Providers, Poster Presentation, Women’s
Health Interdisciplinary Research Symposium,
NIH, Bethesda, MD Oct 2004.
98
Creating a Health Care Intervention for
Intimate Partner Violence: Community-based
Participatory Research with Patients and Health
Care Providers, Poster Presentation, The
Society for Gynecologic Investigation 2004
Annual Meeting, Houston, TX Mar 2004.
BRIAN CLARK, Ph.D, MD —
Clinical Cancer Genetics, Family History in the
Management of Hereditary Cancer Syndromes,
Hereditary Tumor Registries: Research and
Clinical Care. Catholica University Medical
School, Santiago, Chile, March 18-19, 2004.
Focused Update on New Therapies for
Colorectal Cancer. Talk – Recognizing and
Managing Hereditary Colon Cancer Risk.
Cleveland Clinic Foundation Taussig Cancer
Center. Hilton Hotel, Independence, Ohio
October 27, 2004.
Cleveland Clinic Lerner College of Medicine,
Cleveland Clinic Foundation, Cleveland, Ohio.
Foundations of Clinical Medicine Course. Given
to 32 medical students. January 7, 2005.
Grand Rounds For Clinical Research, Cleveland
Clinic Foundation, Cleveland, Ohio. Clinical
and Ethical Issues in Genetics Research. January
25, 2005.
WGN TV – November 4, 2004 - Trisomy 18
Genetic Counseling. Cleveland Clinic Medical
Genetics and Harvard University interviewed.
January 29, 2005.
Magee-Womens Hospital, Department of
Obstetrics and Gynecology and Reproductive
Sciences, Grand Rounds. May 16, 2005.
Hereditary Breast and Ovarian Cancer and Case
Presentation.
Annual Update In Gynecological Oncology,
Magee-Womens Hospital, University of
Pittsburgh, November 18, 2005. Cancer
Genetics.
Helping Women Experiencing Intimate Partner
Violence. Presentation, Women’s Health
Conference, University of Pittsburgh,
Pittsburgh, PA Aug 2004.
Magee-Womens Hospital, Department of
Ultrasound Grand Rounds, December 7, 2005.
Craniofacial dysmorphology.
Once Is Not Enough: Effective Strategies For
Domestic Violence Education. Poster
Presentation, The 27th Annual Society for
General Internal Medicine Annual Meeting,
Chicago, IL May 2004.
More on the vascular action of relaxin. Research
Seminars presented at the Department of
Zoology, University of Melbourne; Baker
Research Institute, Melbourne; Department of
Physiology and Pharmacology, Monash
KIRK CONRAD, MD —
University; Department of Ob/Gyn, Adelaide,
Australia. January-June 2004.
Mechanisms of maternal renal and cardiovascular adaptations to pregnancy. FASEB Summer
Research Conference. Molecular and Cellular
Signaling in the Perinatal Cardiovascular
System. Tucson, August 2004.
Evidence that relaxin is a vascular-derived, locally-acting relaxing and compliance factor. Fourth
International Conference on Relaxin and
Related Peptides. Jackson Hole, September
2004.Evidence that relaxin is a vascular-derived,
locally-acting relaxing and compliance factor.
No Name Society, Amelia Island, FL November
2004.
More on the vascular action of relaxin. Ob/Gyn
Grand Rounds, Burlington, November 2004.
Vascular actions of relaxin. Research Seminar
presented to the Department of Physiology and
Functional Genomics, University of Florida,
Gainsville, March 2005.
Factors that regulate renal function in pregnancy. IUPS Satellite Symposium. Perinatal environment, programming and postnatal consequences. San Diego, March 2005.
Placental hypoxia inducible transcription factors
in normal and pathological pregnancies.
Research Seminar presented to the Department
of Physiology and Functional Genomics,
University of Florida, Gainsville, August 2005.
BONNIE COYNE, MD —
The Use of Ultrasound in the Evaluation of
Abnormal Uterine Bleeding. OB/Gyn Grand
Rounds, Magee-Womens Hospital, Pittsburgh,
PA. June 29, 2004.
Abnormal Uterine Bleeding. Ultrasound Grand
PA. January 5, 2005.
The Use of Ultrasound in the Evaluation of
Acute Pelvic Pain. B/Gyn Grand Rounds,
Magee-Womens Hospital, Pittsburgh, PA,
December 13, 2005.
MITCHELL CREININ, MD —
Association of Reproductive Health
Professionals Annual Meeting, Washington, DC.
(2004) Invited Speaker: Evidence-Based Medical
Abortion Therapies, Contraception and the
Periodic Well-Woman Visit.
Department of Obstetrics and Gynecology
Grand Rounds: Hormonal Contraception: What
the Drug Reps Don’t Tell YouSt. John Hospital
and Medical Center, Detroit, MI. Department of
Obstetrics and Gynecology.
Grand Rounds: First and Second Trimester
AbortionUniversity of Colorado, Denver, CO.
Department of Obstetrics and Gynecology.
Grand Rounds: Medical Management of
Elective and Spontaneous AbortionThe Ohio
State University, Columbus, OH. Department of
Obstetrics and Gynecology.
Grand Rounds: Medical Management of
Elective and Spontaneous AbortionUniversity of
Miami, Miami, FL. Department of Obstetrics
and Gynecology.
Grand Rounds: Modern Combined Hormonal
ContraceptionUniversity of Maryland,
Baltimore, MD. Department of Obstetrics and
Gynecology Grand Rounds: Medical Abortion.
JULIE DELOIA, Ph.D —
“The Impact of the Human Genome Project on
Clinical Medicine” - April 7, 2004.
“Proteomics”, May 21, 2004.
“Pharmacogenetics”, July 6, 2004.
University of Pittsburgh Cancer Institute,
Pittsburgh, PA, 2005.
Ovarian Cancer Symposium, Pittsburgh, PA,
2005.
Relay for Life in Latrobe, PA, 2005 .
Women’s Health Advocacy Forum, July 29,
2005.
CHARLENE DEZUTTI, Ph.D —
Richardson-Harman, N., Fichorova, R., Belec,
L., Chen, S., Dezzutti, C., Doncel, G., Herold,
B., Hillier, S., Landay, A., Mayer, K.,
Onderdonk, A., Poli, G., Roberts, P. LackmanSmith, C., Beer, B., Bromley, C., Reichelderfer,
P., and Cummins, J. Estimating changes in interleukin-1? concentrations in biological matrices
as a step towards its use as a measure of vaginal
inflammation and possible increased risk of HIV-
99
1 infection. Keystone Symposia HIV
Pathogenesis. Keystone CO, 2006.
ASCUS and AGUS Pap Smears/ThinPrep/HPV
Testing – What Should we be Doing?
Dezzutti, C., Landay, A., Richardson-Harman,
N., Ganz, T., Hancock, K., Onderdonk, A.,
Roberts, P., Valore, E., Wahl, S.M., Wild, T.,
Lackman-Smith, C., Beer, B., Reichelderfer, P.,
and Cummins, J. Innate Immunity and Topical
Microbides: A Multi-Center Evaluation of
Lactoferrin Recovery from Complex Biological
Matrices. Microbicides April 2006, Cape Town,
South Africa.
Latest Concepts in Screening and Management
of Gynecologic Cancers, Division of
Gynecologic Oncology, University of Louisville,
Glasgow, Kentucky, March 24, 2004.
J. Cummins, J., Richardson-Harman, N.,
Bremer, J., Anton, P., Dampf, D., Dezzutti, C.,
Elliott, J., Fletcher, P., Grivel, J.C., Guenthner,
P., Gupta, P., Lurain, N., Margolis, L.,
Shattock, R., Beer, B., Lackman-Smith, C., and
Reichelderfer P. A Multi-Center Evaluation of
Tissue Explant Models Used for Pre-Clinical
Assessment of Topical Microbicides.
Microbicides April 2006, Cape Town, South
Africa.
DANIEL EDELESTONE, MD —
The William B. Stromme Lecture in Maternal
Fetal Medicine, “Vaginal Breech Delivery: What
to Do When You Really Have to Do One?
University of Minnesota, Minneapolis,
Minnesota.
New Pap Test Modalities. Grand Rounds,
Department of Obstetrics, Gynecology, &
Women’s Health, University of Louisville
School of Medicine, June 2004.
Ovarian Cancer: Latest developments in screening and treatment. Latest Concepts in Screening
and Management of Gynecologic Cancers,
Division of Gynecologic Oncology, University of
Louisville, Louisville, Kentucky, May 2004.
Scientific Challenges in the Diagnosis and
Treatment of Ovarian Cancer. Louisville Sigma
Xi Lecture Series, Louisville, Kentucky, October
2004.
“Update on Ovarian Cancer“. Annual Primary
Care Review Course, Department of Family and
Community Medicine, University of Louisville
School of Medicine, Louisville, Kentucky, 2004.
May 19, 2005, Percy W. Wadman, MD,
Memorial Lectureship, “Principles of Fetal
Oxygenation,” Baystate Medical Center,
Springfield, Massachusetts.
CXCR4 expression in ovarian cancer is associated with peritoneal dissemination. American
Association for Cancer Research, Orlando,
Florida, March 2004.
ROBERT P. EDWARDS, MD —
Patient attitudes toward self-sampling for HPVDNA testing. Society of Gynecologic
Oncologists, Miami Beach, Florida, March 2005.
Immunotherapy and Gyn Cancers.” Guest
Speaker at Ob/Gyn Resident Research Day,
University of Alabama at Birmingham,
Birmingham, Alabama, June 2004.
Ovarian Cancer: Latest Developments in
Screening and Treatment. Latest Concepts in
Screening and Management of Gynecologic
Cancers, University of Louisville School of
Medicine, Division of Gynecologic Oncology,
Evansville, Indiana, January 28, 2004.
New Therapies for Ovarian Cancer. Grand
Rounds, St. Mary’s Medical Center, Evansville,
Indiana, February 4, 2004.
100
New Pap Test Modalities. Grand Rounds,
Baptist Hospital East, Louisville, Kentucky,
April 2004.
New Therapies for Ovarian Cancer. Grand
Rounds, Methodist Hospital, Henderson,
Indiana, February 4, 2004.
Ex vivo assay prediction of progression free
interval following platinum chemotherapy in primary ovarian cancer. Presented at the annual
WAGO Conference, June 15-18, 2005, Santa
Fe, New Mexico.
Phase II study of paclitaxel poliglumex (PPX)
/Carboplatin © for 1st line induction and maintenance therapy of stage III/IV ovarian or primary peritoneal carcinoma. American Society of
Clinical Oncology Meeting, Orlando, Florida,
May 2005.
“Intraperitoneal Chemotherapy”. 25th
Anniversary Meeting of The Society of
Gynecologic Oncologists of Canada, Quebec,
Canada, 2005.
International Symposium on Peritoneal Therapy
for Ovarian Cancer, Louisville, Kentucky
(Course Director/Moderator), 2005.
“IP Therapy in Ovarian Cancer: New
Directions”. International Symposium on
Peritoneal Therapy for Ovarian Cancer,
Louisville, Kentucky, 2005.
“Cervical Cancer Screening: New Guidelines”.
Greater Louisville Oncology Nursing Society,
Louisville, Kentucky, 2005.
ROBIN GANDLEY, Ph.D —
Implications for Hyperuricemia During
Pregnancy: A rodent model ToxTalks, Mill
Valley, CA. July 2005.
Arterial Models to Assess the Vascular Pathology
of the Pregnancy-Specific Disorder
Preeclampsia. Dean’s Invited Lunch, Graduate
School of Public Health, University of
Pittsburgh, Pittsburgh, PA. Jan 2004.
Significance of Hyperuricema in Preeclampsia.
ToxTalks, Mill Valley, CA July 2003.
Ghetti C, Gregory WT, Edwards SR, Hamilton
S, Smith V, Gold R, Clark AL.Risk Factors for
Surgically Managed Pelvic Organ Prolapse and
Urinary Incontinence. American Urogynecologic
Society 26th Scientific Meeting. Atlanta, GA
September 15-17,2005.
Pelvic Organ Descent and the Perception of
Prolapse. American Journal Obstetrics and
Gynecology. 2005 Jul; 193(1):53-7.
GABRIELLA GOSMAN, MD —
The Ethics of Borderline Viability, Panel
Discussion, Pittsburgh Obstetrical and
Gynecological Society, Pittsburgh, PA, March
29, 2004.
Focused Assessment of Surgical Performance:
Difficulty with Faculty Compliance, CREOG
and APGO Annual Meeting, Salt Lake City,
Utah, March 2005.
RICHARD S. GUIDO, MD —
Optical Detection of High-Grade Cervical
Neoplasia In Vivo: Results of a 604 Patient Pilot
Study. Departments of Obstetrics and
Gynecology, U. Alabama at Birmingham AL,
Arrowhead Regional Medical Center, Colton
CA, U Arizona, Tucson AZ, U Oklahoma,
Oklahoma City OK, Magee-Womens Hospital,
Pittsburgh PA, Dartmouth U, Hanover NH,
Beth Israel Deaconess Medical Center, Boston
MA. Presented at the Annual Meeting for the
Society for Gynecologic Oncologists, New
Orleans, LA, February 4, 2003.
Optical Detection of Cervical Neoplasia: Results
from a Randomized, Duel-Arm, Multi-Center
Clinical Trial. Society of Gynecologic Oncology,
Feb 7-11, 2004.
Vasopressin injection during vaginal hysterectomy: A randomized, placebo-controlled trial.
ACOG, May 1-5, 2004.
The effect of the menstrual cycle phases on the
optical algorithms developed from diffuse
reflectance. ACOG, May 1-5, 2004.
Optical detection of cervical Neoplasia: Results
from a randomized, duel-arm, multicenter trial.
ACOG, May 1-5, 2004.
Focused Assessment of Surgical Performance:
Difficulty with Faculty Compliance. CREOG &
APGO, March 3-5, 2005.
BRYNA HARWOOD, MD —
“Contraceptive Selection and Counseling”,
Presentation, Grand Rounds, West Penn
Hospital, Department of Obstetrics and
Gynecology, Pittsburgh, PA, September 2004.
“Contraception for the Internist”, Presentation,
Workshop, Society of General Internal Medicine
Annual Meeting, New Orleans, LA, May 2005.
“Contraceptive Update: IUD”, Presentation,
Grand Rounds, Eastern Virginia Medical
School, Department of Obstetrics and
Gynecology, Norfolk, VA, February 2005.
Grand Rounds, Johns Hopkins Medical School,
Department of Obstetrics and Gynecology,
Baltimore, MD, March 2005.
Grand Rounds, Tripler Army Hospital,
Department of Obstetrics and Gynecology,
Honolulu, HI, June 2005.
JENNIFER HAYES, MD —
A Pilot Clinical Trial of Ultrasound-guided
Postplacental Insertion of Levonorgestrel IUS”.
Poster presentation at American College of
101
Obstetricians and Gynecologists Annual
Meeting, Washington DC, May 2006.
“Postplacental IUD Insertion”. Department of
Obstetrics, Gynecology, and Reproductive
Sciences Grand Rounds, Magee-Womens
Hospital. Pittsburgh PA.May 2006.
LAURA HEWITSON, Ph.D —
Genetic and Environmental Manipulations in
Non-Human Primates: Implications for Infant
Development. Department of Environmental
and Occupational Health Seminar Series,
University of Pittsburgh School of Public
Health, March 4, 2004.
LYNDON M. HILL, MD —
Ultrasound: MRI Detection of Congenital
Anomalies. 2004 AIUM Annual Convention,
Phoenix, AZ. June 19-23, 2004.
Sonographic Evaluation of the Fetal Face.
Pennsylvania Federation Cleft Palate Clinics
Meeting, Pittsburgh, PA. September 11, 2004.
Sonographic Assessment of the Normal and
Abnormal Placenta. Advanced Applied
Ultrasound in Obstetrics Seminar, New Orleans,
LA. October 7-9, 2004.
Sonographic Assessment of Ovarian Masses.
Advanced Applied Ultrasound in Obstetrics
Seminar, New Orleans, LA. October 7-9, 2004.
The Biophysical Profile Score. Advanced
Applied Ultrasound in Obstetrics Seminar, New
Orleans, LA. October 7-9, 2004.
Umbilical Artery Doppler. Maternal-FetalMedicine Division Seminar, Magee-Womens
Hospital, Pittsburgh, PA. October 29, 2004.
Sonographic Assessment of Ovarian Masses.
North Carolina Ultrasound Annual Symposium,
Charlotte, NC. March 11-12, 2005.
Abnormal Placenta. North Carolina Ultrasound
Annual Symposium, Charlotte, NC. March 1112, 2005.
102
Sonography of the Placenta and Umbilical Cord.
Michigan Sonographers’ Society, Detroit, MI.
April 1-2, 2005.
Obstetric Ultrasound: Helpful Hints. Obstetrics,
Gynecology and Reproductive Sciences, Grand
Rounds, Pittsburgh, PA. April 26, 2005.
3D OB Ultrasound: Practical Tips. Department
of Obstetrics and Gynecology, Grand Rounds,
Georgetown University Hospital, Washington,
DC. May 18, 2005.
Abnormal Placenta. Noon Conference,
Radiology Department, University of Pittsburgh
Medical Center, Pittsburgh, PA, September 12,
2005.
Sonographic Fetal Assessment – Does It Alter
Outcome? 30th Annual Magee Alumni Day,
October 26, 2005.
SHARON HILLIER, Ph.D —
Persistent Vaginitis, Kentucky Coalition of NP’s,
April 22, 2004.
International Women’s Health Issues, American
Association of University Womens, Pittsburgh,
PA, April 28, 2004.
Update on the Diagnosis and Management of
Bacterial Vaginosis, STD Update, Massachusetts
Department of Public Health, Boston, MA, May
6, 2004.
Bacterial Vaginosis: Information for the
Experienced Clinician, Nurse Practitioners for
Community Education, NPACE, Bahamas, May
16, 2004.
Accurate Diagnosis of Vaginal Infections in the
Laboratory: Why Routine Cultures Aren’t the
Answer, American Society for Microbiology
Meeting (ASM), May 24, 2004.
Sonography of the Ovary: Benign and
Malignant. Michigan Sonographers’ Society,
Detroit, MI. April 1-2, 2005.
Do Bacteria Attached to Menses Components
and Discharge Vaginally During Menstruation?
Rostam Scientific Advisory Board Meeting,
Charleston, SC, June 4-6, 2004.
3-D Sonographic Assessment of Uterine
Anomalies. Michigan Sonographers’ Society,
Detroit, MI. April 1-2, 2005.
Vaginitis, Pfizer Women’s Health Advisory
Board Meeting, New York, NY, June 21-22,
2004.
Impact of Lactobacillus crispatus on Vaginal
Colonization by Anaerobic Gram Negative Rods
among Women with BV Treated with
Metronidazole: Results of a Randomized,
Placebo-Controlled Trial of Lactobacillus crispatus CTV-05, Anaerobe Meeting, Annapolis,
MD, July 17-21, 2004.
Research Issues in Vaginitis, 12th Annual Course
on Principles of STD/HIV, University of
Washington, Seattle, WA, July 26, 2004.
Microbicides, 12th Annual Course on Principles
of STD/HIV, University of Washington, Seattle,
WA, July 26, 2004.
The US Development Programme in
Microbicides, Royal Society of Medicine,
London, September 9-10, 2004.
Vaginitis, The Central Association’s of ACOG
Annual Meeting, Washington, DC, October 15,
2004.
Advances in Bacterial Vaginosis from the Guru,
Nurse Practitioners for Community Education,
Boston, MA, December 4-7, 2004.
Management of Bacterial Vaginosis, The
American Society for Colposcopy and Cervical
Pathology (ASCCP), April 28-May 1, 2005,
Hagerstown, MD.
The Normal Vaginal Ecosystem, The American
Society for Colposcopy and Cervical Pathology
(ASCCP), April 28-May 1, 2005, Hagerstown,
MD.
Management of Yeast Vaginitis and
Trichomoniasis, The American Society for
Colposcopy and Cervical Pathology (ASCCP),
April 28-May 1, 2005, Hagerstown, MD.
The Role of Lactobacilli in Vaginal Health,
Biffidus Foundation, Japan, May 24-29, 2005.
Topical Microbicides for Prevention of
STDs/HIV, Center for AIDS and STDs,
University of Washington, Seattle, WA, July 2526, 2005.
Research Issues in Vaginitis, Center for AIDS
and STDs, University of Washington, Seattle,
WA, July 25-26, 2005.
W. ALLEN HOGGE, MD —
Recurrent Vaginosis, Nurse Practitioners for
Community Education, Boston, MA, December
4-7, 2004.
Presidential Speaker: South Atlantic Association
of Obstetricians and Gynecologists Annual
Meeting, January 2004.
Vaginal Lactobacillus Colonization: Probiotic
Approaches to Recolonization, University of
Georgia, December 8-9, 2004.
John M. Nokes Lectureship, University of
Virginia, March 2004.
News from the Secret Garden: Strategies for the
Prevention of Group B Strep and Bacterial
Vaginosis, Milwaukee (Infectious Disease
Society), December 14-25, 2004.
International meetings - American Association
for Cancer Research annual meeting, 2004 and
2005 (Poster presentation).
Management of Recurrent Vaginitis, WAPA,
Seattle, WA, January 29-February 2, 2005.
What Makes a Good Vagina Go Bad? Why
Women Get Vaginitis, Contraceptive
Technology, March 9-12, 2005, San Francisco,
CA.
Management of Recurrent Vaginitis,
Contraceptive Technology, March 9-12, 2005,
Washington, DC.
Update on Herpes, The American Society for
Colposcopy and Cervical Pathology (ASCCP),
April 28-May 1, 2005, Hagerstown, MD.
LIH-CHING HSU, Ph.D —
CARL HUBEL, Ph.D —
Soluble vascular endothelial growth factor receptor-1 (soluble fms-like tyrosine kinase 1, sflt-1) is
increase in serum of postpartum women with a
history of preeclampsia. Vienna, Austria, 17
November 2004; 14th World Congress of the
International Society for the Study of
Hypertension in Pregnancy.
The number of KDR+/CD34+ endothelial progenitor cells in the peripheral circulation is
increased during normal but not preeclamptic
pregnancies. The 52nd Annual Meeting of the
Society for Gynecologic Investigation. March
2005.
103
Is the Vasodilator S-nitroso-albumin Implicated
in Impaired Vascular Function in Preeclampsia?
14th World Congress of the International
Society for the Study of Hypertension in
Pregnancy, Vienna Austria, November 2004.
“Therapeutic implications of relaxin administration in preeclampsia” oral presentation at Tox
Talks Conference, San Francisco, CA, June 2005
Endothelial Progenitor Cell Dysfunction and
Preeclampsia. Tox Talx 2005. Mill Valley, CA
June 29, 2005.
“Reproductive health issues in women with
inflammatory bowel disease”. Patient and family
IBD educational conference. Sponsored by the
Crohn’s and Colitis Foundation of America.
November, 2003.
Preeclampsia and Future Cardiovacular Disease:
Classic and Novel Risk Factors. North American
Pregnancy (NASSHP)., 2nd Combined U.S. and
Canadian Annual Scientific Meeting, Oglebay
Resort and Conference Center, Wheeling, WV,
August 12-14, 2005.
Symposium/workshop co-chair: “Oxidative
Stress”, 14th World Congress of the
Hypertension in Pregnancy, Vienna Austria,
November 2004.
Session/Group Leader, “Preeclampsia and
Future Cardiovascular Disease” North American
Pregnancy (NASSHP)., 2nd Combined U.S. and
Canadian Annual Scientific Meeting, Oglebay
Resort and Conference Center.
ARUN JEYABALAN, MD —
“Renal Disease and Pregnancy” presented at
University of Pittsburgh Women’s Health
Seminar Series, 2004.
“Expression of matrix metalloproteinase-2 protein in upregulated in small arteries from pregnant and relaxin-treated rats” oral presentation
at Society of Gynecologic Investigation 2004,
Houston, TX.
“Matrix metalloproteinase-2 protein is upregulated in small arteries from pregnant and relaxintreated rats” oral presentation at Relaxin 2004,
4th International Conference on Relaxin &
Related Peptides, Jackson Hole, WY.
“Matrix metalloproteinase-9 but not matrix metalloproteinase-2 activity is upregulated in small
arteries from rats acutely treated with relaxin”
poster presentation at the Society of
Gynecologic Investigation 52nd Annual Meeting
2005, Los Angeles, CA.
104
“Immunosuppressive drug use in pregnancy”
Division of Rheumatology Seminar Series,
University of Pittsburgh, April 2005.
BRINDA KALRO, MD —
Insulin Resistance in Polycystic Ovary
Syndrome. Grand Rounds, Department of
Obstetrics and Gynecology, Emory University
School of Medicine, April 2004.
Overview of Ovulation Induction. Grand
Rounds, Department of Ultrasound, MageeWomen’s Hospital, Pittsburgh, February 2005.
DAVID KAUFMANN, MD —
“First Trimester Sonography”. Radiology
Resident Noon Conference UPMC School of
Medicine, Pittsburgh, PA. April 2004.
“Ultrasound Screening for Aneuploidy in the
First and Second Trimesters”. OB/Gyn Grand
Rounds Magee-Womens Hospital, Pittsburgh,
PA. December 2004.
“First Trimester Screens”. Ultrasound Grand
Rounds Magee-Womens Hospital, Pittsburgh,
PA. March 2005.
JOSEPH L. KELLEY, MD —
Stromal Tumors of the Ovary. Presented at the
Didactic Conference, September 10, 2004,
Magee-Womens Hospital, Pittsburgh, PA..
Skin ellipse technique for mammosite® device
placement (poster). Presented at the Joint
Brachytherapy Meeting, May 13-15, 2004,
Barcelona, Spain.
Human breast tumors manifest both hereditary
deficiency and somatic loss of DNA (Nucleotide
excision) repair (platform presentation).
Presented at the 35th Annual EMS Meeting,
October 4, 2004, Pittsburgh, PA..
Loss of expression of CSB and XPA in both
(nucleotide excision) repair in human breast cancer. Presented at the American Society for
Microbiology conference on DNA Repair and
Mutagenesis: From Molecular Structure to
Biological Consequences, November 11, 2004,
Southampton, Bermuda.
Human breast cancer tumors manifest both
(nucleotide excision) repair. Presented at the
2004 meeting of the Environmental Mutagen
Society, Pittsburgh, Pennsylvania.
Environmental and Molecular Mutagenesis
2004; 44: 211.
Evidence for both hereditary deficiency and
somatic loss of nucleotide excision repair in
human breast cancer. Presented at the Sixth
Annual Midwest DNA Repair Symposium,
University of Kentucky, Lexington, Kentucky,
2004.
Genetic analysis of DNA nucleotide excision
repair deficiency in novel non-tumor adjacent
and tumor cell lines suggests a new paradigm of
breast cancer etiology. Accepted for poster presentation at the US Army Medical Research
Materiel Command Era of Hope Breast Cancer
Research Program Meeting, June 8, 2005,
Philadelphia, Pennsylvania.
Ex vivo assay prediction of progression free
interval following platinum chemotherapy in primary ovarian cancer. Presented at the annual
WAGO Conference, June 15-18, 2005, Santa
Fe, New Mexico.
Contemporary Management of Endometrial
Cancer. Presented as a teleconference for the
UPMC Horizon Tumor Board Conference,
September 2, 2005, Biomedical Science Tower,
Pittsburgh, PA.
Managing Breast Masses in Adolescents. Lecture
to staff in Adolescent Medicine at Childrens
Hospital. Pittsburgh, PA, 2005.
MARIJANE A. KROHN, Ph.D —
The effect of high group B Streptococcus Ia
native antibody on decreased genital colonization. Infectious Diseases Society for Obstetrics
and Gynecology. August 7-9, 2003, The Cap
Codder Resort, Hyannis Massachusetts.
Pro-Inflammatory Cytokines and other Cell
Signaling Analytes Associated with Bacterial
Vaginosis Among Pregnant Women. Infectious
Diseases Society for Obstetrics and Gynecology.
August 5-7, 2004, Loews Coronado Bay Resort,
Coronado, CA.
Vaginal opportunistic pathogens and pro-inflammatory cytokines among pregnant women.
Infectious Diseases Society for Obstetrics and
Gynecology. August 18-21, 2005, Wild Dunes
Resort, Isle of Palms, South Carolina.
JEAN LATIMER, Ph.D —
Elevated levels of somatic mutation in homozygotes and heterozygotes for inactivating mutations in the genes of the FA/BRCA pathway of
DNA repair. Presented at the Sixth Annual
Midwest DNA Repair Symposium, University of
Kentucky, Lexington, Kentucky.
Evidence for both hereditary deficiency and
somatic loss of nucleotide excision repair in
human breast cancer. Presented at the Sixth
Annual Midwest DNA Repair Symposium,
University of Kentucky, Lexington, Kentucky.
Expression Profiling to identify BRCA1-associated breast cancers. Presented at the 12th
SPORE Investigators’ Workshop, Baltimore,
Maryland. Elevated somatic mutation frequencies in homozygotes and heterozygotes for inactivating mutations in the genes of the FA/BRCA
pathway of DNA repair. Presented at the 2004
meeting of the Environmental Mutagen Society,
Pittsburgh, Pennsylvania. Environmental and
Molecular Mutagenesis 44: 201. Human breast
cancer tumors manifest both hereditary deficiency and somatic loss of DNA (nucleotide excision)
repair. Presented at the 2004 meeting of the
Environmental Mutagen Society, Pittsburgh,
Pennsylvania. Environmental and Molecular
Mutagenesis 44: 211. Elevated somatic mutation
frequencies in homozygotes and heterozygotes
for inactivating mutations in the genes of the
FA/BRCA DNA repair pathway. Presented at
the 2004 meeting of the American Society of
Human Genetics, Toronto, Canada. American
Journal of Human Genetics 75 [supplement]: 94.
Loss of expression of CSB and XPA in both
(nucleotide excision) repair in human breast cancer. Presented at the American Society for
Microbiology conference on DNA Repair and
Mutagenesis: From Molecular Structure to
Biological Consequences, Southampton,
Bermuda.
Genetic basis of DNA repair deficiency in sporadic breast cancer. Presented at A Promise In
Action—The Susan G. Komen Breast Cancer
Foundation 2005 Mission Conference,
Washington, D.C.
105
Molecular mechanism of nucleotide excision
repair deficiency in novel breast tumor cell lines.
Presented at A Promise In Action—The Susan
G. Komen Breast Cancer Foundation 2005
Mission Conference, Washington, D.C.
Genetic analysis of DNA nucleotide excision
repair deficiency in novel non-tumor adjacent
and tumor cell lines suggests a new paradigm of
breast cancer etiology. Presented at the US
Army Medical Research and Materiel Command
Era of Hope Breast Cancer Research Program
Meeting, Philadelphia, Pennsylvania. Towards
the identification of stem cells in a novel human
mammary epithelial culture (HMEC) system
that reproducibly demonstrates ductal organotypic in three weeks. Presented at the US Army
Medical Research and Materiel Command Era
of Hope Breast Cancer Research Program
Meeting, Philadelphia, Pennsylvania. Towards
the identification of stem cells in a novel human
mammary epithelial culture (HMEC) system
that reproducibly demonstrates ductal organotypic in three weeks. Presented at the 2005
University of Pittsburgh Cancer Institute
Scientific Retreat, University of Pittsburgh,
Pittsburgh, Pennsylvania. Longitudinal bone
marrow mutational biomonitoring of genotoxic
breast cancer chemotherapy. Presented at the
2005 University of Pittsburgh Cancer Institute
Scientific Retreat, University of Pittsburgh,
Pittsburgh, Pennsylvania. Variability in bone
marrow mutational response in breast cancer
patients treated with genotoxic chemotherapy.
Accepted for presentation at the joint meeting of
the 9th International Conference on
Environmental Mutagens and the 2005 annual
meeting of the Environmental Mutagen Society.
Environmental and Molecular Mutagenesis (in
press).
TED LEE, MD —
Laparoscopic Sacrocolpoperineopexy Video presentation, the American Association of
Gynecologic Laparoscopist 33rd Annual
Meeting, 2004.
Anatomic Approach to Presacral Neurectomy
Video presentation, the American Association of
Gynecologic Laparoscopist 33rd Annual
Meeting, 2004.
106
Laparoscopic Presacral Neurectomy Video presentation, Society of Gynecologic Surgeons,
2005.
“Crouchinging Tiger and Hidden Dragon” The
story of retroperitoneal, rectovaginal and other
“invisible” endometriosis. Washington Hospital
Center Grand Round 2004, Washington D.C.
“Minimally Invasive Gynecologic Surgery- the
State of the Art” Passavant Hospital, UPMC,
Grand Round, 2005 Pittsburgh, PA.
SUKETU MANSURIA, MD —
Gynecologic Minimally Invasive Surgery: What
the PCP Should Know. UPMC Women’s Health
Division’s Lecture Series. February 2005.
Laparoscopic Sacralcolpoperineopexy. Video
Presentation. 2004 Annual American Association
of Gynecologic Laparoscopists Meeting.
November 2004.
Laparoscopic Suturing Techniques. 2004 District
III ACOG Annual Meeting. September 2004.
Advances in Gynecologic Minimally Invasive
Surgery. Lee Regional Hospital’s Monthly
Lecture Series. September 2004.
Laparoscopic Supracervical Hysterectomy
Workshop sponsored by Gynecare,9/26/2005,
Magee Womens Hospital.
Laparoscopic Supracervical Hysterectomy
Workshop sponsored by Gynecare, 11/17/2005,
Magee Womens Hospital.
“Pelvic Denervation Procedures-Current
Perspective”,Visiting Professor
Lectureship,George Washington University
Hospital, Washington, D.C., 3/14/06-3/15/06.
Professor Round Table Luncheon,
“Laparoscopic Dissection-Tips and Tricks.
American Association of Gynecologic
Laparoscopists, 34th Annual Meeting,
November, 2005 Chicago.
JERRY MARTIN, MD —
What’s New in Ultrasound. OB/Gyn Grand
PA. January 26, 2004.
Ultrasound Grand Rounds, Magee-Womens
Hospital, Pittsburgh, PA. FASTER Trial Report.
May 26, 2004.
Molar Pregnancy. Ultrasound Grand Rounds,
November 9, 2005.
Valedictory. OB/Gyn Grand Rounds, MageeWomens Hospital, Pittsburgh, PA, April 25,
2006.
ELIZABETH, McGEE, MD —
Women’s Health Seminar Series, Montefiore
University Hospital, University of Pittsburgh.
“Ovarian Follicle Recruitment; what does that
have to do with menopause?” May 3rd, 2004.
Cooperative Reproductive Science Research
Center Symposium, Morehouse School of
Medicine “The Role of Smad3 in Reproduction”
May 6, 2004.
Mitotic Spindle Errors & Cell Cycle
Checkpoints in hESC’s. Society for
Developmental Biology Regional Meeting
Washington D.C. May 2005.
Mitotic Spindle Errors & Cell Cycle
Checkpoints in hESC’s. International Society for
Stem Cell Research, San Francisco CA June
2005.
Spindle Checkpoint Regulation in Human
Embryonic Stem Cells American Society for
Cell Biology pre-meeting special interest group
on Human Embryonic Stem Cells. Washington
D.C. Dec. 2004.
KYLE ORWIG, Ph.D —
Cooperative Reproductive Science Research
Center, Morehouse School of Medicine.
Directed workshop “Workshop in ovarian follicle culture techniques” May 6-7 2004.
Frontiers in Stem Cells Course: Special Seminar
in Fertility After Cancer. “Current Strategies
and Future Promise for Fertility Preservation in
Women” May 10, 2004.
NICHD Reproductive Sciences Branch, Center
Directors Meeting, Pittsburgh PA. “Preantral
follicle development” May 20th 2004.
Obstetrics and Gynecology Basic Research
Seminar Series, University of Vermont College
of Medicine. “The Role of Smad3 in
Reproduction” August 5th 2004.
Reproductive Scientist Development Program
Annual Meeting, Santa Fe, New Mexico. “Smad
family signaling in folliculogenesis” October
2004.
Stem cells in the male germline. Keystone
Symposium on Stem Cells. Keystone Resort,
Keystone, Colorado. January 26, 2004.
Stem cell engineering in the male germline.
University of Pittsburgh Senior Vice
Chancellor’s Research Seminar. February 20,
2004.
Stem cells in the male germline. Ottawa Health
Research Institute Seminar Series. Ottawa,
Ontario. April, 2004.
Fertility after cancer treatment. Frontiers in
Human Embryonic Stem Cells Advanced training course. Pittsburgh Development Center,
Pittsburgh, PA. May 9, 2004.
Animal models for stem cell research. American
Association of Laboratory Animal Science.
Ellicott City, MD. September 2004.
Keystone Symposium on Stem Cells, January
2004.
The University of Chicago Endocrinology
Research Seminar Series “Early ovarian follicle
development” January 24th 2005.
Biology and practical application of male
germline stem cells. Ob/Gyn Grand Rounds,
Pittsburgh, PA January 2005.
Magee-Womens Research Institute Works-in
Progress Seminar Series, Pittsburgh PA. In vitro
follicle Culture: a work in progress March 1
2005.
Stem cells in the male germline. Department of
Molecular and Integrative Physiology Seminar
Series, University of Kansas Medical Center,
Kansas City, KS, March 2005.
CHRISTOPHER NAVARA, Ph.D —
Understanding Embryonic Stem Cells and
Realizing their Clinical Potentials Trilateral
Embryonic Stem Cell Meeting. Kobe Japan May
2005.
Stem cells in the male germline. Stowers
Institute for Medical Research, Kansas City, KS,
March 2005.
Stem cells in the male germline. Frontiers in
Human Embryonic Stem Cells Advanced
Training Course. Pittsburgh, PA. May 26, 2005.
107
Male germline stem cells. Stanford University,
Palo Alto, CA, June 18, 2005.
What’s really at stake in stem cell research?
Whitworth College Homecoming Lecture.
Spokane, WA, September 15, 2005.
ROBERT POWERS, Ph.D —
PBL Facilitator for Reproductive Biology
Course, University of Pittsburgh Medical
School, Spring 2005.
Lecturer for Reproductive Biology Course,
University of Pittsburgh Medical School, Spring
2005.
“Clinical Complications of the Placenta”
PBL Facilitator for Reproductive Biology
Course, University of Pittsburgh Medical
School, Spring 2006.
PBL Facilitator for Method in Logic and
Medicine Course, University of Pittsburgh
Medical School, Spring 2006.
Lecturer for Reproductive Biology Course,
University of Pittsburgh Medical School, Spring
2006.
“Embryonic and Fetal Development”.
“Longitudinal Analysis of Seum sFlt-1
Concentrations in Normal Pregnancy and
Preeclampsia, 51st meeting of the Society for
Gynecologic Investigation. 2004.
“Maternal leptin correlates with maternal and
fetal amino acids in preeclampsia. “ 14th World
Congress International Society for the Study of
Hypertension in Pregnancy. 2004.
“Fetal Growth in Preeclampsia: Are All Small
Babies the Same?” Magee-Womens Hospital
Grand Rounds, 2004.
“Differences in cord blood amino acids during
preeclampsia and SGA without preeclampsia.”
Tox Talks 8, 2005.
“Relationship between markers of inflammation,
obesity and pregnancy outcome.” North
American Society for the Study of Hypertension
in Pregnancy, 2005.
108
“Differences in cord blood amino acids during
preeclampsia and SGA without preeclampsia.”
North American Society for the Study of
Hypertension in Pregnancy, 2005.
AUGUSTINE RAJAKUMAR, Ph.D —
Hypoxia and soluble Flt: Implications in
Preeclampsia. Grand Rounds, May 4th 2005,
Renal Division, Beth Israel Hospital, Harvard
Medical School, Boston MA.
Mechanisms of pathogenesis of preeclampsia: 1)
Deficient proteasomal function in placentas of
preeclamptic women and 2) sFlt by peripheral
blood mononuclear cells. Tox Talks 2005, San
Francisco CA.
The proteasomal inhibitor, clasto-lactacystin,
reverses the defect in HIF-1a protein degradation in preeclamptic placentas. 52nd Annual SGI
meeting, March 23-26th 2004, Los Angeles, CA.
Angiotensin II Type 1 Recetpor Activation
Reduces System A Amino Acid Transort in
Human Placental Villi. The 14th world congress
of the international society for the study of
hypertension in pregnancy, Nobember, 2004,
Vienna, Austria.
Soluble fms-like Tyrosine Kinase 1 (sFlt-1) and
placental growth factor (PlGF) expression in
Preeclampsia and small for gestational age pregnancies. The 14th world congress of the international society for the study of hypertension in
pregnancy, and US National Institute of Child
Health and Development Award presentation,
November, 2004, Vienna, Austria.
Angiotensin II (ANG II) type 1 receptor (AT1R) activation reduces system A amino acid transport in human placental villi. 52nd Annual SGI
meeting, March 23-26th 2004, Los Angeles, CA.
Peripheral blood mononuclear cells (PBMCs) of
pregnant women are the potential extra-placental source of soluble VEGF receptor, sFlt contributing to preeclampsia: Regulation by hypoxia. Placenta Association of the Americas,
Asilomar CA. USA. September 25-29, 2004.
“Soluble Flt: Origins and implications in pregnancy outcome. Oral presentation, Workshop on
‘Angiogenesis’, PAA2004, Asilomar,CA
September 25-29,2004.
Differential Expression of Vascular Endothelial
Growth Factor Receptor, Flt-1 in PBMCs of
Pregnant Women. 51st Annual SGI meeting,
March 23-28,2004, Houston Texas.
An Excess of Serum Soluble FMS-like Tyrosine
Kinase-1 (sFlt) Persists Postpartum in Women
with Prior Preeclampsia: Relation to Insulin
Resistance. 51st Annual SGI meeting, March 2328,2004, Houston Texas.
JAMES ROBERTS, MD —
Invited Panelist International Conference on
Improving the Use of Medicines, Chiang Mai
Thailand, 2004.
Dwayne Alexander Award Lecture; Whither
Preeclampsia? NICHD Aspen Summer
Conference Aspen Colorado, August 2004.
Nordic Federation of Obstetrics and
Gynecology Plenary Lecture Pre-eclampsia,
“New Insights into the Disorder”, Helsinki
Finland June 2004.
Hypertension in Pregnancy Invited Participant,
Workshop on Clinical Trials “The
NICHD/NHLBI Randomized Controlled Trial
of Antioxidants to Prevent Preeclampsia”,
November 2004.
Visiting Professor Perinatal Research Center
University of Colorado, “Maternal Feta
Adaptation in Pre-eclampsia”, March 2005.
New York Society of Nephrology,
“Preeclampsia: Can it be Prevented?” January
2005.
JOSEPH SANFILIPPO, MD —
“Adolescent Gynecology,” Visiting Professor,
State University of New York Health Science
Center at Brooklyn Grand Rounds, June 2004,
New York, NY.
“Challenging Medical and Surgical Cases in
Pediatric and Adolescent Gynecology” and
“Debate: Sexuality and Contraception in
Adolescent Gynecology,” Visiting Professor,
University of Cincinnati, Department of
Obstetrics and Gynecology, Annual
Postgraduate Course, August 2004, Cincinnati,
OH.
“Current Concepts in Contraception,” Visiting
Professor, Woodhull Hospital Grand Rounds,
September 2004, , New York, NY.
“Current Concepts in Contraception,” Visiting
Professor, Brookdale Hospital Grand Rounds,
October 2004, New York, NY.
“Adolescent Gynecology,” Visiting Professor,
Columbia Medical Society, October 2004,
Columbia, South Carolina.
“Teaching Pediatric and Adolescent Gynecology
to Students and Residents,” North American
Society for Pediatric and Adolescent Gynecology
Postgraduate Course, November 2004,
Washington, DC.
“Management of Abnormal Uterine Bleeding,”
American Association of Gynecologic
Laparoscopists Postgraduate Course, November
2004”, San Francisco, CA.
“Hormone Therapy: A Clinical Conumbrum,”
Visiting Professor, Johnston Medical Society,
December 2004.
“Abnormal Uterine Bleeding: Adolescence to
Menopause,” Visiting Professor, Saint Barnabas
Medical Center, January 2005, , Livingston, NJ.
“Challenging Medical and Surgical Cases in
Pediatric and Adolescent Gynecology,” Visiting
Professor, Chambersburg Hospital Grand
Rounds, February 2005, Hagerstown, PA.
“Challenging Cases in Pediatric and Adolescent
Gynecology” and “Update in Reproductive
Endocrinology,” Visiting Professor, Medical
College of Wisconsin, April 2005, Milwaukee,
WI.
“What’s New in Infertility,” Visiting Professor,
Mercy Hospital of Pittsburgh, June 2005,
Pittsburgh, PA.
“Endometriosis and other Challenging Surgical
Dilemmas in Pediatric and Adolescent
Gynecology” and “Clinically Challenging
Medical Cases in Pediatric and Adolescent
Gynecology,” Visiting Professor, American
Society of Reproductive Medicine – ESHRE,
June 2005, Copenhagen, Denmark.
“Management of Mullerian Fusion Defects,”
Visiting Professor, Monmouth Medical Center –
Medical Society of New Jersey, Cutting Edge
2005 - July 2005, New Jersey, PA.
PAUL SAMMAK, Ph.D —
Adipose Stem Cells as Autologous Feeder Cells
for Human Embryonic Stem Cells, International
Fat Applied Technology Society, 2005.
109
Pluripotent Human Embryonic Stem Cells Lose
Nuclear Elasticity And Chromatin Dynamics
Upon Commitment To Differentiate, American
Society for Cell Biology Washington, DC.
December 2004.
Non-uniform developmental potential of mouse
clones revealed by Oct4 gene expression and ES
cell derivation, Seoul Symposium on Stem Cell
Research September 2004.
Nuclear Plasticity and Chromatin Mobility during Neuronal Differentation of Human
Embryonic Stem Cells. Athersys, October 2004.
Maturation of Nuclear Architecture in Neural
Progenitor Cells Derived from Pluripotent
Human Embryonic Stem Cells. International
Society for Stem Cell Research, Boston, MA
June 2004.
Chromatin Mobility and Nuclear Architecture in
Human Embryonic Stem Cells, Frontiers in
Human Embryonic Stem Cells Symposium,
University of Pittsburgh. May 2004.
Some Observations on Nuclear Plasticity of
human Embryonic Stem Cells and Development
of Oct-4 GFP expressing cloned mouse blastocysts, Reproductive Endochrinology OB/GYN
University of Pittsburgh. March 2004.
District VII and District VIII Annual District
Meeting, American College of Obstetricians and
Gynecologists, “Endometrial Ablation”
Symposium Participant, September 2005, San
Antonio, Texas.
Visiting Professor, Mercy Hospital, The James
T. Dattilo, MD Lectureship, “Pre-op and Postop Considerations of Patients with
Thrombophilias,” October 2005.
Visiting Professor, 31st Annual Symposium on
Obstetrics & Gynecology, Washington
University Medical Center, St. Louis, “Pediatric
and Adolescent Gynecology Medical Problems”
and “Pediatric and Adolescent Gynecology
Surgical Challenges,” St. Louis, Missouri.
110
Global Congress on Minimally Invasive
Gynecology, American Association of
Gynecologic Laparoscopists 34th Annual
Meeting, “Abnormal Uterine Bleeding,”
“Endometrial Ablation Panel Member for
Laparoscopy in Challenging Situations,” and
Hormone Therapy-Benefits/Risks – The
Women’s Health Initiative,” November 2005.
Grand Rounds, Geisinger Medical Center,
“Clinically Challenging Cases in Pediatric and
Adolescent Gynecology,” December 2005,
Danville, Pennsylvania.
Grand Rounds, Upstate Medical Center,
December 2005 “Dysfunctional Uterine
Bleeding,” Syracuse, New York.
Visiting Professor, West Virginia University,
January 2006 “Medical and Surgical Aspects of
Pediatric and Adolescent Gynecology,”
Morgantown, West Virginia.
Grand Rounds, Allegheny General Hospital,
February 2006 “Reproductive Health Update
Including Mood Disorders,” Pittsburgh,
Pennsylvania.
Controversies & Update in Gynecology,
Pediatric and Adolescent Medicine, Gynecologic
Oncology and Reproductive Endocrinology,
February 2006 “Ectopic Pregnancy: How to best
use modern algorithms for management”,
“Dysfunctional Uterine Bleeding in the
Adolescent”, “Medical Problems in Pediatric and
Adolescent Gynecology”, Surgical Problems in
Pediatric and Adolescent Gynecology”, PCOS.
Visiting Professor, Wheeling Ob-Gyn Society,
March 2006. The Non-Contraceptive Benefits
of Oral Contraceptives and the Unique
Properties of the Novel Progestin,
Drospirenone. West Virginia.
Visiting Professor, Lawrence Society, March
2006. Medical Problems in Pediatric and
Adolescent Gynecology and Surgical Challenges
in Pediatric and Adolescent
Gynecology/Minimally Invasive Surgery.
Asheville, NC.
Grand Rounds, Wright State University School
of Medicine, April 2006. Challenging Medical
and Surgical Cases in Pediatric and Adolescent
Gynecology. Dayton, Ohio.
Medical Approaches to Managing Abnormal
Uterine Bleeding, June 2006. Philadelphia, PA.
Visiting Professor, European Society of Human
Reproduction and Embryology (ESHRE).
“Recurrent spontaneous abortions – pathophysiology and diagnosis” and “Role of uterine reconstruction in recurrent pregnancy loss”. Prague,
June 2006.
GERALD SCHATTEN, Ph.D —
Advances and Challenges in Reproductive
Health Research in the Post Genomic Era
Mumbai, India, January 2005. Realizing the clinical potentials of immune-matched stem cells,
while preventing unethical human reproductive
cloning: Invaluable non-human primate contributions.
Steptoe Lecture / Fertility 2005, Warwick
University - Coventry, UK, April 4 – 7, 2005.
In Gratitude for Dr. Patrick Steptoe’s Pioneering
Achievements: Realizing The Clinical Potentials
Of Immune-Matched Stem Cells, While
Preventing Unethical Human Reproductive
Cloning.
ASRM, Philadelphia, PA, October 16, 2004
Assisted Regenerative Medicine: The Future of
ART?
Expert Panel, University of Washington WA,
October 18, 2004 Stem Cells: The Science,
Policy and Possibilities.
United Nations ‘Human Cloning in All Its
Aspects’ (June); 2004.
Jonas Salk Fellows Lecture: Science and Ethics
of Stem Cell Research; 2005.
Patrick Steptoe Medal; British Fertility Societies
(Coventry, UK); April, 2005.
Keynote Lecture: Inaugural of Taiwan Stem
Cell Research Center (Taipei); April, 2005.
Taiwan Society of Stem Cell Research, Taipei
115, Taiwan, April 15 – 18, 2005.
French-Japanese-US Trinational Stem Cell
Consortium (Riken); April, 2005.
In Vitro Fertilization Assisted Production &
Genetics, Instanbul, Turkey, May 26 – 29, 2005.
Keynote Lecture: World Congress for In Vitro
Fertilization (Istanbul); 2005.
Realizing the Clinical Potentials of ImmuneMatched Stem Cells, While Preventing
Unethical Human Baby Cloning FIR Course
Module, Woods Hole, MA, June 8 – 9, 2005.
Senescence Congress: Discovery of Aging
Mechanisms by NT in hESCs (Cambridge,
UK).
Stem Cell Policy and Advocacy Summit,
Houston TX, June 11 – 12, 2005 Science &
Public Policy Impact Award The Promise of NY
and the Quest for Cures.
Frontiers in Human Embryonic Stem Cells,
Advanced Training Course, Stanford University,
California, June 15 – 23, 2005 hESC Science
and Medicine.
Annual NIH Human Embryonic Stem Cell
Research Meeting, For R24 Infrastructure &
T15 Training Course Grantees, SanFrancisco,
CA, June 21 – 22, 2005 Frontiers in Human
Embryonic Stem Cells.
ISSCR 3rd Annual Meeting, June 23 – 25, 2005.
141ST AVMA Annual Convention, Philadelphia
PA, July 23-25, 2004 Problems/Obstacles
Encountering in Cloning Research.
Seoul Symposium on Stem Cell Research, Seoul
Korea, September 1 – 3, 2004 Realizing the
Biomedical promises of Stem cells responsibly.
SCOR Directors Meeting, Washington DC,
October 6, 2004.
Keynote Lecture: Korean Government
Congress (Seoul); October, 2005.
Indo-US Stem Cell Forum (Mumbai);
September, 2005.
Keynote: American Veterinary Medicine
Association; November, 2005.
CALVIN SIMERLY, PhD. —
International Symposium on Advances and
Challenges in Reproductive Health Research in
the Post Genomic Era, Successful embryogenesis in non-human primates after somatic cell
nuclear transfer is improved by overcoming
microtubule motor and centrosomal protein
depletion during meiotic spindle extraction. 9-12
January, Mumbai, India.
Stem Cell Research Symposium, Realizing the
Clinical Potentials of Immune-Matched Stem
Cells in Biomedicine: Myths and
Misconceptions, The Clarke Center at
Dickinson College, Carlisle, PA March 8, 2005.
Seoul Symposium on Stem Cell Research, Seoul,
South Korea, “Successful Somatic Cell Nuclear
Transfer [SCNT] in Non-Human Primate
[NHP] Embryogenesis: Overcoming
111
Microtubule Motor and Centrosomal Protein
Depletion during Meiotic Spindle Extraction”,
September 1-4, 2004.
American Society for Cell Biology, Washington,
DC, Embryonic Stem Cell Special Interest
Group, “Successful SCNT in Non-Human
Primate Embryogenesis”, December 4, 2004.
HYAGRIV SIMHAN, MD —
Genetics and Preterm Birth. Centers for Disease
Control and Prevention. Atlanta, GA. May 2004.
Serum Biomarkers of Preterm Birth. North
Atlantic Neuro-epidemiology Alliances meeting
of biomarkers and preterm birth. Middelfart,
Denmark. June 2004.
The Effect of the Anti-Inflammatory Cytokines
Interleukin-10 & Interleukin-13 on
Lipopolysaccharide-Stimulated Production of
Prostaglandin E2 by Cultured Human Decidual
Cells. Presented at the Society for Gynecologic
Investigation, Houston, TX, March 2004.
Expression of Toll-like Receptors on WISH and
Decidual Cells. Presented at the Society for
Gynecologic Investigation, Houston, TX, March
2004.
Evaluation and Management of PPROM. 2nd
International Preterm Labour Congress.
Montreux, Switzerland. September 2004.
Cervical anti-inflammatory cytokine concentrations among pregnant smokers. Presented at the
Infectious Diseases Society of Obstetrics and
Gynecology, Sand Diego, CA, August 2004.
The MFMU PROM Study: Maternal & neonatal cytokines, histologic findings, & neonatal
morbidity. Presented at the Society for
Maternal-Fetal Medicine, New Orleans, LA,
February 2004.
Cervical anti-inflammatory cytokine concentrations are increased among pregnant women with
bacterial vaginosis. Presented at the Infectious
Diseases Society of Obstetrics and Gynecology,
Sand Diego, CA, August 2004.
TNF-a promoter polymorphism and glucose
tolerance during pregnancy. Presented at the
Society for Maternal-Fetal Medicine, New
Orleans, LA, February 2004.
JOHN TUROCY, MD —
Racial disparity in midtrimester maternal serum
alphafetoprotein as a marker for spontaneous
preterm birth. Presented at the Society for
February 2004.
Effect of tocolytics on interleukin-8 production
by human amniotic and decidual cells. Presented
at the Society for Maternal-Fetal Medicine, New
112
How does amniotic fluid lamellar body count
compare with FLM, PG, and L/S? Presented at
the Society for Maternal-Fetal Medicine, New
Lecture on Recurrent Pregnancy Loss RPL and
Infertility for Genetics Counseling Interns,
February 2006.
Genetics Conference Magee-Womens Hospital.
Case Presentation and lecture on DiGeorge –
VCFS. January 2006.
Genetics Conference Magee-Womens Hospital.
Case Presentation and lecture on choriocarcinoma for Genetic counseling students. October
2005.
ANTHONY WAKIM, MD —
Elevated vaginal pH and neutrophils are associated with early preterm premature rupture of
membranes. Presented at the Society for
February 2004.
Cetrorelix 2mg. Or GnRH-agonist long protocol in ovum donation cycles. Oral presentation –
European Society for Human Reproduction and
Endocrinology – ESHRE Meeting –
Copenhagen. June 2005.
The MFMU PROM Study: The relationship of
maternal plasma cytokine concentrations and
antibiotics with latency and histologic amnionitis. Presented at the Society for Maternal-Fetal
Medicine, New Orleans, LA, February 2004.
MARGARET WATT-MORSE, MD —
July, 2004 Speaker, Tobacco Free Allegheny
(TFA) Public Private Partnership Launch Event.
Magee-Womens Hospital. Pittsburgh, PA.
January, 2005 Sickle Cell Disease in Pregnancy.
Children’s Hospital of Pittsburgh Symposium
“Sickle Cell Disease: Progress, Patients, and
Solutions”. Pittsburgh, PA.
February, 2005 Recurrent Pregnancy Loss. Core
Lecture Series. University of Pittsburgh,
Department of Obstetrics, Gynecology and
Reproductive Sciences. Pittsburgh, PA.
April, 2005 Smoke-Free Mothers/Smoke-Free
Families Coalition, Moderator. Magee-Womens
Hospital, Pittsburgh, PA.
ANNE WEBER, MD —
Autologous Rectus Fascia is Superior to
Cadaveric Fascia in Pubovaginal Sling
Continence Outcomes. American
Urogynecologic Society, Atlanta, September
2005.
Relationship Between Stage of Pelvic Organ
Prolapse and Symptoms of Pelvic Floor
Dysfunction. Society of Gynecologic Surgeons,
April 2005. International Continence Society,
Montreal, August 2005.
Risk Factors for Anal Sphincter Laceration in
Primiparous Women. Society for Gynecologic
Surgeons, April 2005. International Continence
Society, Montreal, August 2005.
Reliability of Health-Related Quality of Life
Measures One Year Following Pelvic Floor
Surgery. Central Association of Obstetricians
and Gynecologists, October 2004.
Comparison of Measurements Obtained with
Microtip and External Water Pressure
Transducers. International Continence Society
and International Urogynecologic Association,
August 2004.
Stress Incontinence Symptoms by Questionnaire
versus Stress Test Results. American
2005.
Pelvic Symptoms in Women with Pelvic Organ
Prolapse. American Urogynecologic Society, San
Diego, CA, July 2004.
Risk of Severe Perineal Laceration by Type of
Delivery. American Urogynecologic Society,
Atlanta, September 2005.
Comparison of Morbidity Between Vaginal and
Cesarean Deliveries. American Urogynecologic
Society, Hollywood, FL, September 2003.
Pelvic Floor Muscle Strength in Women with
Advanced Pelvic Organ Prolapse. American
2005.
Visiting Professor, Resident Research Day, Mayo
Clinic Rochester. “Randomized Trials in
Gynecology.” June 2005.
Preoperative Sexual Function in Women
Planning Abdominal Sacrocolpopexy.
International Continence Society, Montreal,
August 2005.
Physical Activity in Women with Advanced
Pelvic Organ Prolapse. International Continence
Society, Montreal, August 2005.
Prophylactic Antibiotic Use for Urodynamics in
Women: A Decision Analysis. American College
of Obstetricians and Gynecologists, San
Francisco, May 2005.
Prophylactic Castration at the Time of
Hysterectomy in the United States, 1979-2001.
American College of Obstetricians and
Gynecologists, San Francisco, May 2005.
Rates of Hysterectomy for Uterine Myomas and
Myomectomy in the United States, 1979-2001.
Society of Gynecologic Surgeons, April 2005.
American Urogynecologic Society Fellows’
Research Retreat. “NIH Funding Mechanisms.”
“The NIH Review Process.” April 2005.
Visiting Professor, Resident Research Day,
University of Rochester. “Clinical Trials in
Gynecology and Urogynecology.” June 2004.
Postgraduate Course: Gynecologic Surgery
Horizons in the 21st century, sponsored by
Cooper University Hospital, Camden, NJ.
Impact of Vaginal Delivery on Future Pelvic
Floor Defects and Dysfunction; Assessment of
Connective Tissue Deficiencies Relevant to
Pelvic Floor Dysfunction; and How Much Value
Do We Truly Gain from Pre-Operative Testing
for Our Surgical Plan. April 2004.
Visiting Professor, Resident Research Day,
University of California San Francisco. “Clinical
Trials in Gynecology and Urogynecology.”
November 2003.
113
HAROLD WIESENFELD, MD —
“Debate: Should Confirmatory Testing of
NAATs Be Routine for Chlamydia and
Gonococcal Infections in Populations with <4%
Prevalence? 2004 National STD Prevention
Conference, Philadelphia, PA. March 2004.
“Managing Chronic Vaginal Infections” 11th
Annual Current Topics in Ob/Gyn.
Northeastern Ohio Universities College of
Medicine, Rootstown, OH, October 2004.
“STDs in 2004- Update for the Busy Clinician”
NPACE Nurse Practitioner Associates for
Continuing Education (NPACE) Winter
Meeting, Boston, MA, December 2004.
114
Neurologic Injuries in Obstetrics and
Gynecology: Recognition, Treatment and
Prevention Grand Rounds, Mercy Hospital,
Pittsburgh, PA June 2004.
Sexual Dysfunction caused by Pelvic
Disorders—Update in Internal Medicine 2004
David Lawrence Convention Center, Pittsburgh,
Pennsylvania, Nov 2004.
Surgical Treatment Options for Stress Urinary
Incontinence. Clinical Seminar at 53rd Annual
Clinical meeting of the American College of
Obstetrics and Gynecology, San Francisco, CA.,
May 2005.
TEACHING ACTIVITIES
Residency Training Program in Obstetrics & Gynecology
July 1, 2005 through June 30, 2006
In October, 2005, Gabriella G. Gosman, MD, was appointed as the new program director
of our Obstetrics and Gynecology residency training program. Doctor Gosman served as
the Assistant Program Director for two years prior to this appointment. The previous
Program Director, Joseph S. Sanfilippo, MD, M.B.A., assumed more administrative responsibilities and was appointed as the President of ASRM (American Society of Reproductive
Medicine) and the Chair of the Scientific Program Committee for ACOG (American
College of Obstetricians and Gynecologists) Annual Clinical Meeting.
The training program spans four years with nine house officers at each level. The residency
is designed to offer the proper balance between academic/scholarly activities and clinical
experience acquired through the supervised care of patients. Clinical experience is structured so that each house officer acquires the requisite training to establish eligibility for
certification by the American Board of Obstetrics and Gynecology. All residents are
required to complete a research project. The focus may be either clinical or basic science in
nature. Each resident identifies a faculty member to guide and advise them in accomplishing their project. Resident’s efforts are presented at The T. Terry Hayashi Resident
Research Day held in June of each year.
For the graduating class of 2006, five are pursuing fellowships two of them will be fellows
at Magee. Two are pursing academic careers as generalists, one of them staying at Magee.
Two have embarked on private practice careers. Among our current fourth-year residents,
six of the nine are planning sub-specialty fellowship training.
We continue to attract the very top candidates from medical schools nationally and were
extremely successful in this year’s Match. It is clear from repeated comments made by
applicants, their respective faculty advisors, and our own colleagues around the country,
that our training program is conservatively placed in the top five residencies in Obstetrics
and Gynecology in the country. During the 2005-2006 interview season, we screened 291
applicants (209 from LCME schools, 6 from osteopathic schools, and 76 international medical graduates), invited 118 to interview and ultimately interviewed 92 prospective residents.
Among these we interviewed were 25 students who were members of AOA at their respective medical schools and 28 students who would qualify for AOA but their medical schools
did not elect members until after the residency applicant interview season. Also among this
group were several applicants who held other advanced degrees at the Masters or PhD level
in addition to their medical degree.
During the past academic year, our residents were the recipients of the following awards:
Michele Odrobina, MD, Third-Year Resident: University of Pittsburgh School of
Medicine, Recipient of the Gold Foundation Humanism and Excellence in Teaching “Little
Apple” Award (this is the third straight year she has received this award).
Carolyn Sufrin MD, Third-Year Resident: University of Pittsburgh School of Medicine
Finalist: Gold Foundation Humanism and Excellence in Teaching “Little Apple” Award.
Amanda Nickles Fader, MD, Senior Resident: University of Pittsburgh School of
Medicine, Best Ob/Gyn Resident Teacher as selected by Third-Year Medical Students.
Michele Odrobina, MD, Third-Year Resident, University of Pittsburgh School of
Medicine, Best Third-Year Ob/Gyn Resident Teacher as selected by Third-Year Medical
Students.
115
Carolyn Sufrin, MD: Invited to speak at undergraduate institution on international health
as part of a 1 day course for undergraduates on the global health crisis.
Carolyn Sufrin, MD: Yale/Johnson and Johnson Scholarship- scholarship to spend 6 wks
in Eritrea at national maternity hospital.
Susan Lareau, MD, Second-Year Resident: University of Pittsburgh School of Medicine,
Best Ob/Gyn Resident Teacher as selected by Third-Year Medical Students.
Melanie Ochalski, MD, First-Year Resident: University of Pittsburgh School of Medicine,
Best Ob/Gyn Resident Teacher as selected by Third-Year Medical Students.
Susan Lareau, MD, Second-Year Resident: Berlex Best Second-Year Teacher as Selected
by First-Year Residents.
Ashlyn Holstein Savage, MD, Senior Resident: American Association of Gynecologic
Laparoscopists - Special Excellence in Endoscopic Procedures Award.
Amy Broach, MD, Third-Year Resident: Society of Laparoscopic Surgeons - Outstanding
Resident Award.
Published Peer-Reviewed Articles:
Melanie Endres, MD: Prevention of alcohol-induced developmental delays and learning
abnormalities in a model of fetal alcohol syndrome. American Journal of Obstetrics and
Gynecology, Volume 193, Issue 3, Supplement 1, September 2005, Pages 1028-1034. M.
Endres, L. Toso, R. Roberson, J. Park, D. Abebe, S. Poggi and C.Y. Spong
David Rapkin, MD: Is Severe Perineal Damage Increased in Women With Prior Anal
Sphincter Injury? Obstet Gynecol.2006; 107: 27S-285. Edwards H, Grotegut C, Harmanu
O. H., Rapkin D, Dandolu V.
Amy Whitaker, MD: HIV sentinel surveillance among women seeking elective pregnancy
termination, San Francisco. Sex Transm Dis. 2005 Sep;32(9):590-2. Drey EA, Darney PD,
Louie B, Kellogg TA, Kang MS, Prabhu R, Whitaker AK, Chin J, Molina A, McFarland W.
Amy Whitaker, MD: Misoprostol compared with laminaria before early second-trimester
surgical abortion: a randomized trial. Obstet Gynecol. 2005 Aug;106(2):234-41. Goldberg
AB, Drey EA, Whitaker AK, Kang MS, Meckstroth KR, Darney PD.
Amy Park, MD: Mucocele of the Appendix: An Important Clinical Parity. The Journal of
Emergency Medicine, 2005 May;30(3):303-306. Roberge, RJ, Park, Amy J
Amanda Nickles Fader, MD: Predicting platinum resistance in primary ovarian cancer
patients). Gyn Oncology (first author).
Amanda Nickles Fader, MD: Case Report: Abdominal pregnancy after hysterectomy.
Journal of Obstetrics and Gynecology (the first author).
Abstracts presented:
Amy Park, MD: RASP, AUGS, October 2006 – Oral Presentation. Does apical suport
affect Prolapse in the Anterior + Posterior Vagina
Amanda Nickles Fader, MD: SGO 2006, Sentinel Lymph Node Technology in Cervical
Cancer – Poster Presentation.
Amanda Nickles Fader, MD: SGO 2006, Predicting Platinum Resistance in Primary
Ovarian Cancer Patients – Poster Presentations.
116
TEACHING ACTIVITIES
Amanda Nickles Fader, MD: WAGO-invited to give oral presentation. Sentinel Lymph
Node in Cervical Cancer Study. Unable to attend due to personal illness. A Nickles Fader
J. Kelly, R. Edwards, H. Schellhas, S. Hosford, J. Comerci, H. Gallion.
Amanda Nickles Fader, MD: WAGO – poster: Ex Vivo Assay Prediction of Progression
Free Interval Following Platinum Chemotherapy in Primary Ovarian Cancer. A Nickles
Fader J. Kelly, R. Edwards, H. Schellhas, S. Hosford, J. Comerci, H. Gallion.
Amanda Nickles Fader, MD: Ex Vivo Chemoresponse Assay Predicts Progression Free
Interval Following Platinum-based Chemotherapy in Primary Ovarian Cancer –
Manuscript. Amanda Nickles Fader, Joseph Kelley, John Comerci, Sarah Hosford, Helmut
Schellhaus, Holly Gallion.
Amanda Nickles Fader, MD: ChemoFx® Assay is an Independent Predictor of Response
to Platinum-Based Chemotherapy in Primary Ovarian Cancer Abstract/Poster?
Amanda Nickles Fader, MD: Intraoperative sentinel node detection using Technetium99m sulfur colloid predicts nodal metastases in patients with early-stage cervical cancer.
Abstract Presentation.
Teresa Erb, MD: ESHRE2005- Copenhagen, 2005. 21st Annual Meeting of ESHRE. 21st
Annual Meeting of ESHRE - Copenhagen 2005. RE: Acceptance abstract—Oral presentation.
Kathleen Himes, MD: SGI 2006, Canada. A Short Time Interval From Cervical
Conization to Subsequent Pregnancy Is Associated with Preterm Birth - Oral Presentation.
117
Listed below are the names and medical schools of origin of our current complement of
house officers by year of training. Lastly, we have listed the names and initial career choices
of our graduating house officer from the classes of 2004 and 2005.
DEPARTMENT OF OBSTETRICS, GYNECOLOGY
and REPRODUCTIVE SCIENCES
OB/GYN RESIDENTS 2006-2007
FOURTH-YEAR RESIDENTS
Amy N. Broach, MD - East Carolina University School of Medicine
Vanita B. Dharan, MD - Drexel University College of Medicine
Elizabeth A. Frankman, MD - University of Minnesota at Minneapolis
Emily S. Lebovitz, MD - Drexel University College of Medicine
Michele R. Odrobina, MD - State University of New York at Buffalo
Minita Patel, MD - University of Medicine and Denistry of New Jersey
Suzanne E. Peterson, MD - University of Washington School of Medicine
Lauren E. Pray, MD - Case Western Reserve School of Medicine
Carolyn B. Sufrin, MD - Johns Hopkins University School of Medicine
THIRD-YEAR RESIDENTS
Jennifer L. Baumbach, MD - University of Arizona College of Medicine
Kathleen A. Carroll, MD - University of Pittsburgh School of Medicine
Catherine G. Hilliker, MD - Indiana University School of Medicine
Susan M. Lareau, MD - University of Virginia School of Medicine
Amanda N. Malina, MD - University of Pittsburgh School of Medicine
Gina M. Mantia, MD - State University of New York at Stony Brook
Stephanie M. Owens, MD - University of Washington School of Medicine
Stephen W. Tobia, MD - University of Miami School of Medicine
SECOND-YEAR RESIDENTS
Sharon L. Achilles, MD - University of Pittsburgh School of Medicine
Sarah E. Hutchison, MD - Case Western Reserve School of Medicine
Elizabeth E. Krans, MD - University of Mississippi School of Medicine
Jamie L. Lesnock, MD - Vanderbilt University School of Medicine
Melanie E. Ochalski, MD - University of Medicine and Dentistry of New Jersey
Amber M. Naresh, MD, MPH - Tulane University School of Medicine
David A. Rapkin, MD - Temple University School of Medicine
Bunja J. Rungruang, MD - University of Alabama School of Medicine
Wendy S. Vitek, MD - University of Rochester School of Medicine and Dentistry
FIRST-YEAR RESIDENTS
Erin F. Cook, MD - University of Alabama School of Medicine
Madeleine B. Courtney-Brooks, MD - Washington U., St. Louis School of Medicine
Heidi Brown Filippone, MD - Brown Medical School
Nicole M. Donnellan, MD - University of Pittsburgh School of Medicine
Marcia E. Klein-Patel, MD, Ph.D - University of Medicine & Dentistry of New Jersey
Gregory W. Mallek, MD - Oregon Health & Sciences University
Daniela E. Morato, MD - University of Maryland School of Medicine
Sallie S. Oliphant, MD - University of North Carolina, Chapel Hill School of Medicine
Amber Samuel, MD - Baylor College of Medicine
118
TEACHING ACTIVITIES
2005 GRADUATES
Tracy Irwin, MD, M.P.H., Private Practice - Chicago, Illinois
Merrideth Leggat, MD, Faculty - University of Pittsburgh School of Medicine Department
of Obstetrics, Gynecology and Reproductive Sciences
Diem Nguyen, MD, Private Practice – Pittsburgh, Pennsylvania
Elizabeth Roberts, MD, Private Practice - Richmond, Virginia
Kathryn Simons, MD, Private Practice - Washington, Pennsylvania
Melissa Thrall, MD, National Health Service - Page, Arizona
Brian Wilcox, MD, Private Practice - Scranton, Pennsylvania
Shirley Woo, MD, Private Practice - Pittsburgh, Pennsylvania
2006 GRADUATES
Beatrice Chen, MD, Fellowship - Family Planning and Contraceptive Research University
of Pittsburgh School of Medicine, Department of Obstetrics, Gynecology and
L’Tricia D.O. Chery, MD, Private Practice
Teresa M. Erb, MD, Faculty - University of Pittsburgh School of Medicine Department of
Obstetrics, Gynecology and Reproductive Sciences
Amanda Nickles Fader, MD, Gynecologic Oncology Fellowship, Cleveland Clinic,
Cleveland, Ohio
Kim Gecsi, MD, Private Practice – Norwalk, Ohio
Katherine Himes, MD, Fellowship - Maternal-Fetal Medicine Fellowship, University of
Pittsburgh Medical Center
Amy Park, MD, Fellowship - Female Pelvic Medicine and Reconstructive Surgery,
Cleveland Clinic, Cleveland, Ohio
Ashlyn Savage, MD, Faculty - Department of Ob/Gyn, MUSC, Charleston, South
Carolina
Amy Whitaker, MD, Fellowship - Family Planning and Contraceptive Research, University
of Chicago Hospitals, Chicago Illinois
119
CLINICAL FELLOWSHIP
The Department offers fellowship training in the following seven subspecialty areas of
obstetrics and gynecology:gynecology oncology, contraceptive research and family planning,
maternal-fetal medicine, gynecologic minimally invasive surgery, reproductive genetics,
reproductive infectious diseases and female pelvic medicine and reconstructive surgery.
Gynecologic Oncology – An American Board of Obstetrics and Gynecology (ABOG)
approved fellowship. One position per year for a three-year fellowship in Gynecologic
Oncology. Fellows obtain advanced clinical and research training, with participation in the
core Clinical Research Training Program. In addition, a variety of tracks are available
should the fellow wish to pursue a Master of Science in Clinical Research. Fellows will gain
exposure to NIH-funded trials through the Gynecologic Oncology Group (GOG),
Radiation Therapy Oncology Group (RTOG) and many other ongoing clinical and basic
research projects. Clinical training is enhanced by active multidisciplinary collaboration
with the Departments of Obstetrics and Gynecology, Radiation Oncology and Surgical
Oncology (at UPMC Shadyside). Director: Joseph Kelley, MD
Contraceptive Research and Family Planning – This fellowship is one of only a few
funded fellowships in family planning in the United States. This two-year fellowship is
designed to include training in family planning clinical care, experience in gynecologic
surgery and related family planning procedures, participation in the design and performance of clinical trials, and international field work. During the two years, the fellow is
encouraged to complete course work at the Graduate School of Public Health at the
University of Pittsburgh to satisfy the requirements of a Master’s Degree in Public Health.
Course work can involve a multidisciplinary approach or a departmental curriculum including biostatistics, epidemiology and health care administration. The program is intended to
foster the pursuit of an academic career by an overall emphasis on and preparation for clinical research and teaching. The fellow will be specially trained in contraceptive counseling,
Norplant insertion and removal, IUD insertion and removal and the fitting of diaphragms.
Additionally, the fellow will gain expertise in treating complications of hormonal contraception. Although these procedures may have been learned during residency, a concentrated
experience will enable the fellow to be proficient with unusual or complicated cases. The
fellow will receive specialized training and become very experienced in performing first
trimester procedures including manual vacuum aspiration and medical abortions. The fellow will have similar experience with second trimester abortions by dilation and evacuation
(D&E). Director: Mitchell Creinin, MD
Maternal-Fetal Medicine – An approved fellowship in MFM offers two positions per year.
Extensive clinical training is provided using the large obstetrical population as 400 maternal
transport patients per year. Experience in ultrasound, reproductive genetics, neonatology
and statistical methodology is part of the training. Basic research in cardiovascular physiology, pharmacology, infectious diseases and molecular biology are available through the
Magee-Womens Research Institute. Areas of clinical research focus include: preterm birth
prevention, pharmacologic agents for the inhibition of labor, infectious diseases, preeclampsia and medical complications of pregnancy. Director: Steve Caritis, MD
120
Reproductive Endocrinology and Infertility – The Department has a one-year intense
academic training program which focuses on minimally invasive surgery. The program is
designed to provide extensive training in endoscopic surgery from the gynecologic and general surgical perspectives. A research project is an integral part of the program with the
expectation that it is submitted at a national level and published in a peer-reviewed journal.
TEACHING ACTIVITIES
Other activities include active participation in resident and student teaching programs and
private patient sessions. Director: Joseph Sanfilippo, MD
Reproductive Genetics – The Department has a two or three year fellowship program in
Reproductive Genetics and offers one position per year. The program focuses on methods
of fetal diagnosis and therapy, natural history of fetal malformations and role of heredity in
gynecologic cancer. A broad base of clinical and laboratory training is offered.
Director: W. Allen Hogge, MD
Reproductive Infectious Diseases – Trains obstetricians-gynecologists to become experts
in infections of the reproductive tract. It is a two-year fellowship which offers one position
per year. The program focuses on infectious diseases in obstetric and gynecologic patients
but includes exposure to medical infectious disease, STDs and neonatal infections.
Exposure to current laboratory techniques in microbiology, molecular biology and
immunology is also offered as well as biostatistics and epidemiology. The fellows’ efforts in
basic science and clinical investigation are also fostered and expected. Director: Harold
Wiesenfeld, MD
Urogynecology and Pelvic Reconstructive Surgery – The fellowship in Female Pelvic
Medicine and Reconstructive Surgery at Magee-Womens Hospital of the UPMC and the
University of Pittsburgh is designed as a three year curriculum for individuals who have
completed residency training in obstetrics and gynecology or urology. The curriculum is
designed to provide broad training and experience in clinical care and research in women
with pelvic floor disorders. Clinical rotations include in-patient and out-patient urogynecologic urology, geriatrics, colorectal surgery and gastroenterology. Surgical approaches to
pelvic floor disorders include abdominal, vaginal and laparoscopic procedures. Research
rotations will include the opportunity to participate in both basic science (laboratory)
research and clinical research. Fellows will have the opportunity to obtain a Master’s degree
from the Graduate School of Public Health in Clinical Research Training during the first
two years of the fellowship. Clinical experience in obstetrics is available but not required as
part of the fellowship. Director: Anne Weber, MD
121
122
CLINICAL REVENUE DATA AND TRENDING
GYNECOLOGIC SPECIALTIES
(includes Midlife Health Center)
Charges and Payments - Three Year Trending (FY04, FY05, FY06)
Charges
Payments
$10,000,000
$8,322,332
$8,000,000
$6,000,000
$7,000,411
$4,791,997
$4,000,000
$3,146,664
$2,727,344
$2,034,879
$2,000,000
$0
FY04
FY05
FY06
GYNECOLOGIC ONCOLOGY
Charges
Payments
$7,000,000
$6,189,438
$6,000,000
$5,000,000
$4,000,000
$3,776,992
$3,641,353
$3,000,000
$2,000,000
$1,868,678
$1,229,314
$1,215,379
$1,000,000
$0
FY04
FY05
FY06
123
MFM
Charges
$6,000,000
$5,739,126
Payments
$5,976,564
$5,182,967
$5,000,000
$4,000,000
$2,347,788
$3,000,000
$2,244,656
$2,284,992
$2,000,000
$1,000,000
$0
FY04
FY05
FY06
REI/IVF
Charges
$9,000,000
Payments
$8,041,420
$8,000,000
$7,099,371
$7,000,000
$6,000,000
$6,969,548
$4,789,259
$4,778,959
$4,013,548
$5,000,000
$4,000,000
$3,000,000
$2,000,000
$1,000,000
$0
FY04
124
FY05
FY06
GENETICS
Charges
Payments
$415,943
$450,000
$400,000
$350,000
$279,521
$300,000
$248,264
$250,000
$200,000
$142,043
$150,000
$99,269
$99,939
$100,000
$50,000
$0
FY04
FY05
FY06
ULTRASOUND
Charges
Payments
$12,000,000
$10,022,641
$9,910,783
$10,000,000
$8,750,032
$8,000,000
$6,000,000
$4,000,000
$2,952,418
$3,297,906
$3,270,158
$2,000,000
$0
FY04
FY05
FY06
125
UROGYNECOLOGY
Charges
$4,000,000
Payments
$3,534,413
$3,494,228
$3,133,573
$3,000,000
$2,000,000
$1,050,971
$1,028,758
$882,557
$1,000,000
$0
FY04
FY05
FY06
DEPARTMENT OF OBSTETRICS, GYNEOCOLOGY
& REPRODUCTIVE SERVICES
Charges
$45,000,000
$42,206,749
Payments
$44,138,009
$39,619,807
$40,000,000
$35,000,000
$30,000,000
$25,000,000
$18,042,033
$17,117,879
$20,000,000
$17,181,227
$15,000,000
$10,000,000
$5,000,000
$0
FY04
126
FY05
FY06
$3,776,992
$3,641,353
$5,739,126
$7,099,371
$6,189,438
$5,976,564
$5,182,967
$8,322,332
$10,022,641
$9,910,783
$8,750,032
$8,041,420
$7,000,411
$10,000,000
Ultrasound
Gyncologic
Oncology
$3,534,413
$3,534,413
$3,133,573
$3,494,228
$4,791,997
FY05
MFM
REI/IVF
$279,521
FY04
Urogynecology
$415,943
$248,264
$2,902,567
$6,000,000
Gynecological
Specialties
Genetics
General ObGyn
$4,000,000
$7,336,663
$8,000,000
$3,256,026
Charges by Division - Three Year Trending (FY04, FY05, FY06)
FY06
$12,000,000
$2,000,000
$0
127
128
Ultrasound
$1,000,000
Gyncologic
Oncology
$1,050,971
$1,229,314
$1,215,379
$1,028,758
$1,868,678
$2,284,992
$0
$3,270,158
$3,297,906
$2,952,418
$2,347,788
$2,244,656
$3,146,664
$2,727,344
$3,000,000
$882,557
$2,034,879
$4,013,548
$4,778,959
$4,789,259
FY05
MFM
$99,269
$5,000,000
REI/IVF
$142,043
$99,939
$1,174,618
FY04
Urogynecology
Gynecological
Specialties
Genetics
General ObGyn
$2,000,000
$3,450,916
$4,000,000
$1,758,574
Payments by DIVISION - Three Year Trending (FY04, FY05, FY06)
FY06
$6,000,000
FY 2006 Charges by DIVISION
Urogynecology
$3,534,413 (8%)
Gynecologic Specialties/MLC
$8,322,332 (19%)
Genetics
$279,521 (1%)
General ObGyn
$2,902,567 (7%)
REI/IVF
$6,969,548
(16%)
Ultrasound
$10,022,641
(23%)
MFM
$5,976,564 (14%)
Gynecological Oncology
$6,189,438 (14%)
FY 2006 Payments by DIVISION
Gynecologic Specialties/MLC
$3,146,664 (19%)
Genetics
$99,269 (1%)
General ObGyn
$1,174,618 (7%)
Urogynecology
$1,028,758 (6%)
Ultrasound
$3,270,158
(19%)
Gynecological
Oncology
$1,868,678 (11%)
REI/IVF
$4,013,548 (24%)
MFM
$2,284,992 (14%)

University of Pittsburgh School of Medicine

Transcription

Similar documents

Center for Women`s Health - University of Illinois College of Medicine

AUGUST 6-8,2o1o FoNTAINEBLEAU HoTEL MIAMI BEACH, FLoRIDA

Seija Grenman - The Nordic Federation of Societies of Obstetrics

informational flyer - Tufts University School of Medicine

OBGYN Issue 9

Plisic, Ljiljana

ANDREW H. RICE, D.P.M., FACFAS LJILJANA PLISIC, M.D.

ferticare - Minerva Events

Confe Acco - Taylor Blessey LLP

women`shealth - Department of Obstetrics, Gynecology and